Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Infectious Diseases›Condition·Updated Jul 11, 2026·v1

Staphylococcus aureus

Staphylococcus aureus is a Gram-positive coccus that is the leading cause of death from bacteremia worldwide. It causes a wide range of infections from skin abscesses to endocarditis, osteomyelitis, and toxin-mediated syndromes. Management requires prompt classification into MSSA or MRSA, early source control, and empiric therapy guided by local resistance patterns. De-escalation using MRSA nares PCR reduces nephrotoxicity. Cefazolin is first-line for MSSA; vancomycin with AUC/MIC monitoring for MRSA. Oral switch is safe in selected patients. ID consultation, antimicrobial stewardship, and infection control measures including universal decolonization in ICUs improve outcomes.

High Evidence731 references·11,125 words·45 min read·v1
Staphylococcus aureusMRSAMSSAbacteremiainfective endocarditisantimicrobial stewardshipvancomycincefazolinlinezoliddaptomycinceftobiproledecolonizationsource control

Quick Reference

RxDrug of choiceFor MRSA bacteremia: vancomycin (target AUC/MIC 400-600). For MSSA bacteremia: cefazolin 2 g IV q8h.
AltAlternativesDaptomycin 6-10 mg/kg IV q24h, ceftobiprole 500 mg IV q6-8h, linezolid 600 mg PO/IV q12h, ceftaroline 600 mg IV q8h.
⊘AvoidAvoid routine addition of gentamicin or rifampin for bacteremia; avoid dual β-lactam therapy for MRSA (CAMERA2).
DxTest of choiceBlood cultures (2 sets) + MRSA nares PCR (NPV 96.5% for MRSA pneumonia).
ScKey scoreAPACHE-II ≥14 identifies high-risk MRSA BSI (35% clinical failure).
→When to referAll S. aureus bacteremia and endocarditis, persistent bacteremia ≥48h, prosthetic joint infection, osteomyelitis, abscesses requiring drainage, and when ID consultation is not already involved.
Early source control, rapid de-escalation using nares PCR, and preference for β-lactams over vancomycin when MSSA is confirmed are the three pillars that reduce mortality and nephrotoxicity.
Staphylococcus aureus is the leading cause of death from bacteremia worldwide, with a case fatality rate of 15-30% and an estimated 300,000 deaths annually. It causes a broad spectrum of infections, from minor skin abscesses to life-threatening endocarditis, pneumonia, and toxin-mediated syndromes. Management hinges on prompt classification by methicillin susceptibility (MSSA vs MRSA), early source control, and appropriate empiric therapy guided by local epidemiology. De-escalation using MRSA nares PCR (NPV >96%) reduces nephrotoxicity and cost. Definitive therapy should be tailored: cefazolin is preferred for MSSA due to lower AKI risk, while vancomycin with AUC/MIC targeting is standard for MRSA. Early oral switch is safe in selected low-risk patients. Infectious disease consultation, antimicrobial stewardship, and infection control measures including universal decolonization in ICUs improve outcomes.

Overview and Recommendations

Key Facts

  • •Staphylococcus aureus is a Gram-positive, coagulase-positive coccus and the leading cause of death from bacteremia worldwide, with an estimated 300,000 deaths annually and a case fatality rate of 15-30% even with appropriate therapy, making it one of the most lethal bacterial pathogens.
  • •The organism is classified by methicillin susceptibility into MSSA (methicillin-susceptible) and MRSA (methicillin-resistant), the latter mediated by the mecA gene on SCCmec elements; MRSA accounts for ~40% of invasive isolates globally and carries a higher recurrence risk (sHR 1.69).
  • •Virulence is driven by a potent arsenal: Panton-Valentine leukocidin (PVL) causes necrotizing pneumonia and recurrent SSTIs; TSST-1 triggers toxic shock syndrome; α-hemolysin mediates lung tissue destruction; and biofilm-forming strains (especially CC8/spa t008) predict higher readmission rates in device-related infections.
  • •The spectrum of disease spans from superficial furuncles and cellulitis to life-threatening bacteremia, infective endocarditis, vertebral osteomyelitis, and toxin-mediated syndromes, with metastatic seeding occurring in >30% of bloodstream infections.
  • •In the United States, the age-adjusted incidence of S. aureus bacteremia is 33.9 per 100,000 person-years, with highest rates in older adults, males, Black individuals, and people who inject drugs; community-associated MRSA (USA300 clone) disproportionately affects prisoners, athletes, and men who have sex with men.

Clinical Importance

  • •Suspect S. aureus infection in any patient with purulent skin abscesses, recurrent furuncles, or rapidly progressive cellulitis, especially in young, otherwise healthy individuals without healthcare exposure, this pattern is classic for CA-MRSA (USA300).
  • •In patients with fever and risk factors such as indwelling catheters, injection drug use, hemodialysis, or recent hospitalization, obtain two sets of blood cultures before starting antibiotics; a single positive bottle represents true infection in 89.8% of cases.
  • •Ask specifically about new back pain (suggests vertebral osteomyelitis or spinal epidural abscess), joint pain (septic arthritis), chest pain or hemoptysis (septic pulmonary emboli from right-sided endocarditis), and headache or focal neurologic deficits (CNS infection).
  • •Examine for skin abscesses, heart murmurs (especially new or changing murmurs suggest endocarditis), joint effusions, spinal tenderness, and neurologic deficits, the presence of a prosthetic valve or cardiac device raises the likelihood of seeding.
  • •Order blood cultures from two separate sites, and send an MRSA nares PCR swab, a negative result has a negative predictive value of 96.5% for ruling out MRSA pneumonia and bloodstream infection, enabling early de-escalation of anti-MRSA therapy.
  • •Perform transthoracic echocardiography (TTE) in all patients with S. aureus bacteremia; proceed to transesophageal echocardiography (TEE) if there is persistent bacteremia ≥48 hours, persistent fever >72 hours, metastatic foci, or an implantable cardiac device, TEE increases endocarditis detection from 2-15% to 14-28%.
  • •Measure time to blood culture positivity (TTP): a TTP <13 hours independently predicts infective endocarditis (OR 3.59) with a negative predictive value of 96% for ruling out endocarditis when longer.
  • •For suspected S. aureus pneumonia, consider the diagnosis in patients with severe community-acquired pneumonia, especially if preceded by influenza, presenting with hemoptysis, rapid respiratory decline, and cavitary lesions on imaging.
  • •When evaluating a patient with positive blood cultures, assess for persistent bacteremia: repeat cultures at 24-48 hours, persistent positivity ≥2 days confers a 90-day mortality of 39% and mandates aggressive source control and search for metastatic infection.
  • •In cases of prosthetic joint infection (PJI), suspect S. aureus when a patient with a prior arthroplasty develops acute pain, swelling, and erythema of the joint within a median of 1 day after positive blood culture; PJI occurs in 19% of SAB patients with preexisting hardware.
  • •For children, a limp or refusal to bear weight may be the only sign of acute hematogenous osteomyelitis; the metaphysis of long bones (femur, tibia, humerus) is most commonly involved.
  • •Always consider differential diagnoses: necrotizing fasciitis (severe pain out of proportion), gout (crystal analysis), viral pneumonia (PCR panels), and nonbacterial thrombotic endocarditis (modified Duke criteria).

Diagnosis and Treatment

  • •Initiate empiric anti-MRSA therapy when local MRSA prevalence exceeds 10-20%, the patient has severe sepsis or septic shock, or there are risk factors for MRSA (prior colonization, injection drug use, hemodialysis, recent hospitalization).
  • •For suspected MRSA bacteremia or endocarditis, administer vancomycin 15-20 mg/kg IV every 8-12 hours with a target AUC/MIC ratio of 400-600 mg·h/L (trough 15-20 µg/mL if AUC monitoring unavailable); alternative: daptomycin 6 mg/kg IV once daily for bacteremia, 8-10 mg/kg for endocarditis.
  • •For suspected MSSA bacteremia, start cefazolin 2 g IV every 8 hours (preferred over antistaphylococcal penicillins due to significantly lower risk of acute kidney injury, NNT=18); if penicillin-susceptible, benzylpenicillin 1.8 g IV every 4 hours is an option.
  • •For uncomplicated skin abscess, perform incision and drainage and consider adjunctive oral antibiotics: trimethoprim-sulfamethoxazole (160/800 mg) one double-strength tablet orally twice daily or clindamycin 300-450 mg orally three times daily for 5-7 days.
  • •For severe SSTI with systemic toxicity, use intravenous vancomycin or daptomycin; linezolid 600 mg IV/orally every 12 hours is an alternative with good tissue penetration and lower nephrotoxicity.
  • •Achieve source control urgently: remove all infected intravascular catheters within 72 hours (failure to do so increases 90-day mortality), drain abscesses ≥5 cm, debride necrotic tissue, and for native valve endocarditis consider early valve surgery if heart failure, uncontrolled infection, or embolic complications develop.
  • •De-escalate anti-MRSA therapy to a β-lactam (cefazolin or antistaphylococcal penicillin) when MRSA nares PCR returns negative (NPV >96%) and cultures confirm MSSA, this reduces nephrotoxicity and cost; de-escalate by day 4 of therapy when possible.
  • •Use therapeutic drug monitoring for vancomycin: target an AUC0-24/MIC of 400-600 (assuming MIC 1 mg/L); Bayesian dosing is preferred; avoid relying solely on trough monitoring.
  • •Duration of therapy: 14 days for uncomplicated bacteremia (negative follow-up cultures at 48-72 hours, no endocarditis, no metastatic foci, defervescence within 72 hours); 4-6 weeks for complicated bacteremia (endocarditis, deep-seated infection, persistent bacteremia ≥48 hours).
  • •Consider early oral switch in clinically stable, low-risk patients with uncomplicated bacteremia who have cleared blood cultures and have a removable source: the SABATO trial showed noninferiority of oral step-down after 5-7 days of IV therapy (13% vs 12% composite outcome); use linezolid 600 mg orally twice daily for MRSA or cephalexin 500 mg orally four times daily for MSSA.
  • •For left-sided endocarditis, the POET trial supports oral switch after at least 10 days of IV therapy with noninferior outcomes (9.0% vs 12.1%); oral options include a fluoroquinolone plus rifampin or linezolid.
  • •Avoid routine addition of gentamicin, it increases nephrotoxicity without improving survival; avoid rifampin as adjunctive therapy for uncomplicated MRSA bacteremia (ARREST trial showed no benefit, HR 0.96).
  • •Avoid dual β-lactam therapy (e.g., vancomycin plus anti-MRSA β-lactam) for MRSA bacteremia, CAMERA2 showed no improvement in 90-day mortality and increased acute kidney injury (23% vs 6%).
  • •For persistent MRSA bacteremia ≥5 days despite optimized vancomycin, switch to daptomycin 8-10 mg/kg IV daily plus ceftaroline 600 mg IV every 8 hours, this combination showed reduced in-hospital mortality in a pilot trial (0% vs 26%).
  • •Monitor renal function daily during treatment with vancomycin or antistaphylococcal penicillins; monitor creatine phosphokinase (CPK) weekly if on daptomycin; monitor complete blood count weekly if on linezolid for more than 2 weeks due to risk of thrombocytopenia.
  • •Refer to infectious diseases specialist for all cases of S. aureus bacteremia and endocarditis, ID consultation reduces 10-year mortality (HR 0.42) and risk of new bacteremia (OR 0.45).
  • •For prosthetic joint infection, manage with surgical debridement, retention of prosthesis (DAIR) combined with rifampin-containing regimen if debridement is adequate; success rates are 69% for hip and 54% for knee.
  • •For osteomyelitis, treat with 4-6 weeks of parenteral or highly bioavailable oral therapy after adequate debridement; longer courses (>6 weeks) do not improve outcomes in fracture-related infection.
  • •Do not base therapy solely on vancomycin MIC ≥2 µg/mL, consider alternative agents (daptomycin, ceftaroline, ceftobiprole) as failure rates are high.
  • •In ICUs, implement universal decolonization with chlorhexidine bathing and intranasal mupirocin to reduce MRSA clinical isolates (HR 0.63) and all-pathogen bloodstream infection (NNT=54 to prevent one BSI).

Board Review — High Yield

  • •Persistent bacteremia ≥2 days, 90-day mortality 39% vs 22% for 1 day.
  • •MRSA nares PCR NPV >96%, enables safe de-escalation of empiric anti-MRSA therapy.
  • •Cefazolin preferred over antistaph penicillins for MSSA, lower AKI risk (SNAP, CloCeBa).
  • •Vancomycin AUC/MIC target 400-600, replaces trough monitoring alone.
  • •POET trial, oral switch noninferior in left-sided endocarditis after ≥10 days IV.
  • •CAMERA2, adding β-lactam to vancomycin for MRSA BSI increased AKI without mortality benefit.
  • •ARREST, no benefit of adjunctive rifampin for S. aureus bacteremia.
  • •SABATO trial, early oral switch (5-7 days IV) noninferior in low-risk SAB.
  • •REDUCE MRSA, universal decolonization in ICU reduces all-cause BSI (NNT=54).
  • •Mupirocin resistance, associated with usage >25 DDD/1000 patient-days.

Deep Dive — Evidence Details

References

  1. [1]

    Liu C, Bayer A, Cosgrove SE et al.. “Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21208910 ↗

    L1GUIDELINECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Special Hosts and Populations
  2. [2]

    Stevens DL, Bisno AL, Chambers HF et al.. “Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 24973422 ↗

    L1GUIDELINECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment
  3. [3]

    Stevens DL, Bisno AL, Chambers HF et al.. “Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 24947530 ↗

    L1GUIDELINECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment
  4. [4]

    Liu C, Bayer A, Cosgrove SE et al.. “Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21217178 ↗

    L1GUIDELINECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Special Hosts and Populations
  5. [5]

    Rybak MJ, Le J, Lodise TP et al.. “Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 32658968 ↗

    L1GUIDELINECited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Special Hosts and Populations
  6. [6]

    Mourad A, Nwafo N, Skalla L et al.. “Oral Versus Intravenous Antibiotic Therapy for Staphylococcus aureus Bacteremia or Endocarditis: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39290168 ↗

    L1SR_OBSCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications
  7. [7]

    Wunderink RG, Niederman MS, Kollef MH et al.. “Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2012). PMID: 22247123 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History
  8. [8]

    . “Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.” The Lancet. Infectious diseases (2024). PMID: 38636536 ↗

    L2SR_OBSCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Prognosis and Natural History, Special Hosts and Populations
  9. [9]

    Reddy EA, Shaw AV, Crump JA. “Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2010). PMID: 20510282 ↗

    L2SR_OBSCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Diagnosis and Workup, Prognosis and Natural History, Special Hosts and Populations
  10. [10]

    de Kretser D, Mora J, Bloomfield M et al.. “Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37921609 ↗

    L5TRIAL_NONRANDOMCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment
  11. [11]

    Parente DM, Cunha CB, Mylonakis E et al.. “The Clinical Utility of Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Screening to Rule Out MRSA Pneumonia: A Diagnostic Meta-analysis With Antimicrobial Stewardship Implications.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2018). PMID: 29340593 ↗

    L2SR_OBSCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  12. [12]

    McDanel JS, Roghmann MC, Perencevich EN et al.. “Comparative Effectiveness of Cefazolin Versus Nafcillin or Oxacillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections Complicated by Bacteremia: A Nationwide Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2017). PMID: 28379314 ↗

    L3COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Complications
  13. [13]

    Iversen K, Ihlemann N, Gill SU et al.. “Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis.” The New England journal of medicine (2018). PMID: 30152252 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History
  14. [14]

    Holland TL, Cosgrove SE, Doernberg SB et al.. “Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia.” The New England journal of medicine (2023). PMID: 37754204 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History
  15. [15]

    Lee TC, Barina LA, Walls G et al.. “Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia.” The New England journal of medicine (2026). PMID: 42308484 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History, Special Hosts and Populations
  16. [16]

    Fowler VG, Boucher HW, Corey GR et al.. “Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.” The New England journal of medicine (2006). PMID: 16914701 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History
  17. [17]

    O'Riordan W, Green S, Overcash JS et al.. “Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.” The New England journal of medicine (2019). PMID: 30726689 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History
  18. [18]

    Huang SS, Septimus E, Kleinman K et al.. “Targeted versus universal decolonization to prevent ICU infection.” The New England journal of medicine (2013). PMID: 23718152 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Complications, Prevention and Infection Control
  19. [19]

    Corey GR, Kabler H, Mehra P et al.. “Single-dose oritavancin in the treatment of acute bacterial skin infections.” The New England journal of medicine (2014). PMID: 24897083 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Complications
  20. [20]

    Bode LG, Kluytmans JA, Wertheim HF et al.. “Preventing surgical-site infections in nasal carriers of Staphylococcus aureus.” The New England journal of medicine (2010). PMID: 20054045 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup
  21. [21]

    . “Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.” Lancet (London, England) (2022). PMID: 35065702 ↗

    L2SR_OBSCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  22. [22]

    Burdet C, Saïdani N, Dupieux C et al.. “Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial.” Lancet (London, England) (2025). PMID: 41115439 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History
  23. [23]

    . “Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial.” Lancet (London, England) (2026). PMID: 42309115 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History
  24. [24]

    Thwaites GE, Scarborough M, Szubert A et al.. “Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2017). PMID: 29249276 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History
  25. [25]

    Anderson DJ, Chen LF, Weber DJ et al.. “Enhanced terminal room disinfection and acquisition and infection caused by multidrug-resistant organisms and Clostridium difficile (the Benefits of Enhanced Terminal Room Disinfection study): a cluster-randomised, multicentre, crossover study.” Lancet (London, England) (2017). PMID: 28104287 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Prognosis and Natural History, Prevention and Infection Control
  26. [26]

    Schumm MA, Hadaya JE, Mody N et al.. “Filtering Facepiece Respirator (N95 Respirator) Reprocessing: A Systematic Review.” JAMA (2021). PMID: 33656543 ↗

    L2SR_OBSCited in: Definition, Classification and Causative Organisms, Prevention and Infection Control
  27. [27]

    Mellett M, Lawandi A, Caya C et al.. “Antibiotic synergy against Staphylococcus aureus: a systematic review and meta-analysis.” Antimicrobial agents and chemotherapy (2025). PMID: 40526084 ↗

    L1SR_OBSCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  28. [28]

    Kuehl R, Morata L, Boeing C et al.. “Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study.” The Lancet. Infectious diseases (2020). PMID: 32763194 ↗

    L2COHORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History
  29. [29]

    Tong SYC, Lye DC, Yahav D et al.. “Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.” JAMA (2020). PMID: 32044943 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History
  30. [30]

    Huang SS, Septimus EJ, Kleinman K et al.. “Nasal Iodophor Antiseptic vs Nasal Mupirocin Antibiotic in the Setting of Chlorhexidine Bathing to Prevent Infections in Adult ICUs: A Randomized Clinical Trial.” JAMA (2023). PMID: 37815567 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  31. [31]

    Geriak M, Haddad F, Rizvi K et al.. “Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.” Antimicrobial agents and chemotherapy (2019). PMID: 30858203 ↗

    L1RCTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment
  32. [32]

    Lappin E, Ferguson AJ. “Gram-positive toxic shock syndromes.” The Lancet. Infectious diseases (2009). PMID: 19393958 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications
  33. [33]

    Davis MF, Iverson SA, Baron P et al.. “Household transmission of meticillin-resistant Staphylococcus aureus and other staphylococci.” The Lancet. Infectious diseases (2012). PMID: 22917102 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Antimicrobial Resistance and Stewardship
  34. [34]

    Thwaites GE, Edgeworth JD, Gkrania-Klotsas E et al.. “Clinical management of Staphylococcus aureus bacteraemia.” The Lancet. Infectious diseases (2011). PMID: 21371655 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  35. [35]

    Nickerson EK, West TE, Day NP et al.. “Staphylococcus aureus disease and drug resistance in resource-limited countries in south and east Asia.” The Lancet. Infectious diseases (2009). PMID: 19179228 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  36. [36]

    Moise PA, North D, Steenbergen JN et al.. “Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions.” The Lancet. Infectious diseases (2009). PMID: 19778764 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  37. [37]

    Aiello AE, Lowy FD, Wright LN et al.. “Meticillin-resistant Staphylococcus aureus among US prisoners and military personnel: review and recommendations for future studies.” The Lancet. Infectious diseases (2006). PMID: 16728319 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship
  38. [38]

    Clements A, Halton K, Graves N et al.. “Overcrowding and understaffing in modern health-care systems: key determinants in meticillin-resistant Staphylococcus aureus transmission.” The Lancet. Infectious diseases (2008). PMID: 18582835 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Complications
  39. [39]

    Harbarth S, Fankhauser C, Schrenzel J et al.. “Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients.” JAMA (2008). PMID: 18334690 ↗

    L2TRIAL_NONRANDOMCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship, Prognosis and Natural History, Prevention and Infection Control
  40. [40]

    Schweizer ML, Chiang HY, Septimus E et al.. “Association of a bundled intervention with surgical site infections among patients undergoing cardiac, hip, or knee surgery.” JAMA (2015). PMID: 26034956 ↗

    L2TRIAL_NONRANDOMCited in: Definition, Classification and Causative Organisms, Prevention and Infection Control
  41. [41]

    Aiken AM, Mturi N, Njuguna P et al.. “Risk and causes of paediatric hospital-acquired bacteraemia in Kilifi District Hospital, Kenya: a prospective cohort study.” Lancet (London, England) (2011). PMID: 22133536 ↗

    L2COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Special Hosts and Populations
  42. [42]

    Lakhundi S, Zhang K. “Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology.” Clinical microbiology reviews (2018). PMID: 30209034 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  43. [43]

    Tong SY, Davis JS, Eichenberger E et al.. “Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.” Clinical microbiology reviews (2015). PMID: 26016486 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship
  44. [44]

    De Oliveira DMP, Forde BM, Kidd TJ et al.. “Antimicrobial Resistance in ESKAPE Pathogens.” Clinical microbiology reviews (2020). PMID: 32404435 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  45. [45]

    Becker K, Heilmann C, Peters G. “Coagulase-negative staphylococci.” Clinical microbiology reviews (2014). PMID: 25278577 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  46. [46]

    Kavanagh N, Ryan EJ, Widaa A et al.. “Staphylococcal Osteomyelitis: Disease Progression, Treatment Challenges, and Future Directions.” Clinical microbiology reviews (2018). PMID: 29444953 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Clinical Presentation, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Complications
  47. [47]

    David MZ, Daum RS. “Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic.” Clinical microbiology reviews (2010). PMID: 20610826 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  48. [48]

    Gadsby NJ, Musher DM. “The Microbial Etiology of Community-Acquired Pneumonia in Adults: from Classical Bacteriology to Host Transcriptional Signatures.” Clinical microbiology reviews (2022). PMID: 36165783 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control
  49. [49]

    Boggio CMT, Veronese F, Armari M et al.. “Skin microbiota in atopic dermatitis: victim or executioner?” Clinical microbiology reviews (2025). PMID: 40459300 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment
  50. [50]

    Saiman L, Waters V, LiPuma JJ et al.. “Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis.” Clinical microbiology reviews (2024). PMID: 39158301 ↗

    L1REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Complications
  51. [51]

    Schlievert PM, Davis CC. “Device-Associated Menstrual Toxic Shock Syndrome.” Clinical microbiology reviews (2020). PMID: 32461307 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment
  52. [52]

    Tande AJ, Currier BL, Osmon DR. “Spinal Epidural Abscess.” The New England journal of medicine (2026). PMID: 42019020 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Complications
  53. [53]

    de Benedictis FM, Kerem E, Chang AB et al.. “Complicated pneumonia in children.” Lancet (London, England) (2020). PMID: 32919518 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Complications, Prognosis and Natural History, Special Hosts and Populations
  54. [54]

    DeLeo FR, Otto M, Kreiswirth BN et al.. “Community-associated meticillin-resistant Staphylococcus aureus.” Lancet (London, England) (2010). PMID: 20206987 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Prevention and Infection Control
  55. [55]

    Rossi F, Diaz L, Wollam A et al.. “Transferable vancomycin resistance in a community-associated MRSA lineage.” The New England journal of medicine (2014). PMID: 24738669 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  56. [56]

    Renz N, Trampuz A, Perka C et al.. “Outcome and Failure Analysis of 132 Episodes of Hematogenous Periprosthetic Joint Infections-A Cohort Study.” Open forum infectious diseases (2022). PMID: 35355896 ↗

    L3COHORTCited in: Definition, Classification and Causative Organisms, Prognosis and Natural History
  57. [57]

    Bruun T, Oppegaard O, Kittang BR et al.. “Etiology of Cellulitis and Clinical Prediction of Streptococcal Disease: A Prospective Study.” Open forum infectious diseases (2015). PMID: 26734653 ↗

    L2COHORTCited in: Definition, Classification and Causative Organisms
  58. [58]

    Tong SYC, Fowler VG, Skalla L et al.. “Management of Staphylococcus aureus Bacteremia: A Review.” JAMA (2025). PMID: 40193249 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History
  59. [59]

    Raff AB, Kroshinsky D. “Cellulitis: A Review.” JAMA (2016). PMID: 27434444 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications, Special Hosts and Populations
  60. [60]

    Heidary M, Khosravi AD, Khoshnood S et al.. “Daptomycin.” The Journal of antimicrobial chemotherapy (2018). PMID: 29059358 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  61. [61]

    Livermore DM. “Future directions with daptomycin.” The Journal of antimicrobial chemotherapy (2008). PMID: 18829725 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  62. [62]

    Moellering RC. “MRSA: the first half century.” The Journal of antimicrobial chemotherapy (2011). PMID: 22010206 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  63. [63]

    Tenover FC, Goering RV. “Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology.” The Journal of antimicrobial chemotherapy (2009). PMID: 19608582 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors
  64. [64]

    Dryden MS. “Complicated skin and soft tissue infection.” The Journal of antimicrobial chemotherapy (2010). PMID: 20876627 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Empiric Management, Acute Care and Source Control, Special Hosts and Populations
  65. [65]

    Troeman DPR, Van Hout D, Kluytmans JAJW. “Antimicrobial approaches in the prevention of Staphylococcus aureus infections: a review.” The Journal of antimicrobial chemotherapy (2019). PMID: 30376041 ↗

    L1REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Prevention and Infection Control
  66. [66]

    Morgan M. “Methicillin-resistant Staphylococcus aureus and animals: zoonosis or humanosis?” The Journal of antimicrobial chemotherapy (2008). PMID: 18819971 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms
  67. [67]

    Barrett L, Atkins B. “The clinical presentation of prosthetic joint infection.” The Journal of antimicrobial chemotherapy (2014). PMID: 25135085 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup
  68. [68]

    Cuervo G, Chesdachai S, Hindy JR et al.. “Clinical Features of Adult Patients with Isolated Pulmonary Valve Endocarditis: A Systematic Review.” Microorganisms (2026). PMID: 42354833 ↗

    L4SR_OBSCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Severity Assessment and Risk Stratification, Prognosis and Natural History
  69. [69]

    Lowenthal A, Weisblum-Neuman H, Birk E et al.. “Clinical Features and Comparison of Kingella and Non-Kingella Endocarditis in Children, Israel.” Emerging infectious diseases (2021). PMID: 33622463 ↗

    L3REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, History and Evolution of Treatment, Special Hosts and Populations
  70. [70]

    Lee YW, Huh JW, Hong SB et al.. “Severe Pneumonia Caused by Corynebacterium striatum in Adults, Seoul, South Korea, 2014-2019.” Emerging infectious diseases (2022). PMID: 36287034 ↗

    L3REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control
  71. [71]

    Moellering RC. “A 39-year-old man with a skin infection.” JAMA (2007). PMID: 18056894 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  72. [72]

    Sakoulas G, Olson J, Yim J et al.. “Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent Staphylococcus aureus Bacteremia.” Antimicrobial agents and chemotherapy (2016). PMID: 27572414 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  73. [73]

    Totten KMC, Patel R. “Phage Activity against Planktonic and Biofilm Staphylococcus aureus Periprosthetic Joint Infection Isolates.” Antimicrobial agents and chemotherapy (2021). PMID: 34662191 ↗

    L5CASE_REPORTCited in: Definition, Classification and Causative Organisms
  74. [74]

    . “Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050.” Lancet (London, England) (2024). PMID: 39299261 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Prognosis and Natural History, Prevention and Infection Control, Special Hosts and Populations
  75. [75]

    Tissari P, Zumla A, Tarkka E et al.. “Accurate and rapid identification of bacterial species from positive blood cultures with a DNA-based microarray platform: an observational study.” Lancet (London, England) (2009). PMID: 20004964 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  76. [76]

    Sánchez-Villamil JP, Morales-Peña VA, Flórez-Joya JF. “Prevalence of methicillin-resistant Staphylococcus aureus carriers in dental care staff: A systematic review and meta-analysis.” Biomedica : revista del Instituto Nacional de Salud (2026). PMID: 42413096 ↗

    L1SR_OBSCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors
  77. [77]

    Khatatba LZ, Daraghmeh DN. “Bacterial profiles, antibiotic resistance, and recurrence of UTIs during pregnancy: a prospective cohort study from Palestine.” BMC infectious diseases (2026). PMID: 42426664 ↗

    L2COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Special Hosts and Populations
  78. [78]

    Cusumano JA, Dupper AC, Malik Y et al.. “Staphylococcus aureus Bacteremia in Patients Infected With COVID-19: A Case Series.” Open forum infectious diseases (2020). PMID: 33269299 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup
  79. [79]

    Newman N, Bantikassegn A, West TG et al.. “An Unusual Etiology of Lemierre-Like Syndrome: Preseptal Cellulitis due to Methicillin-Resistant Staphylococcus aureus.” Open forum infectious diseases (2022). PMID: 35531375 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Complications
  80. [80]

    Bethe A, Schink AK, Brombach J et al.. “Panton-Valentine Leukocidin-Positive Staphylococcus aureus in Family and Pet Cat.” Emerging infectious diseases (2024). PMID: 39043433 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  81. [81]

    Shoji K, Yoshida K, Takenouchi M et al.. “Skin Infections Caused by Panton-Valentine Leukocidin and Methicillin-Susceptible Staphylococcus aureus in Child, Japan.” Emerging infectious diseases (2025). PMID: 40439546 ↗

    L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Special Hosts and Populations
  82. [82]

    Dasenbrook EC, Checkley W, Merlo CA et al.. “Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis.” JAMA (2010). PMID: 20551409 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Prognosis and Natural History, Special Hosts and Populations
  83. [83]

    Klevens RM, Morrison MA, Nadle J et al.. “Invasive methicillin-resistant Staphylococcus aureus infections in the United States.” JAMA (2007). PMID: 17940231 ↗

    L4OTHERCited in: Definition, Classification and Causative Organisms, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  84. [84]

    Hogan S, O'Gara JP, O'Neill E. “Novel Treatment of Staphylococcus aureus Device-Related Infections Using Fibrinolytic Agents.” Antimicrobial agents and chemotherapy (2018). PMID: 29203484 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  85. [85]

    Hull RC, Wright RCT, Sayers JR et al.. “Antibiotics Limit Adaptation of Drug-Resistant Staphylococcus aureus to Hypoxia.” Antimicrobial agents and chemotherapy (2022). PMID: 36409116 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Prognosis and Natural History
  86. [86]

    Gehrke AE, Mendoza-Bertelli A, Ledo C et al.. “Neutralization of Staphylococcus aureus Protein A Prevents Exacerbated Osteoclast Activity and Bone Loss during Osteomyelitis.” Antimicrobial agents and chemotherapy (2022). PMID: 36533935 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors
  87. [87]

    Valour F, Trouillet-Assant S, Riffard N et al.. “Antimicrobial activity against intraosteoblastic Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2015). PMID: 25605365 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  88. [88]

    Ai Q, Wang S, Chen Z et al.. “Synergistic antibacterial activity and prevention of drug resistance of daptomycin combined with fosfomycin against methicillin-resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2025). PMID: 40530996 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  89. [89]

    Truong-Bolduc QC, Wang Y, Lawton BG et al.. “NorA and Tet38 efflux pumps enable Staphylococcus aureus survival in the cystic fibrosis airway environment, resistance to antibiotics, and coinfection with Pseudomonas aeruginosa.” Antimicrobial agents and chemotherapy (2025). PMID: 40631986 ↗

    L5OTHERCited in: Definition, Classification and Causative Organisms, Prognosis and Natural History
  90. [90]

    Shah S, Clarke LG, Ludwig J et al.. “Carbapenem combination therapy versus standard of care for persistent methicillin-susceptible Staphylococcus aureus bacteraemia.” The Journal of antimicrobial chemotherapy (2024). PMID: 38946294 ↗

    L3OTHERCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control
  91. [91]

    Kihlberg P, Bech Johannesen T, Stegger M et al.. “Reliability of disc diffusion testing and molecular epidemiology of penicillin-susceptible Staphylococcus aureus bacteraemia.” The Journal of antimicrobial chemotherapy (2025). PMID: 40492523 ↗

    L4OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  92. [92]

    Goodman AL, Easom N, Bielopolski D et al.. “A review of the randomized clinical trial results from the Staphylococcus aureus network adaptive platform (SNAP) meticillin-susceptible (MSSA) and penicillin-susceptible (PSSA) domains and CloCeBa.” The Journal of antimicrobial chemotherapy (2026). PMID: 42396858 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  93. [93]

    Huang GJ, Chen ZQ, Long CQ et al.. “Beyond dysbiosis: microbial metabolites as key remodelers of nasal mucosal immune tolerance in chronic rhinosinusitis.” Frontiers in immunology (2026). PMID: 42382746 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms
  94. [94]

    Berg DM, Binkley A, Foster SD et al.. “Clinical Microbiology in Xylazine-Associated Wound Infections.” Open forum infectious diseases (2025). PMID: 40799792 ↗

    L3OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  95. [95]

    Fabre V, Cosgrove SE, Hsu YJ et al.. “Multicenter Evaluation of Antibiotic Use and Antibiotic Stewardship Programs in Latin American Hospitals.” Open forum infectious diseases (2025). PMID: 40689250 ↗

    L4OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship
  96. [96]

    Alonso-Menchén D, Bouza E, Valerio M et al.. “Non-nosocomial Healthcare-Associated Infective Endocarditis: A Distinct Entity? Data From the GAMES Series (2008-2021).” Open forum infectious diseases (2023). PMID: 37564744 ↗

    L3OTHERCited in: Definition, Classification and Causative Organisms
  97. [97]

    Flurin L, Fisher CR, Wolf MJ et al.. “Comparison of Blood-Based Shotgun and Targeted Metagenomic Sequencing for Microbiological Diagnosis of Infective Endocarditis.” Open forum infectious diseases (2023). PMID: 38075017 ↗

    L4OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup
  98. [98]

    Kim DY, Kim UJ, Yu Y et al.. “Microbial Etiology of Pyogenic Vertebral Osteomyelitis According to Patient Characteristics.” Open forum infectious diseases (2020). PMID: 32523973 ↗

    L4OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup
  99. [99]

    McCormick DW, Kaplan J, Whigham C et al.. “The Changing Epidemiology and Microbiology of Patients With Prostate Abscess: Increase in Staphylococcal Infection.” Open forum infectious diseases (2021). PMID: 34805434 ↗

    L4OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Clinical Presentation
  100. [100]

    Panesso D, Planet PJ, Diaz L et al.. “Methicillin-Susceptible, Vancomycin-Resistant Staphylococcus aureus, Brazil.” Emerging infectious diseases (2015). PMID: 26402569 ↗

    L4OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  101. [101]

    Boudebouch N, Sarih M, Chakib A et al.. “Blood Culture-Negative Endocarditis, Morocco.” Emerging infectious diseases (2017). PMID: 29048299 ↗

    L4OTHERCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup
  102. [102]

    Baum M, Anuka E, Davidovich-Cohen M et al.. “ST913-IVa-t991 Methicillin-Resistant Staphylococcus aureus among Pediatric Patients, Israel.” Emerging infectious diseases (2024). PMID: 39043440 ↗

    L4OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Special Hosts and Populations
  103. [103]

    Xu Q, Almudervar A, Casey JR et al.. “Nasopharyngeal bacterial interactions in children.” Emerging infectious diseases (2012). PMID: 23092680 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Special Hosts and Populations
  104. [104]

    Williamson DA, Zhang J, Ritchie SR et al.. “Staphylococcus aureus infections in New Zealand, 2000-2011.” Emerging infectious diseases (2014). PMID: 24960446 ↗

    L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Special Hosts and Populations
  105. [105]

    LeBlanc L, Pépin J, Toulouse K et al.. “Fluoroquinolones and risk for methicillin-resistant Staphylococcus aureus, Canada.” Emerging infectious diseases (2006). PMID: 17073089 ↗

    L3OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  106. [106]

    Silva MJDR, Stephen AH, Dias E et al.. “Aortic Infections-A Narrative Review.” Surgical infections (2026). PMID: 42421298 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms
  107. [107]

    Busti A, Annoni G, Napoleone CP. “Endocarditis in Adults with Congenital Heart Disease.” Methodist DeBakey cardiovascular journal (2026). PMID: 42403547 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Complications
  108. [108]

    Deng L, Ling X, Li L et al.. “Advances in Scalp Microbiome Research: Molecular Insights into the Metabolism-Inflammation-Barrier Axis and Dandruff Pathogenesis.” Molecules (Basel, Switzerland) (2026). PMID: 42357491 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms
  109. [109]

    Ramadani A, Marco G, Vazquez O et al.. “Osteoarticular Infections in Immunocompetent Children Due to Atypical, Fastidious or Unusual Bacterial Pathogens: A Review.” Pathogens (Basel, Switzerland) (2026). PMID: 42347261 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms
  110. [110]

    Karthikeyan A, Javaid A, Charway GNA et al.. “Prophages in Skin Pathogens: From Virulence to Therapy.” Pathogens (Basel, Switzerland) (2026). PMID: 42347211 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms
  111. [111]

    Shallcross LJ, Fragaszy E, Johnson AM et al.. “The role of the Panton-Valentine leucocidin toxin in staphylococcal disease: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2012). PMID: 23103172 ↗

    L1SR_OBSCited in: Microbiology and Pathogenesis, Severity Assessment and Risk Stratification, Prognosis and Natural History
  112. [112]

    Deen J, von Seidlein L, Andersen F et al.. “Community-acquired bacterial bloodstream infections in developing countries in south and southeast Asia: a systematic review.” The Lancet. Infectious diseases (2012). PMID: 22632186 ↗

    L2SR_OBSCited in: Microbiology and Pathogenesis, Diagnosis and Workup
  113. [113]

    Berger S, Kunerl A, Wasmuth S et al.. “Menstrual toxic shock syndrome: case report and systematic review of the literature.” The Lancet. Infectious diseases (2019). PMID: 31151811 ↗

    L4SR_OBSCited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Complications
  114. [114]

    Anpalagan K, Dotel R, MacFadden DR et al.. “Does Adjunctive Clindamycin Have a Role in Staphylococcus aureus Bacteremia? A Protocol for the Adjunctive Treatment Domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) Randomized Controlled Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38801783 ↗

    L5TRIAL_NONRANDOMCited in: Microbiology and Pathogenesis
  115. [115]

    Bart SM, Farley JJ, Bala S et al.. “Geographic Shifts in Antibacterial Drug Clinical Trial Enrollment: Implications for Generalizability.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32161946 ↗

    L2TRIAL_NONRANDOMCited in: Microbiology and Pathogenesis
  116. [116]

    François B, Jafri HS, Chastre J et al.. “Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.” The Lancet. Infectious diseases (2021). PMID: 33894131 ↗

    L1RCTCited in: Microbiology and Pathogenesis, History and Evolution of Treatment, Complications
  117. [117]

    Contou D, Colin G, Travert B et al.. “Menstrual Toxic Shock Syndrome: A French Nationwide Multicenter Retrospective Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 33906228 ↗

    L3COHORTCited in: Microbiology and Pathogenesis, Severity Assessment and Risk Stratification, Special Hosts and Populations
  118. [118]

    Critchley IA, Eckburg PB, Jandourek A et al.. “Review of ceftaroline fosamil microbiology: integrated FOCUS studies.” The Journal of antimicrobial chemotherapy (2011). PMID: 21482569 ↗

    L5RCTCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment
  119. [119]

    Karlowsky JA, Steenbergen J, Zhanel GG. “Microbiology and Preclinical Review of Omadacycline.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 31367743 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  120. [120]

    Gordon RJ, Lowy FD. “Pathogenesis of methicillin-resistant Staphylococcus aureus infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18462090 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  121. [121]

    Appelbaum PC. “Microbiology of antibiotic resistance in Staphylococcus aureus.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2007). PMID: 17712742 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  122. [122]

    Cameron DR, Howden BP, Peleg AY. “The interface between antibiotic resistance and virulence in Staphylococcus aureus and its impact upon clinical outcomes.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21865195 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  123. [123]

    Miller LG, Diep BA. “Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18220477 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  124. [124]

    Jones RN. “Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2010). PMID: 20597676 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  125. [125]

    Cho SY, Chung DR. “Infection Prevention Strategy in Hospitals in the Era of Community-Associated Methicillin-Resistant Staphylococcus aureus in the Asia-Pacific Region: A Review.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2017). PMID: 28475795 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Prevention and Infection Control
  126. [126]

    Campbell AJ, Dotel R, Blyth CC et al.. “Adjunctive protein synthesis inhibitor antibiotics for toxin suppression in Staphylococcus aureus infections: a systematic appraisal.” The Journal of antimicrobial chemotherapy (2019). PMID: 30307507 ↗

    L5SR_OBSCited in: Microbiology and Pathogenesis
  127. [127]

    Pham TM, Zhang Y, Nevers M et al.. “Trends in infection incidence and antimicrobial resistance in the US Veterans Affairs Healthcare System: a nationwide retrospective cohort study (2007-22).” The Lancet. Infectious diseases (2024). PMID: 39151443 ↗

    L3COHORTCited in: Microbiology and Pathogenesis
  128. [128]

    Hidron AI, Low CE, Honig EG et al.. “Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia.” The Lancet. Infectious diseases (2009). PMID: 19467478 ↗

    L5CASE_REPORTCited in: Microbiology and Pathogenesis, Clinical Presentation
  129. [129]

    Yaw LK, Robinson JO, Ho KM. “A comparison of long-term outcomes after meticillin-resistant and meticillin-sensitive Staphylococcus aureus bacteraemia: an observational cohort study.” The Lancet. Infectious diseases (2014). PMID: 25185461 ↗

    L3COHORTCited in: Microbiology and Pathogenesis, Complications, Prognosis and Natural History
  130. [130]

    Sievert DM, Rudrik JT, Patel JB et al.. “Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18257700 ↗

    L4CASE_REPORTCited in: Microbiology and Pathogenesis, Prevention and Infection Control
  131. [131]

    Jiang J-H, Cameron DR, Nethercott C et al.. “Virulence attributes of successful methicillin-resistant Staphylococcus aureus lineages.” Clinical microbiology reviews (2023). PMID: 37982596 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  132. [132]

    Grousd JA, Rich HE, Alcorn JF. “Host-Pathogen Interactions in Gram-Positive Bacterial Pneumonia.” Clinical microbiology reviews (2019). PMID: 31142498 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  133. [133]

    Hodille E, Rose W, Diep BA et al.. “The Role of Antibiotics in Modulating Virulence in Staphylococcus aureus.” Clinical microbiology reviews (2017). PMID: 28724662 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  134. [134]

    Speziale P, Foster TJ, Arciola CR. “The endothelium at the interface between tissues and Staphylococcus aureus in the bloodstream.” Clinical microbiology reviews (2025). PMID: 39807893 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  135. [135]

    Spaulding AR, Salgado-Pabón W, Kohler PL et al.. “Staphylococcal and streptococcal superantigen exotoxins.” Clinical microbiology reviews (2013). PMID: 23824366 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Complications
  136. [136]

    Frank KL, Del Pozo JL, Patel R. “From clinical microbiology to infection pathogenesis: how daring to be different works for Staphylococcus lugdunensis.” Clinical microbiology reviews (2008). PMID: 18202439 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  137. [137]

    Heilbronner S, Foster TJ. “Staphylococcus lugdunensis: a Skin Commensal with Invasive Pathogenic Potential.” Clinical microbiology reviews (2020). PMID: 33361142 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Prognosis and Natural History
  138. [138]

    Kahl BC, Becker K, Löffler B. “Clinical Significance and Pathogenesis of Staphylococcal Small Colony Variants in Persistent Infections.” Clinical microbiology reviews (2016). PMID: 26960941 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup
  139. [139]

    Trastoy R, Manso T, Fernández-García L et al.. “Mechanisms of Bacterial Tolerance and Persistence in the Gastrointestinal and Respiratory Environments.” Clinical microbiology reviews (2018). PMID: 30068737 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  140. [140]

    Baker MA, Sands KE, Huang SS et al.. “The Impact of Coronavirus Disease 2019 (COVID-19) on Healthcare-Associated Infections.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34370014 ↗

    L3OTHERCited in: Microbiology and Pathogenesis
  141. [141]

    Diep BA, Gill SR, Chang RF et al.. “Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus.” Lancet (London, England) (2006). PMID: 16517273 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  142. [142]

    Suh GA, Lodise TP, Tamma PD et al.. “Considerations for the Use of Phage Therapy in Clinical Practice.” Antimicrobial agents and chemotherapy (2022). PMID: 35041506 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Antimicrobial Resistance and Stewardship
  143. [143]

    Garcia LG, Lemaire S, Kahl BC et al.. “Antibiotic activity against small-colony variants of Staphylococcus aureus: review of in vitro, animal and clinical data.” The Journal of antimicrobial chemotherapy (2013). PMID: 23485724 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  144. [144]

    Moran GJ, Krishnadasan A, Gorwitz RJ et al.. “Methicillin-resistant S. aureus infections among patients in the emergency department.” The New England journal of medicine (2006). PMID: 16914702 ↗

    L4OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  145. [145]

    Köser CU, Holden MT, Ellington MJ et al.. “Rapid whole-genome sequencing for investigation of a neonatal MRSA outbreak.” The New England journal of medicine (2012). PMID: 22693998 ↗

    L4OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  146. [146]

    Schuler F, Barth PJ, Niemann S et al.. “A Narrative Review on the Role of Staphylococcus aureus Bacteriuria in S. aureus Bacteremia.” Open forum infectious diseases (2021). PMID: 34189162 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  147. [147]

    Corsini Campioli C, Go JR, Abu Saleh O et al.. “Antistaphylococcal Penicillin vs Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Spinal Epidural Abscesses.” Open forum infectious diseases (2021). PMID: 33738321 ↗

    L3REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control
  148. [148]

    Chertow DS, Memoli MJ. “Bacterial coinfection in influenza: a grand rounds review.” JAMA (2013). PMID: 23321766 ↗

    L5CASE_REPORTCited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications
  149. [149]

    Shah A, Romagnoli R, Dhingra N et al.. “Mediastinitis after cardiac surgery, from microbes to management: a systematic review.” Mediastinum (Hong Kong, China) (2026). PMID: 42427474 ↗

    L2SR_OBSCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Prognosis and Natural History, Prevention and Infection Control
  150. [150]

    Orhan Z, Doğan S, Mohamud SM et al.. “Antimicrobial resistance profiles of ESKAPE pathogens isolated in a microbiology laboratory in Somalia: a two-year retrospective study.” BMC infectious diseases (2026). PMID: 42410515 ↗

    L4COHORTCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  151. [151]

    Joris G, Jozef D, Petra H et al.. “How stable are antimicrobial susceptibility profiles in serial clinical isolates? A retrospective study informing repeat-testing strategies.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2026). PMID: 42398659 ↗

    L4COHORTCited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  152. [152]

    Palmer A, Carter M, Yeo J et al.. “Hospital-Admitted Injection-Related Infections Among Incarcerated People Who Inject Drugs in Australia: A Retrospective Cohort Study.” The Medical journal of Australia (2026). PMID: 42289398 ↗

    L4COHORTCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Complications, Prognosis and Natural History
  153. [153]

    Diekema DJ, Hsueh PR, Mendes RE et al.. “The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program.” Antimicrobial agents and chemotherapy (2019). PMID: 31010862 ↗

    L4OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship
  154. [154]

    Boyd JM, Price EE, Roman Rodriguez F et al.. “Treatment of Staphylococcus aureus with environmentally relevant concentrations of triclosan activates SaeRS-dependent virulence factor expression.” Antimicrobial agents and chemotherapy (2025). PMID: 40531055 ↗

    L5OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control
  155. [155]

    Kwiecinski JM, Jelani DA, Fuentes EJ et al.. “Therapeutic Inhibition of Staphylococcus aureus ArlRS Two-Component Regulatory System Blocks Virulence.” Antimicrobial agents and chemotherapy (2022). PMID: 35736133 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  156. [156]

    Mahé A, Verneuil N, Coupri D et al.. “D-alanylation of lipoteichoic acids inhibitor provides anti-virulence and anti-resistance effects against methicillin-resistant Staphylococcus epidermidis.” Antimicrobial agents and chemotherapy (2025). PMID: 40116514 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  157. [157]

    McConville TH, Austin ED, Geng W et al.. “In Vitro Cytotoxicity and Clinical Correlates of MRSA Bacteremia.” Antimicrobial agents and chemotherapy (2021). PMID: 34748383 ↗

    L4OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup
  158. [158]

    Kong X, Wang B, Chen X et al.. “Hinokiflavone Attenuates the Virulence of Methicillin-Resistant Staphylococcus aureus by Targeting Caseinolytic Protease P.” Antimicrobial agents and chemotherapy (2022). PMID: 35862746 ↗

    L5OTHERCited in: Microbiology and Pathogenesis, History and Evolution of Treatment
  159. [159]

    Daly SM, Elmore BO, Kavanaugh JS et al.. “ω-Hydroxyemodin limits staphylococcus aureus quorum sensing-mediated pathogenesis and inflammation.” Antimicrobial agents and chemotherapy (2015). PMID: 25645827 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  160. [160]

    Gomi S, Price E, Burgoyne H et al.. “Omadacycline exhibits anti-inflammatory properties and improves survival in a murine model of post-influenza MRSA pneumonia.” Antimicrobial agents and chemotherapy (2025). PMID: 40757816 ↗

    L5OTHERCited in: Microbiology and Pathogenesis, Prognosis and Natural History
  161. [161]

    Luther MK, Parente DM, Caffrey AR et al.. “Clinical and Genetic Risk Factors for Biofilm-Forming Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2018). PMID: 29530854 ↗

    L4OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors
  162. [162]

    Khodaverdian V, Pesho M, Truitt B et al.. “Discovery of antivirulence agents against methicillin-resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2013). PMID: 23689713 ↗

    L5OTHERCited in: Microbiology and Pathogenesis, Prevention and Infection Control
  163. [163]

    Guillamet MCV, Vazquez R, Deaton B et al.. “Host-Pathogen-Treatment Triad: Host Factors Matter Most in Methicillin-Resistant Staphylococcus aureus Bacteremia Outcomes.” Antimicrobial agents and chemotherapy (2018). PMID: 29203479 ↗

    L4OTHERCited in: Microbiology and Pathogenesis
  164. [164]

    Xu W, Yan P, Li Y et al.. “The toxin-antitoxin system SavRS contributes to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus by mediating cell wall thickening.” The Journal of antimicrobial chemotherapy (2025). PMID: 40985144 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  165. [165]

    Koszczol C, Bernardo K, Krönke M et al.. “Subinhibitory quinupristin/dalfopristin attenuates virulence of Staphylococcus aureus.” The Journal of antimicrobial chemotherapy (2006). PMID: 16895938 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  166. [166]

    Deplano A, Hallin M, Bustos Sierra N et al.. “Persistence of the Staphylococcus aureus epidemic European fusidic acid-resistant impetigo clone (EEFIC) in Belgium.” The Journal of antimicrobial chemotherapy (2023). PMID: 37358399 ↗

    L4OTHERCited in: Microbiology and Pathogenesis
  167. [167]

    Gomez-Villegas SI, Rincon S, Carvajal LP et al.. “Validation of a modified rapid test to detect the cefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus from bloodstream infections in hospitals from North and Latin America.” The Journal of antimicrobial chemotherapy (2025). PMID: 40126549 ↗

    L4OTHERCited in: Microbiology and Pathogenesis
  168. [168]

    Guo Y, Han R, Zhang G et al.. “Setting of the tentative epidemiological cut-off values of contezolid for Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Streptococcus pneumoniae and Streptococcus agalactiae.” The Journal of antimicrobial chemotherapy (2023). PMID: 36849586 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  169. [169]

    Deplano A, Dodémont M, Denis O et al.. “European external quality assessments for identification, molecular typing and characterization of Staphylococcus aureus.” The Journal of antimicrobial chemotherapy (2018). PMID: 30099486 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  170. [170]

    Pant N, Wallis SC, Roberts JA et al.. “In vitro effect of synovial fluid from patients undergoing arthroplasty surgery on MRSA biofilm formation.” The Journal of antimicrobial chemotherapy (2022). PMID: 35045178 ↗

    L5OTHERCited in: Microbiology and Pathogenesis
  171. [171]

    Kaneko H, Yanagi Y, Otake S et al.. “The emerging threat of methicillin-resistant Staphylococcus aureus (MRSA) clone ST22-PT, carrying both Panton-Valentine leucocidin and toxic shock syndrome toxin 1 genes.” The Journal of antimicrobial chemotherapy (2023). PMID: 36814074 ↗

    L4OTHERCited in: Microbiology and Pathogenesis
  172. [172]

    Hanawa T, Tanaka M, Nagano DS et al.. “Innate immune recognition and immunomodulatory effects of bacteriophages: implications for phage therapy.” Frontiers in immunology (2026). PMID: 42367797 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  173. [173]

    Fairholm JD, Paul GT, Birket S et al.. “Microbial and host innate immune factors affecting the persistence of Staphylococcus aureus in cystic fibrosis airways.” Frontiers in cellular and infection microbiology (2026). PMID: 42318016 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Complications, Prognosis and Natural History
  174. [174]

    Ge Y, Wang Y, He X et al.. “Comprehensive management of hemodialysis catheter-related bloodstream infections: a narrative review.” Frontiers in cellular and infection microbiology (2026). PMID: 42312032 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors
  175. [175]

    de Waha S, Noack T, Kister T et al.. “Tricuspid valve endocarditis in people who inject drugs: strategies to reduce mortality and recurrent infection.” Annals of cardiothoracic surgery (2026). PMID: 42292592 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Clinical Presentation
  176. [176]

    Calvão J, Iselin C, Wasmayr J et al.. “Pathogenesis of cutaneous T-cell lymphoma: Malignant inflammation, immune reprogramming, and microenvironmental drivers.” The Journal of investigative dermatology (2026). PMID: 42274451 ↗

    L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis
  177. [177]

    Musgrove MA, Kenney RM, Kendall RE et al.. “Microbiology Comment Nudge Improves Pneumonia Prescribing.” Open forum infectious diseases (2018). PMID: 30057928 ↗

    L4OTHERCited in: Microbiology and Pathogenesis, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  178. [178]

    Hindy JR, Quintero-Martinez JA, Lahr BD et al.. “Incidence of Monomicrobial Staphylococcus aureus Bacteremia: A Population-Based Study in Olmsted County, Minnesota-2006 to 2020.” Open forum infectious diseases (2022). PMID: 35794939 ↗

    L2OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors
  179. [179]

    Go JR, Challener D, Corsini Campioli C et al.. “Clinical Significance of Staphylococcus aureus in a Single Positive Blood Culture Bottle.” Open forum infectious diseases (2021). PMID: 35071685 ↗

    L2OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Severity Assessment and Risk Stratification, Prognosis and Natural History
  180. [180]

    Kim JJ, Kang H, Stewart KO. “The Effect of Retained Hardware on Failure Among Prosthetic Joint Infections of the Knee in the Presence and Absence of Staphylococcus aureus.” Open forum infectious diseases (2024). PMID: 38919513 ↗

    L2OTHERCited in: Microbiology and Pathogenesis
  181. [181]

    Pralea A, Has P, Auld D et al.. “Microbes Causing Spinal Epidural Infection in Patients Who Use Drugs.” Open forum infectious diseases (2024). PMID: 39416991 ↗

    L4OTHERCited in: Microbiology and Pathogenesis, History and Evolution of Treatment
  182. [182]

    Khamash DF, Mongodin EF, White JR et al.. “The Association Between the Developing Nasal Microbiota of Hospitalized Neonates and Staphylococcus aureus Colonization.” Open forum infectious diseases (2019). PMID: 30949531 ↗

    L3OTHERCited in: Microbiology and Pathogenesis
  183. [183]

    Muñoz-Gallego I, Viedma E, Esteban J et al.. “Genotypic and Phenotypic Characteristics of Staphylococcus aureus Prosthetic Joint Infections: Insight on the Pathogenesis and Prognosis of a Multicenter Prospective Cohort.” Open forum infectious diseases (2020). PMID: 33005695 ↗

    L2OTHERCited in: Microbiology and Pathogenesis, Clinical Presentation, Severity Assessment and Risk Stratification
  184. [184]

    Simmons SC, Budavari AI, Kusne S et al.. “Culture-Proven Thorn-Associated Infections in Arizona: 10-Year Experience at Mayo Clinic.” Open forum infectious diseases (2017). PMID: 28480288 ↗

    L4OTHERCited in: Microbiology and Pathogenesis
  185. [185]

    Sieber RN, Urth TR, Petersen A et al.. “Phage-Mediated Immune Evasion and Transmission of Livestock-Associated Methicillin-Resistant Staphylococcus aureus in Humans.” Emerging infectious diseases (2020). PMID: 33079052 ↗

    L2OTHERCited in: Microbiology and Pathogenesis, Special Hosts and Populations
  186. [186]

    Coombs GW, Pang S, Daley DA et al.. “Severe Disease Caused by Community-Associated MRSA ST398 Type V, Australia, 2017.” Emerging infectious diseases (2019). PMID: 30561308 ↗

    L4OTHERCited in: Microbiology and Pathogenesis, Prognosis and Natural History
  187. [187]

    Coombs GW, Pearson JC, O'Brien FG et al.. “Methicillin-resistant Staphylococcus aureus clones, Western Australia.” Emerging infectious diseases (2006). PMID: 16494749 ↗

    L2OTHERCited in: Microbiology and Pathogenesis
  188. [188]

    Sharma H, Smith D, Turner CE et al.. “Clinical and Molecular Epidemiology of Staphylococcal Toxic Shock Syndrome in the United Kingdom.” Emerging infectious diseases (2018). PMID: 29350159 ↗

    L4OTHERCited in: Microbiology and Pathogenesis
  189. [189]

    Sun L, Chen Y, Wang D et al.. “Surgical Site Infections Caused by Highly Virulent Methicillin-Resistant Staphylococcus aureus Sequence Type 398, China.” Emerging infectious diseases (2019). PMID: 30561317 ↗

    L4OTHERCited in: Microbiology and Pathogenesis
  190. [190]

    Tristan A, Bes M, Meugnier H et al.. “Global distribution of Panton-Valentine leukocidin--positive methicillin-resistant Staphylococcus aureus, 2006.” Emerging infectious diseases (2007). PMID: 17553275 ↗

    L2OTHERCited in: Microbiology and Pathogenesis
  191. [191]

    Kajumbula H, Fujita AW, Mbabazi O et al.. “Antimicrobial Drug Resistance in Blood Culture Isolates at a Tertiary Hospital, Uganda.” Emerging infectious diseases (2018). PMID: 29260682 ↗

    L2OTHERCited in: Microbiology and Pathogenesis
  192. [192]

    Hageman JC, Uyeki TM, Francis JS et al.. “Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season.” Emerging infectious diseases (2006). PMID: 16707043 ↗

    L4OTHERCited in: Microbiology and Pathogenesis
  193. [193]

    Ferdinands JM, Denison AM, Dowling NF et al.. “A pilot study of host genetic variants associated with influenza-associated deaths among children and young adults.” Emerging infectious diseases (2011). PMID: 22172537 ↗

    L3OTHERCited in: Microbiology and Pathogenesis, Complications, Prognosis and Natural History
  194. [194]

    Hutchinson K, Banks J, Arnold A et al.. “Orthoplastic management of delayed sternal osteomyelitis and non-union: a retrospective case series applying fracture-related infection principles.” International orthopaedics (2026). PMID: 42329262 ↗

    L4CASE_REPORTCited in: Microbiology and Pathogenesis, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  195. [195]

    Shi L, Ruan Y, Wang X et al.. “First fatal human bloodstream infection caused by Macrococcus caseolyticus subsp. caseolyticus in China: genomic insights into virulence and antimicrobial resistance.” Frontiers in cellular and infection microbiology (2026). PMID: 42306534 ↗

    L4CASE_REPORTCited in: Microbiology and Pathogenesis
  196. [196]

    Baur D, Gladstone BP, Burkert F et al.. “Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2017). PMID: 28629876 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  197. [197]

    Tacconelli E, De Angelis G, de Waure C et al.. “Rapid screening tests for meticillin-resistant Staphylococcus aureus at hospital admission: systematic review and meta-analysis.” The Lancet. Infectious diseases (2009). PMID: 19695491 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History
  198. [198]

    Nellums LB, Thompson H, Holmes A et al.. “Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2018). PMID: 29779917 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  199. [199]

    Strömdahl M, Hagman K, Hedman K et al.. “Time to Staphylococcus aureus Blood Culture Positivity as a Risk Marker of Infective Endocarditis: A Retrospective Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39707905 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History
  200. [200]

    Shappell CN, Yu T, Klompas M et al.. “Frequency of Antibiotic Overtreatment and Associated Harms in Patients Presenting With Suspected Sepsis to the Emergency Department: A Retrospective Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 40231968 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History
  201. [201]

    Huang SS, Singh R, McKinnell JA et al.. “Decolonization to Reduce Postdischarge Infection Risk among MRSA Carriers.” The New England journal of medicine (2019). PMID: 30763195 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History, Prevention and Infection Control
  202. [202]

    Peel TN, Astbury S, Cheng AC et al.. “Trial of Vancomycin and Cefazolin as Surgical Prophylaxis in Arthroplasty.” The New England journal of medicine (2023). PMID: 37851875 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History, Prevention and Infection Control
  203. [203]

    Huskins WC, Huckabee CM, O'Grady NP et al.. “Intervention to reduce transmission of resistant bacteria in intensive care.” The New England journal of medicine (2011). PMID: 21488763 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Prevention and Infection Control
  204. [204]

    . “A randomized trial of diagnostic techniques for ventilator-associated pneumonia.” The New England journal of medicine (2006). PMID: 17182987 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup
  205. [205]

    Allegranzi B, Bagheri Nejad S, Combescure C et al.. “Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis.” Lancet (London, England) (2010). PMID: 21146207 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship
  206. [206]

    Minter DJ, Appa A, Chambers HF et al.. “Contemporary Management of Staphylococcus aureus Bacteremia-Controversies in Clinical Practice.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37950887 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  207. [207]

    Boucher HW, Corey GR. “Epidemiology of methicillin-resistant Staphylococcus aureus.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18462089 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  208. [208]

    Saravolatz LD, Stein GE. “Oritavancin: A Long-Half-Life Lipoglycopeptide.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). PMID: 25900171 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Complications
  209. [209]

    Dinh A, Ropers J, Duran C et al.. “Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.” Lancet (London, England) (2021). PMID: 33773631 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History, Special Hosts and Populations
  210. [210]

    Huang SS, Septimus E, Kleinman K et al.. “Chlorhexidine versus routine bathing to prevent multidrug-resistant organisms and all-cause bloodstream infections in general medical and surgical units (ABATE Infection trial): a cluster-randomised trial.” Lancet (London, England) (2019). PMID: 30850112 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History, Prevention and Infection Control
  211. [211]

    Kalra L, Irshad S, Hodsoll J et al.. “Prophylactic antibiotics after acute stroke for reducing pneumonia in patients with dysphagia (STROKE-INF): a prospective, cluster-randomised, open-label, masked endpoint, controlled clinical trial.” Lancet (London, England) (2015). PMID: 26343840 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications, Prognosis and Natural History, Prevention and Infection Control
  212. [212]

    Kalil AC, Van Schooneveld TC, Fey PD et al.. “Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis.” JAMA (2014). PMID: 25321910 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  213. [213]

    Cai Y, Wang R, Liang B et al.. “Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.” Antimicrobial agents and chemotherapy (2010). PMID: 21173186 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Complications
  214. [214]

    van Hal SJ, Paterson DL. “Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates.” Antimicrobial agents and chemotherapy (2010). PMID: 21078939 ↗

    L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors
  215. [215]

    Hurley JC. “The perfidious effect of topical placebo: calibration of Staphylococcus aureus ventilator-associated pneumonia incidence within selective digestive decontamination studies versus the broader evidence base.” Antimicrobial agents and chemotherapy (2013). PMID: 23836178 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors
  216. [216]

    Heizmann WR, Dupont H, Montravers P et al.. “Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies.” The Journal of antimicrobial chemotherapy (2013). PMID: 23772046 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors
  217. [217]

    Milstone AM, Voskertchian A, Koontz DW et al.. “Effect of Treating Parents Colonized With Staphylococcus aureus on Transmission to Neonates in the Intensive Care Unit: A Randomized Clinical Trial.” JAMA (2020). PMID: 31886828 ↗

    L1RCTCited in: Epidemiology, Transmission and Risk Factors, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prevention and Infection Control
  218. [218]

    Ciapponi A, Bardach A, Sandoval MM et al.. “Systematic Review and Meta-analysis of Deaths Attributable to Antimicrobial Resistance, Latin America.” Emerging infectious diseases (2023). PMID: 37877573 ↗

    L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  219. [219]

    Chuang YY, Huang YC. “Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Asia.” The Lancet. Infectious diseases (2013). PMID: 23827369 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors
  220. [220]

    Albrich WC, Harbarth S. “Health-care workers: source, vector, or victim of MRSA?” The Lancet. Infectious diseases (2008). PMID: 18471774 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors
  221. [221]

    Otter JA, French GL. “Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe.” The Lancet. Infectious diseases (2010). PMID: 20334846 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup
  222. [222]

    Bush K, Bradford PA. “Epidemiology of β-Lactamase-Producing Pathogens.” Clinical microbiology reviews (2020). PMID: 32102899 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  223. [223]

    Sauvat L, Verhoeven PO, Gagnaire J et al.. “Vaccines and monoclonal antibodies to prevent healthcare-associated bacterial infections.” Clinical microbiology reviews (2024). PMID: 39120140 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship
  224. [224]

    Galar A, Weil AA, Dudzinski DM et al.. “Methicillin-Resistant Staphylococcus aureus Prosthetic Valve Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management.” Clinical microbiology reviews (2019). PMID: 30760474 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  225. [225]

    Park S, Ronholm J. “Staphylococcus aureus in Agriculture: Lessons in Evolution from a Multispecies Pathogen.” Clinical microbiology reviews (2021). PMID: 33568553 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment
  226. [226]

    Swets MC, Bakk Z, Westgeest AC et al.. “Clinical Subphenotypes of Staphylococcus aureus Bacteremia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38916975 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History
  227. [227]

    Kam KQ, Chen T, Kadri SS et al.. “Epidemiology and Outcomes of Antibiotic De-escalation in Patients With Suspected Sepsis in US Hospitals.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39657050 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History
  228. [228]

    . “Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study.” Lancet (London, England) (2019). PMID: 31257127 ↗

    L3CASE_CONTROLCited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Special Hosts and Populations
  229. [229]

    Bengtsen KH, Falkentoft AC, Le MV et al.. “Incidence of Staphylococcus aureus Bacteremia in Patients Following Implantation of Cardiac Implantable Electronic Devices: A Danish Nationwide Cohort Study.” Open forum infectious diseases (2024). PMID: 39329108 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors
  230. [230]

    Wang A, Gaca JG, Chu VH. “Management Considerations in Infective Endocarditis: A Review.” JAMA (2018). PMID: 29971402 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History, Prevention and Infection Control
  231. [231]

    Hawkey PM, Jones AM. “The changing epidemiology of resistance.” The Journal of antimicrobial chemotherapy (2009). PMID: 19675017 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  232. [232]

    Gouliouris T, Aliyu SH, Brown NM. “Spondylodiscitis: update on diagnosis and management.” The Journal of antimicrobial chemotherapy (2010). PMID: 20876624 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Empiric Management, Acute Care and Source Control
  233. [233]

    Gu B, Kelesidis T, Tsiodras S et al.. “The emerging problem of linezolid-resistant Staphylococcus.” The Journal of antimicrobial chemotherapy (2012). PMID: 22949625 ↗

    L4REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship
  234. [234]

    Ramirez JA, Anzueto AR. “Changing needs of community-acquired pneumonia.” The Journal of antimicrobial chemotherapy (2011). PMID: 21482567 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Prognosis and Natural History
  235. [235]

    Garcia-Alvarez L, Dawson S, Cookson B et al.. “Working across the veterinary and human health sectors.” The Journal of antimicrobial chemotherapy (2012). PMID: 22855878 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors
  236. [236]

    Daneman N, Rishu A, Pinto R et al.. “Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections.” The New England journal of medicine (2024). PMID: 39565030 ↗

    L1OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  237. [237]

    Jernigan JA, Hatfield KM, Wolford H et al.. “Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017.” The New England journal of medicine (2020). PMID: 32242356 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Special Hosts and Populations
  238. [238]

    Wang Y, Chen G, Zhai N et al.. “Risk factors for 28-day mortality and pathogen characteristics of septic shock in children: a 10-year retrospective cohort study.” Frontiers in cellular and infection microbiology (2026). PMID: 42256218 ↗

    L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Special Hosts and Populations
  239. [239]

    Landrum ML, Neumann C, Cook C et al.. “Epidemiology of Staphylococcus aureus blood and skin and soft tissue infections in the US military health system, 2005-2010.” JAMA (2012). PMID: 22760291 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Special Hosts and Populations
  240. [240]

    Bae S, Kim ES, Kim HS et al.. “Risk Factors of Recurrent Infection in Patients with Staphylococcus aureus Bacteremia: a Competing Risk Analysis.” Antimicrobial agents and chemotherapy (2022). PMID: 35762799 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification
  241. [241]

    Rhodes NJ, Rohani R, Yarnold PR et al.. “Machine Learning To Stratify Methicillin-Resistant Staphylococcus aureus Risk among Hospitalized Patients with Community-Acquired Pneumonia.” Antimicrobial agents and chemotherapy (2022). PMID: 36472425 ↗

    L3OTHERCited in: Epidemiology, Transmission and Risk Factors
  242. [242]

    Svishchuk J, Ebbert K, Waddell B et al.. “Epidemiology and impact of methicillin-sensitive Staphylococcus aureus with β-lactam antibiotic inoculum effects in adults with cystic fibrosis.” Antimicrobial agents and chemotherapy (2023). PMID: 37966229 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  243. [243]

    Gross AE, Van Schooneveld TC, Olsen KM et al.. “Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia.” Antimicrobial agents and chemotherapy (2014). PMID: 24957843 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  244. [244]

    Bae S, Kook MS, Chang E et al.. “Risk and Distribution of Metastatic Infections by Primary Infection Focus in Staphylococcus aureus Bacteremia.” Open forum infectious diseases (2025). PMID: 40568004 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  245. [245]

    Biggs HM, Li R, Jackson KA et al.. “Trends in Incidence and Epidemiology of Methicillin-Resistant Staphylococcus aureus Bacteremia, Six Emerging Infections Program Surveillance Sites, 2005-2022.” Open forum infectious diseases (2025). PMID: 40453873 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup
  246. [246]

    Warren DK, Nickel KB, Wallace AE et al.. “Risk Factors for Surgical Site Infection After Cholecystectomy.” Open forum infectious diseases (2017). PMID: 28491887 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  247. [247]

    Kim T, Huh JW, Hong SB et al.. “Epidemiology and Characteristics of Respiratory Syncytial Virus Pneumonia in Critically Ill Adults.” Open forum infectious diseases (2023). PMID: 37035491 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors
  248. [248]

    Blauw M, Foxman B, Wu J et al.. “Risk Factors and Outcomes Associated With Hospital-Onset Peripheral Intravenous Catheter-Associated Staphylococcus aureus Bacteremia.” Open forum infectious diseases (2019). PMID: 30949543 ↗

    L3OTHERCited in: Epidemiology, Transmission and Risk Factors
  249. [249]

    Neofytos D, Stampf S, Hoessly LD et al.. “Bacteremia During the First Year After Solid Organ Transplantation: An Epidemiological Update.” Open forum infectious diseases (2023). PMID: 37323422 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Prevention and Infection Control
  250. [250]

    Molina KC, Lunowa C, Lebin M et al.. “Comparison of Sequential Dalbavancin With Standard-of-Care Treatment for Staphylococcus aureus Bloodstream Infections.” Open forum infectious diseases (2022). PMID: 35899276 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control
  251. [251]

    Stenhem M, Ortqvist A, Ringberg H et al.. “Imported methicillin-resistant Staphylococcus aureus, Sweden.” Emerging infectious diseases (2010). PMID: 20113546 ↗

    L4OTHERCited in: Epidemiology, Transmission and Risk Factors, Special Hosts and Populations
  252. [252]

    Thorlacius-Ussing L, Sandholdt H, Larsen AR et al.. “Age-Dependent Increase in Incidence of Staphylococcus aureus Bacteremia, Denmark, 2008-2015.” Emerging infectious diseases (2019). PMID: 31002300 ↗

    L2OTHERCited in: Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment, Special Hosts and Populations
  253. [253]

    Torres Valenzuela LM, Garza-Leon M, Beltran F et al.. “Trends in pathogens causing microbial keratitis in studies conducted in Mexico: a 38-year literature review.” International ophthalmology (2026). PMID: 42319559 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors
  254. [254]

    Akasha R, Binsaleh NK, Abdalla RAH et al.. “Infectious disease outcomes in end-stage renal disease: the influence of dialysis type on patient vulnerability in Hail region.” Frontiers in medicine (2026). PMID: 42428264 ↗

    L4OTHERCited in: Epidemiology, Transmission and Risk Factors
  255. [255]

    Berbari EF, Kanj SS, Kowalski TJ et al.. “2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). PMID: 26229122 ↗

    L1GUIDELINECited in: Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment
  256. [256]

    Kaasch AJ, López-Cortés LE, Rodríguez-Baño J et al.. “Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial.” The Lancet. Infectious diseases (2024). PMID: 38244557 ↗

    L1RCTCited in: Clinical Presentation, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History
  257. [257]

    Derde LPG, Cooper BS, Goossens H et al.. “Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial.” The Lancet. Infectious diseases (2013). PMID: 24161233 ↗

    L1RCTCited in: Clinical Presentation, History and Evolution of Treatment, Prevention and Infection Control
  258. [258]

    Buehler SS, Madison B, Snyder SR et al.. “Effectiveness of Practices To Increase Timeliness of Providing Targeted Therapy for Inpatients with Bloodstream Infections: a Laboratory Medicine Best Practices Systematic Review and Meta-analysis.” Clinical microbiology reviews (2016). PMID: 26598385 ↗

    L1SR_OBSCited in: Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History
  259. [259]

    Rubinstein E, Kollef MH, Nathwani D. “Pneumonia caused by methicillin-resistant Staphylococcus aureus.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18462093 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  260. [260]

    Aliberti S, Reyes LF, Faverio P et al.. “Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study.” The Lancet. Infectious diseases (2016). PMID: 27593581 ↗

    L2COHORTCited in: Clinical Presentation, Diagnosis and Workup
  261. [261]

    Crum-Cianflone NF. “Bacterial, fungal, parasitic, and viral myositis.” Clinical microbiology reviews (2008). PMID: 18625683 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment
  262. [262]

    van Hal SJ, Jensen SO, Vaska VL et al.. “Predictors of mortality in Staphylococcus aureus Bacteremia.” Clinical microbiology reviews (2012). PMID: 22491776 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History
  263. [263]

    Mergenhagen KA, Starr KE, Wattengel BA et al.. “Determining the Utility of Methicillin-Resistant Staphylococcus aureus Nares Screening in Antimicrobial Stewardship.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31573026 ↗

    L2OTHERCited in: Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  264. [264]

    Lamloumi M, Javerliat I, Duran C et al.. “Characteristics and Risk Factors for Mortality of Vascular Graft Infections: a Cohort Study.” Open forum infectious diseases (2026). PMID: 42415734 ↗

    L2COHORTCited in: Clinical Presentation, Severity Assessment and Risk Stratification, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  265. [265]

    Dufour S, Piroth L, Chirouze C et al.. “Staphylococcus aureus Bloodstream Infection in Patients With Prosthetic Joints in the Prospective VIRSTA Cohort Study: Frequency and Time of Occurrence of Periprosthetic Joint Infection.” Open forum infectious diseases (2019). PMID: 31890721 ↗

    L2COHORTCited in: Clinical Presentation
  266. [266]

    Shenoy ES, Macy E, Rowe T et al.. “Evaluation and Management of Penicillin Allergy: A Review.” JAMA (2019). PMID: 30644987 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications
  267. [267]

    Holland TL, Arnold C, Fowler VG. “Clinical management of Staphylococcus aureus bacteremia: a review.” JAMA (2014). PMID: 25268440 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  268. [268]

    Gould IM. “Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus.” The Journal of antimicrobial chemotherapy (2011). PMID: 21521703 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  269. [269]

    Nissen JL, Skov R, Knudsen JD et al.. “Effectiveness of penicillin, dicloxacillin and cefuroxime for penicillin-susceptible Staphylococcus aureus bacteraemia: a retrospective, propensity-score-adjusted case-control and cohort analysis.” The Journal of antimicrobial chemotherapy (2013). PMID: 23599360 ↗

    L2CASE_CONTROLCited in: Clinical Presentation
  270. [270]

    Duss FR, Garcia de la Mària C, Croxatto A et al.. “Successful treatment with daptomycin and ceftaroline of MDR Staphylococcus aureus native valve endocarditis: a case report.” The Journal of antimicrobial chemotherapy (2019). PMID: 31298264 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  271. [271]

    Takayama A, Meguro K, Yokota M et al.. “Atypical X-linked agammaglobulinemia diagnosed in adulthood with arthritis caused by a hypomorphic BTK splice-site variant: a case report and literature review.” Frontiers in immunology (2026). PMID: 42253969 ↗

    L4CASE_REPORTCited in: Clinical Presentation, History and Evolution of Treatment, Complications
  272. [272]

    Duployez C, Le Guern R, Tinez C et al.. “Panton-Valentine Leukocidin-Secreting Staphylococcus aureus Pneumonia Complicating COVID-19.” Emerging infectious diseases (2020). PMID: 32298228 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Complications
  273. [273]

    Jewell P, Dixon L, Singanayagam A et al.. “Severe Disseminated Infection with Emerging Lineage of Methicillin-Sensitive Staphylococcus aureus.” Emerging infectious diseases (2019). PMID: 30561304 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  274. [274]

    Rigaill J, Grattard F, Grange S et al.. “Community-Acquired Staphylococcus argenteus Sequence Type 2250 Bone and Joint Infection, France, 2017.” Emerging infectious diseases (2018). PMID: 30226182 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  275. [275]

    Bergevin M, Marion A, Farber D et al.. “Severe MRSA Enterocolitis Caused by a Strain Harboring Enterotoxins D, G, and I.” Emerging infectious diseases (2017). PMID: 28418301 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  276. [276]

    Oh JT, Ambler JE, Cassino C et al.. “Development of a Broth Microdilution Method for Exebacase Susceptibility Testing.” Antimicrobial agents and chemotherapy (2021). PMID: 33903102 ↗

    L5OTHERCited in: Clinical Presentation
  277. [277]

    Casapao AM, Leonard SN, Davis SL et al.. “Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection.” Antimicrobial agents and chemotherapy (2013). PMID: 23796929 ↗

    L3OTHERCited in: Clinical Presentation
  278. [278]

    Herren SC, Huemer M, Acevedo CT et al.. “Assessing Antibiotic Tolerance of Staphylococcus aureus Derived Directly from Patients by the Replica Plating Tolerance Isolation System (REPTIS).” Antimicrobial agents and chemotherapy (2021). PMID: 34694884 ↗

    L4OTHERCited in: Clinical Presentation
  279. [279]

    McNeil JC, Sommer LM, Vallejo JG et al.. “Going Back in Time: Increasing Penicillin Susceptibility among Methicillin-Susceptible Staphylococcus aureus Osteoarticular Infections in Children.” Antimicrobial agents and chemotherapy (2023). PMID: 36598265 ↗

    L2OTHERCited in: Clinical Presentation, Special Hosts and Populations
  280. [280]

    Claeys KC, Smith JR, Casapao AM et al.. “Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections.” Antimicrobial agents and chemotherapy (2015). PMID: 25605354 ↗

    L3OTHERCited in: Clinical Presentation
  281. [281]

    Bayer AS, Mishra NN, Chen L et al.. “Frequency and Distribution of Single-Nucleotide Polymorphisms within mprF in Methicillin-Resistant Staphylococcus aureus Clinical Isolates and Their Role in Cross-Resistance to Daptomycin and Host Defense Antimicrobial Peptides.” Antimicrobial agents and chemotherapy (2015). PMID: 26055370 ↗

    L4OTHERCited in: Clinical Presentation
  282. [282]

    Dangerfield B, Chung A, Webb B et al.. “Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia.” Antimicrobial agents and chemotherapy (2013). PMID: 24277023 ↗

    L3OTHERCited in: Clinical Presentation
  283. [283]

    Baxi SM, Clemenzi-Allen A, Gahbauer A et al.. “Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia.” Antimicrobial agents and chemotherapy (2016). PMID: 27324762 ↗

    L2OTHERCited in: Clinical Presentation
  284. [284]

    Casapao AM, Davis SL, Barr VO et al.. “Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.” Antimicrobial agents and chemotherapy (2014). PMID: 24550331 ↗

    L4OTHERCited in: Clinical Presentation
  285. [285]

    San Juan R, Garcia-Reyne A, Caba P et al.. “Safety and efficacy of moxifloxacin monotherapy for treatment of orthopedic implant-related staphylococcal infections.” Antimicrobial agents and chemotherapy (2010). PMID: 20855727 ↗

    L4OTHERCited in: Clinical Presentation
  286. [286]

    Britt NS, Patel N, Shireman TI et al.. “Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia.” The Journal of antimicrobial chemotherapy (2016). PMID: 27999028 ↗

    L3OTHERCited in: Clinical Presentation
  287. [287]

    Vindel A, Trincado P, Cuevas O et al.. “Molecular epidemiology of community-associated methicillin-resistant Staphylococcus aureus in Spain: 2004-12.” The Journal of antimicrobial chemotherapy (2014). PMID: 24990868 ↗

    L2OTHERCited in: Clinical Presentation, Special Hosts and Populations
  288. [288]

    Joseph JP, Meddows TR, Webster DP et al.. “Prioritizing echocardiography in Staphylococcus aureus bacteraemia.” The Journal of antimicrobial chemotherapy (2012). PMID: 23111851 ↗

    L3OTHERCited in: Clinical Presentation
  289. [289]

    Van Besien RF, Vazquez Guillamet MC. “The Evolving Etiology of Hospital-Acquired and Ventilator-Associated Pneumonia.” Clinics in chest medicine (2026). PMID: 42203422 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  290. [290]

    Comune M, Furnari I, Silvestro E et al.. “Neonatal Osteomyelitis Caused by Staphylococcus aureus: Case Series and Review of the Literature.” Children (Basel, Switzerland) (2026). PMID: 42353950 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Complications
  291. [291]

    Webb G, Choi J, Younes A et al.. “Comparing clinical manifestations, treatment strategies and outcomes of Staphylococcus lugdunensis bacteraemia versus Staphylococcus aureus bacteraemia - a retrospective cohort study.” Internal medicine journal (2026). PMID: 42250238 ↗

    L3COHORTCited in: Clinical Presentation
  292. [292]

    Soti Khiabani M, Talari SM, Khodabandeh M. “Ten-Year Epidemiology and Antimicrobial Susceptibility of Pediatric Staphylococcal Scalded Skin Syndrome: A Retrospective Study From a Tertiary Referral Center.” Pediatric dermatology (2026). PMID: 42219159 ↗

    L4COHORTCited in: Clinical Presentation
  293. [293]

    Ali MN, Gahnug M, Jama AA et al.. “Septic pulmonary embolism in Somali children: a retrospective study from a tertiary hospital.” Frontiers in pediatrics (2026). PMID: 42212102 ↗

    L4COHORTCited in: Clinical Presentation
  294. [294]

    Schulz SH, Dally FJ, Vogel J et al.. “Whole-Spine MRI Reveals High Prevalence of Multifocal Spondylodiscitis and Identifies a High-Risk Subgroup: A Retrospective Cohort Study of 274 Patients.” Medicina (Kaunas, Lithuania) (2026). PMID: 42195242 ↗

    L3COHORTCited in: Clinical Presentation
  295. [295]

    Campbell S, MacGregor K, Smith EL et al.. “Clinical Presentation and Outcomes Following Infection With Vibrio spp, Aeromonas spp, Chromobacterium violaceum, and Shewanella spp Water-Associated Organisms in Tropical Australia, 2015-2022.” Open forum infectious diseases (2024). PMID: 38975250 ↗

    L3OTHERCited in: Clinical Presentation
  296. [296]

    Whittington KJ, Malone SM, Hogan PG et al.. “Staphylococcus aureus Bacteremia in Pediatric Patients: Uncovering a Rural Health Challenge.” Open forum infectious diseases (2023). PMID: 37469617 ↗

    L3OTHERCited in: Clinical Presentation, Empiric Management, Acute Care and Source Control, Prognosis and Natural History
  297. [297]

    An TJ, Benvenuti MA, Mignemi ME et al.. “Similar Clinical Severity and Outcomes for Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Pediatric Musculoskeletal Infections.” Open forum infectious diseases (2017). PMID: 28480284 ↗

    L3OTHERCited in: Clinical Presentation
  298. [298]

    Wilson Dib R, Chaftari AM, Hachem RY et al.. “Catheter-Related Staphylococcus aureus Bacteremia and Septic Thrombosis: The Role of Anticoagulation Therapy and Duration of Intravenous Antibiotic Therapy.” Open forum infectious diseases (2018). PMID: 30377625 ↗

    L3OTHERCited in: Clinical Presentation, History and Evolution of Treatment
  299. [299]

    Bodavula P, Liang SY, Wu J et al.. “Pressure Ulcer-Related Pelvic Osteomyelitis: A Neglected Disease?” Open forum infectious diseases (2015). PMID: 26322317 ↗

    L3OTHERCited in: Clinical Presentation
  300. [300]

    Meier R, Wirth T, Hahn F et al.. “Pyogenic Arthritis of the Fingers and the Wrist: Can We Shorten Antimicrobial Treatment Duration?” Open forum infectious diseases (2017). PMID: 28491895 ↗

    L4OTHERCited in: Clinical Presentation, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  301. [301]

    Sinnar SA, Schiff SJ. “The Problem of Microbial Dark Matter in Neonatal Sepsis.” Emerging infectious diseases (2020). PMID: 33080169 ↗

    L5OTHERCited in: Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  302. [302]

    Bordeau V, Cady A, Revest M et al.. “Staphylococcus aureus Regulatory RNAs as Potential Biomarkers for Bloodstream Infections.” Emerging infectious diseases (2016). PMID: 27224202 ↗

    L3OTHERCited in: Clinical Presentation, Diagnosis and Workup
  303. [303]

    Prinz JC, Stadler PC. “Case Report: Paradoxical psoriasis under TNF-α blockade may represent generalized abscessing staphyloderma - GASD syndrome by TNF antagonists.” Frontiers in immunology (2026). PMID: 42344923 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Severity Assessment and Risk Stratification, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications
  304. [304]

    Okomo U, Akpalu ENK, Le Doare K et al.. “Aetiology of invasive bacterial infection and antimicrobial resistance in neonates in sub-Saharan Africa: a systematic review and meta-analysis in line with the STROBE-NI reporting guidelines.” The Lancet. Infectious diseases (2019). PMID: 31522858 ↗

    L1SR_OBSCited in: Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  305. [305]

    Mork RL, Hogan PG, Muenks CE et al.. “Longitudinal, strain-specific Staphylococcus aureus introduction and transmission events in households of children with community-associated meticillin-resistant S aureus skin and soft tissue infection: a prospective cohort study.” The Lancet. Infectious diseases (2019). PMID: 31784369 ↗

    L2COHORTCited in: Diagnosis and Workup
  306. [306]

    Patel JB, Gorwitz RJ, Jernigan JA. “Mupirocin resistance.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19673644 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  307. [307]

    McDanel JS, Perencevich EN, Diekema DJ et al.. “Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). PMID: 25900170 ↗

    L2OTHERCited in: Diagnosis and Workup
  308. [308]

    Kadri SS, Lai YL, Warner S et al.. “Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals.” The Lancet. Infectious diseases (2020). PMID: 32916100 ↗

    L2OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  309. [309]

    den Heijer CD, van Bijnen EM, Paget WJ et al.. “Prevalence and resistance of commensal Staphylococcus aureus, including meticillin-resistant S aureus, in nine European countries: a cross-sectional study.” The Lancet. Infectious diseases (2013). PMID: 23473661 ↗

    L4OTHERCited in: Diagnosis and Workup, Special Hosts and Populations
  310. [310]

    García-Álvarez L, Holden MT, Lindsay H et al.. “Meticillin-resistant Staphylococcus aureus with a novel mecA homologue in human and bovine populations in the UK and Denmark: a descriptive study.” The Lancet. Infectious diseases (2011). PMID: 21641281 ↗

    L4OTHERCited in: Diagnosis and Workup
  311. [311]

    Humphries RM, Pollett S, Sakoulas G. “A current perspective on daptomycin for the clinical microbiologist.” Clinical microbiology reviews (2013). PMID: 24092854 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  312. [312]

    Perry JD. “A Decade of Development of Chromogenic Culture Media for Clinical Microbiology in an Era of Molecular Diagnostics.” Clinical microbiology reviews (2017). PMID: 28122803 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup
  313. [313]

    Laupland KB, Church DL. “Population-based epidemiology and microbiology of community-onset bloodstream infections.” Clinical microbiology reviews (2014). PMID: 25278570 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup
  314. [314]

    Jain R, Kralovic SM, Evans ME et al.. “Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections.” The New England journal of medicine (2011). PMID: 21488764 ↗

    L2OTHERCited in: Diagnosis and Workup, Prevention and Infection Control
  315. [315]

    Turner NA, Hamasaki T, Doernberg SB et al.. “Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial.” JAMA (2025). PMID: 40802264 ↗

    L1OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Complications, Prognosis and Natural History
  316. [316]

    Kallen AJ, Mu Y, Bulens S et al.. “Health care-associated invasive MRSA infections, 2005-2008.” JAMA (2010). PMID: 20699455 ↗

    L2OTHERCited in: Diagnosis and Workup, Prevention and Infection Control, Special Hosts and Populations
  317. [317]

    Saravolatz SN, Martin H, Pawlak J et al.. “Ceftaroline-heteroresistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2014). PMID: 24637680 ↗

    L5OTHERCited in: Diagnosis and Workup
  318. [318]

    Suzuki Y, Kawada-Matsuo M, Thuan VTT et al.. “D-alanine synthesis and exogenous alanine affect the antimicrobial susceptibility of Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2025). PMID: 40503952 ↗

    L5OTHERCited in: Diagnosis and Workup
  319. [319]

    Chan LC, Basuino L, Diep B et al.. “Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2015). PMID: 25753637 ↗

    L5OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  320. [320]

    Ma D, Arya R, Knapick BA et al.. “Methicillin-resistant Staphylococcus aureus has phenotypic variation in mecA expression that alters antibiotic sensitivity.” Antimicrobial agents and chemotherapy (2026). PMID: 41677252 ↗

    L5OTHERCited in: Diagnosis and Workup
  321. [321]

    Karau MJ, Schmidt-Malan SM, Cunningham SA et al.. “Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis.” Antimicrobial agents and chemotherapy (2021). PMID: 34723626 ↗

    L5OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  322. [322]

    Truong-Bolduc QC, Wang Y, Reedy JL et al.. “Staphylococcus aureus Efflux Pumps and Tolerance to Ciprofloxacin and Chlorhexidine following Induction by Mupirocin.” Antimicrobial agents and chemotherapy (2021). PMID: 34930023 ↗

    L5OTHERCited in: Diagnosis and Workup
  323. [323]

    Bortolaia V, Kaas RS, Ruppe E et al.. “ResFinder 4.0 for predictions of phenotypes from genotypes.” The Journal of antimicrobial chemotherapy (2020). PMID: 32780112 ↗

    L5OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  324. [324]

    Lenhard JR, Bulman ZP. “Inoculum effect of β-lactam antibiotics.” The Journal of antimicrobial chemotherapy (2019). PMID: 31170287 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications
  325. [325]

    Rudilla H, Pérez-Guillén I, Rabanal F et al.. “Novel synthetic polymyxins kill Gram-positive bacteria.” The Journal of antimicrobial chemotherapy (2018). PMID: 30215733 ↗

    L5OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Special Hosts and Populations
  326. [326]

    Turner NA, Xu A, Zaharoff S et al.. “Determination of plasma protein binding of dalbavancin.” The Journal of antimicrobial chemotherapy (2022). PMID: 35488862 ↗

    L5OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  327. [327]

    Holland M, Bjanes E, Nizet V et al.. “Bicarbonate modulates delafloxacin activity against MDR Staphylococcus aureus and Pseudomonas aeruginosa.” The Journal of antimicrobial chemotherapy (2022). PMID: 34893834 ↗

    L5OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  328. [328]

    Kaul G, Akhir A, Shukla M et al.. “Nitazoxanide potentiates linezolid against linezolid-resistant Staphylococcus aureus in vitro and in vivo.” The Journal of antimicrobial chemotherapy (2022). PMID: 35748613 ↗

    L5OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  329. [329]

    Hawkey PM. “Pre-clinical experience with daptomycin.” The Journal of antimicrobial chemotherapy (2008). PMID: 18829726 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  330. [330]

    Jin Y, Zhou W, Chen W et al.. “Penicillin-susceptible ST398 with strong biofilm-forming ability poses a significant threat to osteoarticular infections.” The Journal of antimicrobial chemotherapy (2025). PMID: 40601387 ↗

    L4OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  331. [331]

    Hu J, Chen L, Li G et al.. “Prevalence and genetic characteristics of fosB-positive Staphylococcus aureus in duck farms in Guangdong, China in 2020.” The Journal of antimicrobial chemotherapy (2023). PMID: 36691844 ↗

    L5OTHERCited in: Diagnosis and Workup
  332. [332]

    Cañas MA, García-de-la-Mària C, García-González J et al.. “Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains.” The Journal of antimicrobial chemotherapy (2025). PMID: 40424179 ↗

    L5OTHERCited in: Diagnosis and Workup
  333. [333]

    Miller MM, Van Schooneveld TC, Stohs EJ et al.. “Implementation of a Rapid Multiplex Polymerase Chain Reaction Pneumonia Panel and Subsequent Antibiotic De-escalation.” Open forum infectious diseases (2023). PMID: 37564742 ↗

    L3OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  334. [334]

    Honkanen M, Jämsen E, Karppelin M et al.. “Periprosthetic Joint Infections as a Consequence of Bacteremia.” Open forum infectious diseases (2019). PMID: 31214625 ↗

    L2OTHERCited in: Diagnosis and Workup
  335. [335]

    Shaw R, Zander A, Ronnie T et al.. “Assessing the Predictive Value of Methicillin-Resistant Staphylococcus aureus Nares Colonization Among Transplant Recipients and Patients With Neutropenia.” Open forum infectious diseases (2024). PMID: 39050229 ↗

    L3OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Special Hosts and Populations
  336. [336]

    Maurer M, McCulloch M, Willey AM et al.. “Detection of Bacteriuria by Canine Olfaction.” Open forum infectious diseases (2016). PMID: 27186578 ↗

    L2OTHERCited in: Diagnosis and Workup
  337. [337]

    Musher DM, Jesudasen SS, Barwatt JW et al.. “Normal Respiratory Flora as a Cause of Community-Acquired Pneumonia.” Open forum infectious diseases (2020). PMID: 32968689 ↗

    L2OTHERCited in: Diagnosis and Workup
  338. [338]

    Comba IY, Go JR, Vaillant J et al.. “Sequential Time to Positivity as a Prognostic Indicator in Staphylococcus aureus Bacteremia.” Open forum infectious diseases (2024). PMID: 38617074 ↗

    L2OTHERCited in: Diagnosis and Workup, Complications
  339. [339]

    Phillip KI, Webster AS, Ray SM et al.. “Estimating the Burden of Clinically Significant Staphylococcus aureus Infections and Predictors for Hospitalization for Skin and Soft Tissue Infections, Fulton County, Georgia, 2017.” Open forum infectious diseases (2023). PMID: 38107016 ↗

    L2OTHERCited in: Diagnosis and Workup, Antimicrobial Resistance and Stewardship
  340. [340]

    Seidelman J, Ritter AS, Poehlein E et al.. “Multisite Study of the Management of Musculoskeletal Infection After Trauma: The MMUSKIT Study.” Open forum infectious diseases (2024). PMID: 38854390 ↗

    L3OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  341. [341]

    Schneider-Lindner V, Delaney JA, Dial S et al.. “Antimicrobial drugs and community-acquired methicillin-resistant Staphylococcus aureus, United Kingdom.” Emerging infectious diseases (2007). PMID: 18214170 ↗

    L3OTHERCited in: Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  342. [342]

    Francois P, Harbarth S, Huyghe A et al.. “Methicillin-resistant Staphylococcus aureus, Geneva, Switzerland, 1993-2005.” Emerging infectious diseases (2008). PMID: 18258126 ↗

    L4OTHERCited in: Diagnosis and Workup, Special Hosts and Populations
  343. [343]

    Lo WT, Lin WJ, Tseng MH et al.. “Methicillin-resistant Staphylococcus aureus in children, Taiwan.” Emerging infectious diseases (2006). PMID: 16965712 ↗

    L4OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Special Hosts and Populations
  344. [344]

    Alesana-Slater J, Ritchie SR, Heffernan H et al.. “Methicillin-resistant Staphylococcus aureus, Samoa, 2007-2008.” Emerging infectious diseases (2011). PMID: 21749763 ↗

    L4OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prevention and Infection Control
  345. [345]

    Johnson JK, Khoie T, Shurland S et al.. “Skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus USA300 clone.” Emerging infectious diseases (2007). PMID: 17953091 ↗

    L2OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  346. [346]

    Wulf M, van Nes A, Eikelenboom-Boskamp A et al.. “Methicillin-resistant Staphylococcus aureus in veterinary doctors and students, the Netherlands.” Emerging infectious diseases (2006). PMID: 17326948 ↗

    L4OTHERCited in: Diagnosis and Workup
  347. [347]

    Tucker NJ, Chow L, Linde P et al.. “Germanium-embedded bioactive fabric reduces bacterial bioburden and modulates fibroblast and macrophage behavior in vitro.” Frontiers in bioengineering and biotechnology (2026). PMID: 42416535 ↗

    L5OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control
  348. [348]

    Getnet F, Marami D, Mohammed S et al.. “Bacterial pathogens and antimicrobial resistance patterns in infections associated with stillbirths and under-five deaths in Ethiopia: a post-mortem surveillance study.” BMC infectious diseases (2026). PMID: 42410519 ↗

    L4OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control
  349. [349]

    Guo HZ, Xing ZC, Ao T et al.. “Development and validation of a risk prediction model for hospital mortality in adult patients with Staphylococcus aureus bacteremia.” Frontiers in cellular and infection microbiology (2026). PMID: 42394821 ↗

    L3OTHERCited in: Diagnosis and Workup
  350. [350]

    Ulziijargal J, Faermark E, Khenchbish U et al.. “Bacterial profile and antimicrobial resistance in patients with pulmonary infection: a retrospective tertiary hospital-based study.” BMC infectious diseases (2026). PMID: 42387436 ↗

    L4OTHERCited in: Diagnosis and Workup
  351. [351]

    Ammoura J, Alshamaa N, Elamin A et al.. “Antimicrobial resistance and microbiological gap analysis for central nervous system-assocaited bacterial pathogens in Nigeria.” Frontiers in microbiology (2026). PMID: 42382344 ↗

    L4OTHERCited in: Diagnosis and Workup
  352. [352]

    Salam T, Tufael, Siddique MAB et al.. “Multidrug-resistant bacterial infections in a tertiary hospitals: culture positivity, pathogen spectrum, and antibiotic susceptibility.” BMC microbiology (2026). PMID: 42381050 ↗

    L4OTHERCited in: Diagnosis and Workup
  353. [353]

    Sanderford V, Tabliago NRA, Alnami S et al.. “Impact of early vs delayed initiation of dual antimicrobial salvage therapy on clinical outcomes in MRSA bacteremia.” Microbiology spectrum (2026). PMID: 42379823 ↗

    L3OTHERCited in: Diagnosis and Workup
  354. [354]

    Ding T, Liu X, Liao F et al.. “Bacterial pathogen spectrum and antimicrobial resistance in positive pus cultures from hospitalized patients at a maternal and child healthcare specialty hospital in Shenzhen, China, 2021-2025.” Frontiers in cellular and infection microbiology (2026). PMID: 42376315 ↗

    L4OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  355. [355]

    Peng X, Zhou H, Liu W et al.. “In vitro interspecies interactions between methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa: effects on bacterial growth, antibiotic susceptibility, and transcriptomic reprogramming.” Frontiers in cellular and infection microbiology (2026). PMID: 42369189 ↗

    L5OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  356. [356]

    Falcone M, Russo A, Venditti M et al.. “Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2013). PMID: 24046298 ↗

    L4TRIAL_NONRANDOMCited in: Severity Assessment and Risk Stratification
  357. [357]

    Karanika S, Kinamon T, Grigoras C et al.. “Colonization With Methicillin-resistant Staphylococcus aureus and Risk for Infection Among Asymptomatic Athletes: A Systematic Review and Metaanalysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2016). PMID: 27090988 ↗

    L2SR_OBSCited in: Severity Assessment and Risk Stratification
  358. [358]

    López-Cortés LE, Del Toro MD, Gálvez-Acebal J et al.. “Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2013). PMID: 23929889 ↗

    L2SR_OBSCited in: Severity Assessment and Risk Stratification
  359. [359]

    Bhavnani SM, Ambrose PG, Hammel JP et al.. “Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.” Antimicrobial agents and chemotherapy (2015). PMID: 26711755 ↗

    L1RCTCited in: Severity Assessment and Risk Stratification, Prognosis and Natural History
  360. [360]

    Bassetti M, Righi E, Fasce R et al.. “Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit.” The Journal of antimicrobial chemotherapy (2007). PMID: 17540673 ↗

    L4TRIAL_NONRANDOMCited in: Severity Assessment and Risk Stratification
  361. [361]

    Malik U, Armstrong D, Ashworth M et al.. “Association between prior antibiotic therapy and subsequent risk of community-acquired infections: a systematic review.” The Journal of antimicrobial chemotherapy (2018). PMID: 29149266 ↗

    L3SR_OBSCited in: Severity Assessment and Risk Stratification
  362. [362]

    Panagides V, Cuervo G, Llopis J et al.. “Infective Endocarditis After Transcatheter Versus Surgical Aortic Valve Replacement.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37552784 ↗

    L3OTHERCited in: Severity Assessment and Risk Stratification
  363. [363]

    Nelson RE, Evans ME, Simbartl L et al.. “Methicillin-resistant Staphylococcus aureus Colonization and Pre- and Post-hospital Discharge Infection Risk.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30107401 ↗

    L3OTHERCited in: Severity Assessment and Risk Stratification
  364. [364]

    Humphreys H, Fitzpatick F, Harvey BJ. “Gender differences in rates of carriage and bloodstream infection caused by methicillin-resistant Staphylococcus aureus: are they real, do they matter and why?” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). PMID: 26202769 ↗

    L5REVIEW_NARRATIVECited in: Severity Assessment and Risk Stratification
  365. [365]

    Guimaraes AO, Cao Y, Hong K et al.. “A Prognostic Model of Persistent Bacteremia and Mortality in Complicated Staphylococcus aureus Bloodstream Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30165412 ↗

    L3OTHERCited in: Severity Assessment and Risk Stratification
  366. [366]

    García-Granja PE, López J, Vilacosta I et al.. “Impact of Valve Culture in the Prognosis of Active Left-sided Infective Endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30107544 ↗

    L3OTHERCited in: Severity Assessment and Risk Stratification
  367. [367]

    Ebruke BE, Deloria Knoll M, Haddix M et al.. “The Etiology of Pneumonia From Analysis of Lung Aspirate and Pleural Fluid Samples: Findings From the Pneumonia Etiology Research for Child Health (PERCH) Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32710751 ↗

    L4OTHERCited in: Severity Assessment and Risk Stratification
  368. [368]

    Chong YP, Moon SM, Bang KM et al.. “Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study.” Antimicrobial agents and chemotherapy (2012). PMID: 23254436 ↗

    L2COHORTCited in: Severity Assessment and Risk Stratification
  369. [369]

    Jin R, Wang M, Ke J et al.. “Correlation between Staphylococcus aureus colonization and disease severity in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials.” Frontiers in immunology (2026). PMID: 42183252 ↗

    L1SR_MA_RCTCited in: Severity Assessment and Risk Stratification
  370. [370]

    Pericàs JM, Hernández-Meneses M, Muñoz P et al.. “Outcomes and Risk Factors of Septic Shock in Patients With Infective Endocarditis: A Prospective Cohort Study.” Open forum infectious diseases (2021). PMID: 34189153 ↗

    L2COHORTCited in: Severity Assessment and Risk Stratification
  371. [371]

    Lim CJ, Cheng AC, Kennon J et al.. “Prevalence of multidrug-resistant organisms and risk factors for carriage in long-term care facilities: a nested case-control study.” The Journal of antimicrobial chemotherapy (2014). PMID: 24710025 ↗

    L3CASE_CONTROLCited in: Severity Assessment and Risk Stratification
  372. [372]

    van der Meulen LWJ, Bergmans ME, Assil S et al.. “Lack of improvement after short-term topical antistaphylococcal endolysin SA.100 therapy in patients with mild-to-moderate atopic dermatitis: Results from a randomized, vehicle-controlled trial.” British journal of clinical pharmacology (2026). PMID: 42115134 ↗

    L1RCTCited in: Severity Assessment and Risk Stratification
  373. [373]

    Sousa-Regueiro D, Alonso-Alvarez A, Balboa-Barreiro V et al.. “Determinants of cure and survival in vascular graft and endograft infections: a 13-year single-centre cohort study.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2026). PMID: 42119888 ↗

    L3COHORTCited in: Severity Assessment and Risk Stratification
  374. [374]

    Harris AD, Furuno JP, Roghmann MC et al.. “Targeted surveillance of methicillin-resistant Staphylococcus aureus and its potential use to guide empiric antibiotic therapy.” Antimicrobial agents and chemotherapy (2010). PMID: 20479207 ↗

    L2OTHERCited in: Severity Assessment and Risk Stratification
  375. [375]

    Moore CL, Lu M, Cheema F et al.. “Prediction of failure in vancomycin-treated methicillin-resistant Staphylococcus aureus bloodstream infection: a clinically useful risk stratification tool.” Antimicrobial agents and chemotherapy (2011). PMID: 21825294 ↗

    L3OTHERCited in: Severity Assessment and Risk Stratification
  376. [376]

    Pericàs JM, Cervera C, Garcia-de-la-Mària C et al.. “Relationship between Vancomycin MIC and Virulence Gene Expression in Clonal Complexes of Methicillin-Susceptible Staphylococcus aureus Strains Isolated from Left-Sided Endocarditis.” Antimicrobial agents and chemotherapy (2020). PMID: 31907181 ↗

    L4OTHERCited in: Severity Assessment and Risk Stratification
  377. [377]

    Ikeh MAC, Fidel PL, Noverr MC. “Prostaglandin E2 Receptor Antagonist with Antimicrobial Activity against Methicillin-Resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2018). PMID: 29263068 ↗

    L5OTHERCited in: Severity Assessment and Risk Stratification
  378. [378]

    Van Wart SA, Ambrose PG, Rubino CM et al.. “Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.” Antimicrobial agents and chemotherapy (2013). PMID: 24277021 ↗

    L5OTHERCited in: Severity Assessment and Risk Stratification
  379. [379]

    Lefèvre S, Saleh M, Marcellin L et al.. “Daptomycin versus vancomycin in a methicillin-resistant Staphylococcus aureus endophthalmitis rabbit model: bactericidal effect, safety, and ocular pharmacokinetics.” Antimicrobial agents and chemotherapy (2012). PMID: 22371888 ↗

    L5OTHERCited in: Severity Assessment and Risk Stratification
  380. [380]

    Brown J, Brown K, Forrest A. “Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization.” Antimicrobial agents and chemotherapy (2011). PMID: 22123681 ↗

    L3OTHERCited in: Severity Assessment and Risk Stratification
  381. [381]

    Meléndez-Carmona MÁ, Mancheño-Losa M, Ruiz-Sorribas A et al.. “Strain-to-strain variability among Staphylococcus aureus causing prosthetic joint infection drives heterogeneity in response to levofloxacin and rifampicin.” The Journal of antimicrobial chemotherapy (2022). PMID: 36124848 ↗

    L5OTHERCited in: Severity Assessment and Risk Stratification
  382. [382]

    Lalanne S, Cattoir V, Guerin F et al.. “Differential response to antibiotic therapy in staphylococcal infective endocarditis: contribution of an ex vivo model.” The Journal of antimicrobial chemotherapy (2023). PMID: 37248684 ↗

    L5OTHERCited in: Severity Assessment and Risk Stratification
  383. [383]

    Kanerva M, Ollgren J, Lyytikäinen O. “Benchmarking antibiotic use in Finnish acute care hospitals using patient case-mix adjustment.” The Journal of antimicrobial chemotherapy (2011). PMID: 21846673 ↗

    L2OTHERCited in: Severity Assessment and Risk Stratification
  384. [384]

    López-Cortés LE, Velasco C, Retamar P et al.. “Is reduced vancomycin susceptibility a factor associated with poor prognosis in MSSA bacteraemia?” The Journal of antimicrobial chemotherapy (2015). PMID: 26023210 ↗

    L2OTHERCited in: Severity Assessment and Risk Stratification
  385. [385]

    Hong M, Xiang W, Kong L et al.. “Corynebacterium Striatum Infective Endocarditis: A Systematic Review.” Journal of inflammation research (2025). PMID: 41403720 ↗

    L4SR_OBSCited in: Severity Assessment and Risk Stratification
  386. [386]

    Song J, Liu T, Yu Y et al.. “MHR and CRP/Albumin Ratio Correlate with Wagner Grade in Diabetic Foot Ulcers: A Chinese Retrospective Study with Pathogen Analysis.” Diabetes, metabolic syndrome and obesity : targets and therapy (2026). PMID: 42267252 ↗

    L4COHORTCited in: Severity Assessment and Risk Stratification
  387. [387]

    Kato H, Kitaura T, Noma H et al.. “Risk factors for community-acquired metastatic infections without infective endocarditis in patients with Staphylococcus aureus bacteremia: A retrospective cohort study.” Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (2026). PMID: 42162662 ↗

    L3COHORTCited in: Severity Assessment and Risk Stratification, Complications
  388. [388]

    Smit J, Dalager-Pedersen M, Adelborg K et al.. “Influence of Acetylsalicylic Acid Use on Risk and Outcome of Community-Acquired Staphylococcus aureus Bacteremia: A Population-Based Study.” Open forum infectious diseases (2019). PMID: 31660413 ↗

    L3OTHERCited in: Severity Assessment and Risk Stratification
  389. [389]

    Guimaraes AO, Gutierrez J, Maskarinec SA et al.. “Prognostic Power of Pathogen Cell-Free DNA in Staphylococcus aureus Bacteremia.” Open forum infectious diseases (2019). PMID: 31041341 ↗

    L4OTHERCited in: Severity Assessment and Risk Stratification
  390. [390]

    Ross JJ, Ard KL. “Septic Arthritis of the Spinal Facet Joint: Review of 117 Cases.” Open forum infectious diseases (2024). PMID: 38449920 ↗

    L4REVIEW_NARRATIVECited in: Severity Assessment and Risk Stratification, Complications, Prognosis and Natural History
  391. [391]

    Barshes NR, Clark NJ, Bidare D et al.. “Polymicrobial Foot Infection Patterns Are Common and Associated With Treatment Failure.” Open forum infectious diseases (2022). PMID: 36267251 ↗

    L4OTHERCited in: Severity Assessment and Risk Stratification, History and Evolution of Treatment
  392. [392]

    Forsblom E, Frilander H, Ruotsalainen E et al.. “Formal Infectious Diseases Specialist Consultation Improves Long-term Outcome of Methicillin-Sensitive Staphylococcus aureus Bacteremia.” Open forum infectious diseases (2019). PMID: 32128337 ↗

    L3OTHERCited in: Severity Assessment and Risk Stratification
  393. [393]

    Mendy A, Vieira ER, Albatineh AN et al.. “Staphylococcus aureus Colonization and Long-Term Risk for Death, United States.” Emerging infectious diseases (2016). PMID: 27767920 ↗

    L2OTHERCited in: Severity Assessment and Risk Stratification, Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  394. [394]

    Miller LG, Daum RS, Creech CB et al.. “Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections.” The New England journal of medicine (2015). PMID: 25785967 ↗

    L1RCTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History, Special Hosts and Populations
  395. [395]

    Baeten D, Baraliakos X, Braun J et al.. “Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2013). PMID: 24035250 ↗

    L1RCTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications
  396. [396]

    Falagas ME, Giannopoulou KP, Ntziora F et al.. “Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence.” The Journal of antimicrobial chemotherapy (2007). PMID: 17550889 ↗

    L4SR_OBSCited in: Empiric Management, Acute Care and Source Control
  397. [397]

    Holland TL, Raad I, Boucher HW et al.. “Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial.” JAMA (2018). PMID: 30264119 ↗

    L1RCTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History
  398. [398]

    Prokocimer P, De Anda C, Fang E et al.. “Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.” JAMA (2013). PMID: 23403680 ↗

    L1RCTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications
  399. [399]

    Davey P, Brown E, Fenelon L et al.. “Systematic review of antimicrobial drug prescribing in hospitals.” Emerging infectious diseases (2006). PMID: 16494744 ↗

    L2SR_OBSCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  400. [400]

    Ulloa ER, Singh KV, Geriak M et al.. “Cefazolin and Ertapenem Salvage Therapy Rapidly Clears Persistent Methicillin-Susceptible Staphylococcus aureus Bacteremia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31773134 ↗

    L4OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  401. [401]

    Rybak MJ. “The pharmacokinetic and pharmacodynamic properties of vancomycin.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2006). PMID: 16323118 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  402. [402]

    Paterson DL, Depestel DD. “Doripenem.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19527173 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  403. [403]

    Rose W, Fantl M, Geriak M et al.. “Current Paradigms of Combination Therapy in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: Does it Work, Which Combination, and For Which Patients?” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 33993226 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  404. [404]

    Jordan H, Kozierowski K, Pickles R et al.. “Oritavancin for the Treatment of Staphylococcus aureus Bacteremia-A Retrospective Single-arm Cohort Study.” Open forum infectious diseases (2025). PMID: 40657166 ↗

    L4TRIAL_NONRANDOMCited in: Empiric Management, Acute Care and Source Control
  405. [405]

    Katragadda S, Baddour LM, Chesdachai S et al.. “Postoperative Treatment Regimens in Patients With Native Valve Endocarditis due to Staphylococcus aureus Who Undergo Valve Replacement or Repair.” Open forum infectious diseases (2025). PMID: 40207048 ↗

    L3TRIAL_NONRANDOMCited in: Empiric Management, Acute Care and Source Control, Complications
  406. [406]

    Cosimi RA, Beik N, Kubiak DW et al.. “Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review.” Open forum infectious diseases (2017). PMID: 28702467 ↗

    L5SR_OBSCited in: Empiric Management, Acute Care and Source Control
  407. [407]

    Scheper H, Gerritsen LM, Pijls BG et al.. “Outcome of Debridement, Antibiotics, and Implant Retention for Staphylococcal Hip and Knee Prosthetic Joint Infections, Focused on Rifampicin Use: A Systematic Review and Meta-Analysis.” Open forum infectious diseases (2021). PMID: 34258321 ↗

    L1SR_OBSCited in: Empiric Management, Acute Care and Source Control, Prognosis and Natural History
  408. [408]

    Lek A, Wong B, Keeler A et al.. “Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne's Muscular Dystrophy.” The New England journal of medicine (2023). PMID: 37754285 ↗

    L4CASE_REPORTCited in: Empiric Management, Acute Care and Source Control
  409. [409]

    Zasowski EJ, Trinh TD, Claeys KC et al.. “Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection.” Open forum infectious diseases (2021). PMID: 35146040 ↗

    L3COHORTCited in: Empiric Management, Acute Care and Source Control
  410. [410]

    Partridge SR, Kwong SM, Firth N et al.. “Mobile Genetic Elements Associated with Antimicrobial Resistance.” Clinical microbiology reviews (2018). PMID: 30068738 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  411. [411]

    Williamson DA, Carter GP, Howden BP. “Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns.” Clinical microbiology reviews (2017). PMID: 28592405 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  412. [412]

    Septimus EJ, Schweizer ML. “Decolonization in Prevention of Health Care-Associated Infections.” Clinical microbiology reviews (2016). PMID: 26817630 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control
  413. [413]

    Forrest GN, Tamura K. “Rifampin combination therapy for nonmycobacterial infections.” Clinical microbiology reviews (2010). PMID: 20065324 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  414. [414]

    Grundmann H, Aires-de-Sousa M, Boyce J et al.. “Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat.” Lancet (London, England) (2006). PMID: 16950365 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prevention and Infection Control
  415. [415]

    Alomair SM, Al Sulaiman K, Alharbi A et al.. “Effectiveness of cefazolin versus anti-staphylococcal β-lactam for treating methicillin-susceptible Staphylococcus aureus pneumonia in critically ill patients admitted to intensive care units: a multicenter cohort study.” Annals of clinical microbiology and antimicrobials (2026). PMID: 42421008 ↗

    L3COHORTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History
  416. [416]

    Sánchez García M, De la Torre MA, Morales G et al.. “Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit.” JAMA (2010). PMID: 20530779 ↗

    L4OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship
  417. [417]

    Kleinhenz M, Beesetty P, Yang C et al.. “Antibiotic Treatment of Staphylococcus aureus Infection Inhibits the Development of Protective Immunity.” Antimicrobial agents and chemotherapy (2022). PMID: 35266822 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control, Prevention and Infection Control
  418. [418]

    Lepelletier D, Maillard JY, Pozzetto B et al.. “Povidone Iodine: Properties, Mechanisms of Action, and Role in Infection Control and Staphylococcus aureus Decolonization.” Antimicrobial agents and chemotherapy (2020). PMID: 32571829 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Prevention and Infection Control
  419. [419]

    Zelmer AR, Yang D, Gunn NJ et al.. “Osteomyelitis-relevant antibiotics at clinical concentrations show limited effectivity against acute and chronic intracellular S. aureus infections in osteocytes.” Antimicrobial agents and chemotherapy (2024). PMID: 39194210 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control
  420. [420]

    Molina KC, Morrisette T, Miller MA et al.. “The Emerging Role of β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.” Antimicrobial agents and chemotherapy (2020). PMID: 32312776 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  421. [421]

    Truong-Bolduc QC, Wang Y, Ferrer-Espada R et al.. “Staphylococcus aureus AbcA transporter enhances persister formation under β-lactam exposure.” Antimicrobial agents and chemotherapy (2024). PMID: 38364015 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control, Prognosis and Natural History
  422. [422]

    Frapwell CJ, Skipp PJ, Howlin RP et al.. “Antimicrobial Activity of the Quinoline Derivative HT61 against Staphylococcus aureus Biofilms.” Antimicrobial agents and chemotherapy (2020). PMID: 32122902 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control
  423. [423]

    Cooper EC, Curtis N, Cranswick N et al.. “Pristinamycin: old drug, new tricks?” The Journal of antimicrobial chemotherapy (2014). PMID: 24891428 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  424. [424]

    Simon S, Frank BJH, Hartmann S et al.. “Dalbavancin in Gram-positive periprosthetic joint infections.” The Journal of antimicrobial chemotherapy (2022). PMID: 35678452 ↗

    L3OTHERCited in: Empiric Management, Acute Care and Source Control, Complications
  425. [425]

    Laudano JB. “Ceftaroline fosamil: a new broad-spectrum cephalosporin.” The Journal of antimicrobial chemotherapy (2011). PMID: 21482565 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control
  426. [426]

    Hawkey PM. “The growing burden of antimicrobial resistance.” The Journal of antimicrobial chemotherapy (2008). PMID: 18684701 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  427. [427]

    Nicholson OA, Levi E. “Outcomes of single-stage excision in infected preauricular sinus: a retrospective cohort study.” International journal of pediatric otorhinolaryngology (2026). PMID: 42391915 ↗

    L2COHORTCited in: Empiric Management, Acute Care and Source Control
  428. [428]

    Rappo U, Puttagunta S, Shevchenko V et al.. “Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety.” Open forum infectious diseases (2018). PMID: 30648126 ↗

    L1OTHERCited in: Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications
  429. [429]

    Gobao VC, Alfishawy M, Smith C et al.. “Risk Factors, Screening, and Treatment Challenges in Staphylococcus aureus Native Septic Arthritis.” Open forum infectious diseases (2020). PMID: 33511230 ↗

    L2OTHERCited in: Empiric Management, Acute Care and Source Control
  430. [430]

    Yang WT, Meisner JA, Maguire C et al.. “Multidisciplinary Guidance to Care for Persons With Xylazine-Associated Wounds.” Open forum infectious diseases (2025). PMID: 40453883 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control
  431. [431]

    Bowen AC, Carapetis JR, Currie BJ et al.. “Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess.” Open forum infectious diseases (2017). PMID: 29255730 ↗

    L2REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control
  432. [432]

    Dagher M, Fowler VG, Wright PW et al.. “A Narrative Review of Early Oral Stepdown Therapy for the Treatment of Uncomplicated Staphylococcus aureus Bacteremia: Yay or Nay?” Open forum infectious diseases (2020). PMID: 32523971 ↗

    L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control
  433. [433]

    Moenster RP, Wallace-Lacey A, Western H et al.. “Oritavancin vs Standard of Care for Treatment of Nonendovascular Gram-Positive Bloodstream Infections.” Open forum infectious diseases (2023). PMID: 37937043 ↗

    L2OTHERCited in: Empiric Management, Acute Care and Source Control
  434. [434]

    Randad PR, Larsen J, Kaya H et al.. “Transmission of Antimicrobial-Resistant Staphylococcus aureus Clonal Complex 9 between Pigs and Humans, United States.” Emerging infectious diseases (2021). PMID: 33622471 ↗

    L4OTHERCited in: Empiric Management, Acute Care and Source Control
  435. [435]

    Faires MC, Traverse M, Tater KC et al.. “Methicillin-resistant and -susceptible Staphylococcus aureus infections in dogs.” Emerging infectious diseases (2010). PMID: 20031045 ↗

    L3OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment
  436. [436]

    David MZ, Crawford SE, Boyle-Vavra S et al.. “Contrasting pediatric and adult methicillin-resistant Staphylococcus aureus isolates.” Emerging infectious diseases (2006). PMID: 16704812 ↗

    L4OTHERCited in: Empiric Management, Acute Care and Source Control
  437. [437]

    Carrel M, Perencevich EN, David MZ. “USA300 Methicillin-Resistant Staphylococcus aureus, United States, 2000-2013.” Emerging infectious diseases (2015). PMID: 26484389 ↗

    L4OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  438. [438]

    Zhang QJ, Li YX, Yan YX et al.. “Design, synthesis, anti-MRSA activity evaluation, and mechanism of action study of 1,3-diamino-7H-pyrrolo[3,2-f]quinazoline derivatives.” European journal of medicinal chemistry (2026). PMID: 42430954 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship
  439. [439]

    Liu F, Chen H, Huang Y et al.. “Phage-guided rapid enrichment of copper-protocatechuic acid nanoparticles for targeted antibacterial therapy.” Journal of nanobiotechnology (2026). PMID: 42426746 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control
  440. [440]

    Zhou F, Luan J, Wei L et al.. “Synergistic Magneto-Electro-Thermal Biochemical Cascade Modulation Enables Rapid Healing and Functional Restoration of Infected Wounds.” Acta biomaterialia (2026). PMID: 42425219 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control
  441. [441]

    Zhang JQ, Wang Y, Ou JG et al.. “Inflammation-responsive liposomes co-delivering tobramycin and nitric oxide for overcoming mucus barriers against MRSA pneumonia.” Colloids and surfaces. B, Biointerfaces (2026). PMID: 42424783 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control
  442. [442]

    Lai X, Wang S, Ding C et al.. “Enhanced Antibacterial Properties of Lyotropic Liquid Crystalline Nanoparticles via Curvature Modulation.” Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026). PMID: 42423613 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control
  443. [443]

    Khairnar SV, Sommers A, Muldiiarova E et al.. “Chitosan-coated silver nanoparticles amplify glycopeptide efficacy against Staphylococcus aureus.” Frontiers in microbiology (2026). PMID: 42422740 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control
  444. [444]

    Boadi AO, Akenten CW, Thye T et al.. “Characterization of secondary bacterial infections in Buruli ulcer disease in Ghana: a focus on antimicrobial resistant Staphylococcus aureus.” BMC infectious diseases (2026). PMID: 42420877 ↗

    L4OTHERCited in: Empiric Management, Acute Care and Source Control
  445. [445]

    Fonfara M, Stölzl D, Hartmann J et al.. “Clinical and molecular improvements in pediatric patients with atopic dermatitis treated with dupilumab: an analysis from the TREATKids registry.” The Journal of investigative dermatology (2026). PMID: 42413573 ↗

    L2OTHERCited in: Empiric Management, Acute Care and Source Control
  446. [446]

    Luan T, Zhang Y, Zhu W et al.. “Crosslinker-free PVA hydrogel incorporating a water-soluble Ir(III) photosensitizer for antibacterial photodynamic applications in wound healing.” Journal of materials chemistry. B (2026). PMID: 42412212 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control
  447. [447]

    Ayhan YE, Sarı Küçük R, Özkan AN et al.. “Guideline-informed vancomycin therapeutic drug monitoring indications in an adult intensive care unit: a retrospective descriptive study.” BMC anesthesiology (2026). PMID: 42410537 ↗

    L4OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  448. [448]

    Moghaddam AM, Ahmadishoar S, Aval SF. “Synthesis of zinc oxide nanoparticles and their effect on biofilm of methicillin-resistant Staphylococcus aureus isolates.” BMC microbiology (2026). PMID: 42410350 ↗

    L5OTHERCited in: Empiric Management, Acute Care and Source Control
  449. [449]

    Daneman N, Sarwar S, Fowler RA et al.. “Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2013). PMID: 23352693 ↗

    L1SR_OBSCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prevention and Infection Control
  450. [450]

    Ong SWX, Pinto R, Mahar RK et al.. “Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial.” The Lancet. Infectious diseases (2025). PMID: 41237792 ↗

    L2RCTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History
  451. [451]

    Freling S, Wald-Dickler N, Banerjee J et al.. “Real-World Application of Oral Therapy for Infective Endocarditis: A Multicenter, Retrospective, Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36881940 ↗

    L3COHORTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications, Prognosis and Natural History
  452. [452]

    Talan DA, Mower WR, Krishnadasan A et al.. “Trimethoprim-Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess.” The New England journal of medicine (2016). PMID: 26962903 ↗

    L1RCTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History
  453. [453]

    Paul M, Kariv G, Goldberg E et al.. “Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia.” The Journal of antimicrobial chemotherapy (2010). PMID: 20947620 ↗

    L3SR_OBSCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History
  454. [454]

    Ji X-w, Mak WY, Xue F et al.. “Population pharmacokinetics and pulmonary modeling of eravacycline and the determination of microbiological breakpoint and cutoff of PK/PD.” Antimicrobial agents and chemotherapy (2025). PMID: 39878492 ↗

    L4TRIAL_NONRANDOMCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  455. [455]

    Schwameis R, Syré S, Marhofer D et al.. “Pharmacokinetics of Cefuroxime in Synovial Fluid.” Antimicrobial agents and chemotherapy (2017). PMID: 28784675 ↗

    L4TRIAL_NONRANDOMCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prevention and Infection Control
  456. [456]

    Butler-Laporte G, Cheng MP, Thirion DJG et al.. “Clinical Trials Increase Off-Study Drug Use: A Segmented Time-Series Analysis.” Open forum infectious diseases (2020). PMID: 33209948 ↗

    L2TRIAL_NONRANDOMCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  457. [457]

    Bitterman R, Awwad A, Darawsha B et al.. “Ceftaroline versus vancomycin for methicillin-resistant Staphylococcus aureus bacteraemia, a matched cohort study.” The Journal of antimicrobial chemotherapy (2025). PMID: 39871614 ↗

    L3COHORTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History
  458. [458]

    Taher AQM, Aqel R, Alnajjar M et al.. “Posttraumatic Pseudomonas aeruginosa Osteomyelitis in Mosul and Gaza: A Retrospective Cohort Study, 2018-2022.” Open forum infectious diseases (2024). PMID: 39411226 ↗

    L3COHORTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment
  459. [459]

    Sati H, Carrara E, Savoldi A et al.. “The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance.” The Lancet. Infectious diseases (2025). PMID: 40245910 ↗

    L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  460. [460]

    Tacconelli E, Carrara E, Savoldi A et al.. “Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.” The Lancet. Infectious diseases (2017). PMID: 29276051 ↗

    L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  461. [461]

    Simor AE. “Staphylococcal decolonisation: an effective strategy for prevention of infection?” The Lancet. Infectious diseases (2011). PMID: 22115070 ↗

    L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prevention and Infection Control
  462. [462]

    Oehler RL, Velez AP, Mizrachi M et al.. “Bite-related and septic syndromes caused by cats and dogs.” The Lancet. Infectious diseases (2009). PMID: 19555903 ↗

    L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications
  463. [463]

    Magnan C, Plumet L, Morsli M et al.. “A narrative review of coagulase-negative staphylococci in diabetic foot infections.” Clinical microbiology reviews (2025). PMID: 41186420 ↗

    L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  464. [464]

    Haddad Kashani H, Schmelcher M, Sabzalipoor H et al.. “Recombinant Endolysins as Potential Therapeutics against Antibiotic-Resistant Staphylococcus aureus: Current Status of Research and Novel Delivery Strategies.” Clinical microbiology reviews (2017). PMID: 29187396 ↗

    L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  465. [465]

    Beenken KE, Campbell MJ, Reyes-Pardo H et al.. “Mechanistic insights into the pathogenesis and therapeutic recalcitrance of Staphylococcus aureus osteomyelitis.” Clinical microbiology reviews (2026). PMID: 41989162 ↗

    L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  466. [466]

    Howden BP, Davies JK, Johnson PD et al.. “Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.” Clinical microbiology reviews (2010). PMID: 20065327 ↗

    L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  467. [467]

    Álvarez R, López Cortés LE, Molina J et al.. “Optimizing the Clinical Use of Vancomycin.” Antimicrobial agents and chemotherapy (2016). PMID: 26856841 ↗

    L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  468. [468]

    Haynes AS, Wei Z, Anderson P et al.. “Cefadroxil and cephalexin pharmacokinetics and pharmacodynamics in children with musculoskeletal infections.” Antimicrobial agents and chemotherapy (2024). PMID: 38597672 ↗

    L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Special Hosts and Populations
  469. [469]

    Gonzalez D, Delmore P, Bloom BT et al.. “Clindamycin Pharmacokinetics and Safety in Preterm and Term Infants.” Antimicrobial agents and chemotherapy (2016). PMID: 26926644 ↗

    L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications
  470. [470]

    McNeil JC, Sommer LM, Boyle M et al.. “Cefazolin Inoculum Effect and Methicillin-Susceptible Staphylococcus aureus Osteoarticular Infections in Children.” Antimicrobial agents and chemotherapy (2020). PMID: 32660989 ↗

    L3OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History, Special Hosts and Populations
  471. [471]

    Canouï E, Kerneis S, Morand P et al.. “Oral levofloxacin: population pharmacokinetics model and pharmacodynamics study in bone and joint infections.” The Journal of antimicrobial chemotherapy (2022). PMID: 35178577 ↗

    L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  472. [472]

    Rampacci E, Felicetti T, Pietrella D et al.. “Drug efflux transporters in Staphylococcus pseudintermedius: in silico prediction and characterization of resistance.” The Journal of antimicrobial chemotherapy (2022). PMID: 36173389 ↗

    L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  473. [473]

    Taupin D, Karchmer AW, Davis RB et al.. “Uncomplicated Staphylococcus aureus Bacteremia Treatment Duration and Outcomes at an Academic Medical Center.” Open forum infectious diseases (2020). PMID: 33134421 ↗

    L3OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  474. [474]

    Walker B, Heidel E, Shorman M. “Clinical Characteristics and Outcome of Staphylococcus aureus Prostate Abscess, Ten-Year Experience at a Tertiary Care Center.” Open forum infectious diseases (2019). PMID: 31430373 ↗

    L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment
  475. [475]

    Okada N, Niimura T, Saisyo A et al.. “Pharmacovigilance Study on Eosinophilic Pneumonia Induced by Anti-MRSA Agents: Analysis Based on the FDA Adverse Event Reporting System.” Open forum infectious diseases (2023). PMID: 37601729 ↗

    L3OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  476. [476]

    Sawada K, Inose R, Goto R et al.. “Effectiveness of Noncertified Pharmacist-Led Antimicrobial Stewardship Programs in a Medium-Sized Hospital Without an Infectious Disease Specialist: A Retrospective Pre-Post Study.” Open forum infectious diseases (2023). PMID: 36949877 ↗

    L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  477. [477]

    Fabre V, Cosgrove SE, Lessa FC et al.. “Antibiotic Use in Medical-Surgical Intensive Care Units and General Wards in Latin American Hospitals.” Open forum infectious diseases (2024). PMID: 39494448 ↗

    L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prevention and Infection Control
  478. [478]

    Novak AR, Krsak M, Kiser TH et al.. “Pharmacokinetic Evaluation of Cefazolin in the Cerebrospinal Fluid of Critically Ill Patients.” Open forum infectious diseases (2021). PMID: 35111872 ↗

    L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prevention and Infection Control
  479. [479]

    Greenfield A, Marsh K, Siegfried J et al.. “Impact of Streptococcus pneumoniae Urinary Antigen Testing in Patients With Community-Acquired Pneumonia Admitted Within a Large Academic Health System.” Open forum infectious diseases (2021). PMID: 34993258 ↗

    L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment
  480. [480]

    Nichols CN, Wardlow LC, Coe KE et al.. “Clinical Outcomes With Definitive Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia With Retained Daptomycin and Ceftaroline Combination Therapy vs De-escalation to Monotherapy With Vancomycin, Daptomycin, or Ceftaroline.” Open forum infectious diseases (2021). PMID: 34337094 ↗

    L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  481. [481]

    Abbara S, Guillemot D, Smith DRM et al.. “Antimicrobial Resistance as Risk Factor for Recurrent Bacteremia after Staphylococcus aureus, Escherichia coli, or Klebsiella spp. Community-Onset Bacteremia.” Emerging infectious diseases (2024). PMID: 38666612 ↗

    L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  482. [482]

    McCaig LF, McDonald LC, Mandal S et al.. “Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care.” Emerging infectious diseases (2006). PMID: 17283622 ↗

    L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  483. [483]

    Legg A, Boast A, Piera K et al.. “Flucloxacillin plasma and urinary concentrations with and without probenecid and urinary biomarker profiles in healthy volunteers.” British journal of clinical pharmacology (2026). PMID: 42414075 ↗

    L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  484. [484]

    Barahim EK, Smith EP, Yong ST et al.. “Evaluation of Antimicrobial Peptide-Antibiotic Combination Treatment for Tackling Ocular and Systemic Staphylococcus aureus Infections.” International journal of molecular sciences (2026). PMID: 42353286 ↗

    L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  485. [485]

    Lamilla C, Rubilar O, San Martin I et al.. “Biotechnological Potential of Rhizospheric Bacillus Strains from Lonquimay, Chile, as Producers of Antimicrobial Biosurfactants.” International journal of molecular sciences (2026). PMID: 42353120 ↗

    L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  486. [486]

    Bușilă M, Tăbăcaru A, Botezatu AV et al.. “Tuning Anticancer Activity and Antimicrobial Response of ZnO Nanoparticles Through Halogenosilane Surface Modification.” International journal of molecular sciences (2026). PMID: 42353108 ↗

    L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  487. [487]

    Cottet C, Kikot PA, Nobile ML et al.. “Active Chitosan Films Enriched with Yerba Mate Kombucha Infusion: Formulation and Characterization.” International journal of molecular sciences (2026). PMID: 42353065 ↗

    L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  488. [488]

    da Silva MEB, Kamio ABS, da Silva MGR et al.. “Antimicrobial efficacy of hypochlorite-based gels for disinfecting heat-polymerized and 3D printed denture bases.” The Journal of prosthetic dentistry (2026). PMID: 42348746 ↗

    L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  489. [489]

    Kayani A, Raza A, Zhou Q et al.. “Orchestrating Diabetic Wound Healing by a Sunlight-Activated AIEgen-Selenide Nanospray: From Infection Control to Tissue Regeneration.” ACS applied materials & interfaces (2026). PMID: 42347974 ↗

    L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  490. [490]

    Gupta N, Bhattacharya S, Lela L et al.. “Advances in phytochemical-derived nanotherapeutics for multimodal eradication of multidrug-resistant Staphylococcus aureus.” Frontiers in pharmacology (2026). PMID: 42344795 ↗

    L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  491. [491]

    Li K, Wang K, Zhang G et al.. “An Acceptor-Donor-Acceptor Semiconductor Conjugated Polymer-Based Composite Hydrogel for Photothermal/Photodynamic Dual Phototherapy of Infected Wounds.” ACS applied materials & interfaces (2026). PMID: 42333676 ↗

    L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
  492. [492]

    Zervou FN, Zacharioudakis IM, Ziakas PD et al.. “Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus colonization in HIV infection: a meta-analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 25031291 ↗

    L2SR_OBSCited in: History and Evolution of Treatment, Complications, Special Hosts and Populations
  493. [493]

    Pujol M, Miró JM, Shaw E et al.. “Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32725216 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications
  494. [494]

    Fowler VG, Das AF, Lipka-Diamond J et al.. “Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT).” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38297916 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications, Prognosis and Natural History
  495. [495]

    Mitchell BG, Hall L, White N et al.. “An environmental cleaning bundle and health-care-associated infections in hospitals (REACH): a multicentre, randomised trial.” The Lancet. Infectious diseases (2019). PMID: 30858014 ↗

    L1RCTCited in: History and Evolution of Treatment, Prognosis and Natural History, Prevention and Infection Control
  496. [496]

    Ibrahim LF, Hopper SM, Orsini F et al.. “Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial.” The Lancet. Infectious diseases (2019). PMID: 30853250 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications, Special Hosts and Populations
  497. [497]

    Johnson DW, Badve SV, Pascoe EM et al.. “Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial.” The Lancet. Infectious diseases (2013). PMID: 24119840 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications, Prevention and Infection Control, Special Hosts and Populations
  498. [498]

    Huang SS, Septimus E, Hayden MK et al.. “Effect of body surface decolonisation on bacteriuria and candiduria in intensive care units: an analysis of a cluster-randomised trial.” The Lancet. Infectious diseases (2015). PMID: 26631833 ↗

    L1RCTCited in: History and Evolution of Treatment, Prevention and Infection Control
  499. [499]

    Daum RS, Miller LG, Immergluck L et al.. “A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses.” The New England journal of medicine (2017). PMID: 28657870 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications, Prognosis and Natural History, Special Hosts and Populations
  500. [500]

    Perl TM, Cullen JJ, Wenzel RP et al.. “Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections.” The New England journal of medicine (2002). PMID: 12063371 ↗

    L1RCTCited in: History and Evolution of Treatment
  501. [501]

    Yu VL, Goetz A, Wagener M et al.. “Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis.” The New England journal of medicine (1986). PMID: 3523240 ↗

    L2RCTCited in: History and Evolution of Treatment
  502. [502]

    Rodvold KA, McConeghy KW. “Methicillin-resistant Staphylococcus aureus therapy: past, present, and future.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 24343828 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  503. [503]

    de Jonge E, Schultz MJ, Spanjaard L et al.. “Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial.” Lancet (London, England) (2003). PMID: 14522530 ↗

    L1RCTCited in: History and Evolution of Treatment
  504. [504]

    Lipsky BA, Armstrong DG, Citron DM et al.. “Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.” Lancet (London, England) (2005). PMID: 16291062 ↗

    L1RCTCited in: History and Evolution of Treatment
  505. [505]

    Keighley MR, Arabi Y, Alexander-Williams J et al.. “Comparison between systemic and oral antimicrobial prophylaxis in colorectal surgery.” Lancet (London, England) (1979). PMID: 86666 ↗

    L1RCTCited in: History and Evolution of Treatment
  506. [506]

    Smack DP, Harrington AC, Dunn C et al.. “Infection and allergy incidence in ambulatory surgery patients using white petrolatum vs bacitracin ointment. A randomized controlled trial.” JAMA (1996). PMID: 8805732 ↗

    L1RCTCited in: History and Evolution of Treatment
  507. [507]

    Pugin J, Auckenthaler R, Lew DP et al.. “Oropharyngeal decontamination decreases incidence of ventilator-associated pneumonia. A randomized, placebo-controlled, double-blind clinical trial.” JAMA (Unknown). PMID: 2023353 ↗

    L1RCTCited in: History and Evolution of Treatment
  508. [508]

    Fowler VG, Allen KB, Moreira ED et al.. “Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial.” JAMA (2013). PMID: 23549582 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications, Prevention and Infection Control
  509. [509]

    Harris AD, Pineles L, Belton B et al.. “Universal glove and gown use and acquisition of antibiotic-resistant bacteria in the ICU: a randomized trial.” JAMA (2013). PMID: 24097234 ↗

    L1RCTCited in: History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Prevention and Infection Control
  510. [510]

    Segers P, Speekenbrink RG, Ubbink DT et al.. “Prevention of nosocomial infection in cardiac surgery by decontamination of the nasopharynx and oropharynx with chlorhexidine gluconate: a randomized controlled trial.” JAMA (2006). PMID: 17119142 ↗

    L1RCTCited in: History and Evolution of Treatment
  511. [511]

    Moran GJ, Krishnadasan A, Mower WR et al.. “Effect of Cephalexin Plus Trimethoprim-Sulfamethoxazole vs Cephalexin Alone on Clinical Cure of Uncomplicated Cellulitis: A Randomized Clinical Trial.” JAMA (2017). PMID: 28535235 ↗

    L1RCTCited in: History and Evolution of Treatment, Complications
  512. [512]

    Oliveira DC, Tomasz A, de Lencastre H. “Secrets of success of a human pathogen: molecular evolution of pandemic clones of meticillin-resistant Staphylococcus aureus.” The Lancet. Infectious diseases (2002). PMID: 11944188 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  513. [513]

    Cetinkaya Y, Falk P, Mayhall CG. “Vancomycin-resistant enterococci.” Clinical microbiology reviews (2000). PMID: 11023964 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  514. [514]

    Shirtliff ME, Mader JT. “Acute septic arthritis.” Clinical microbiology reviews (2002). PMID: 12364368 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  515. [515]

    Skurray RA, Rouch DA, Lyon BR et al.. “Multiresistant Staphylococcus aureus: genetics and evolution of epidemic Australian strains.” The Journal of antimicrobial chemotherapy (1988). PMID: 2838448 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  516. [516]

    Griffith RS. “Vancomycin use--an historical review.” The Journal of antimicrobial chemotherapy (1984). PMID: 6394574 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  517. [517]

    Donnelly JP. “Bacterial complications of transplantation: diagnosis and treatment.” The Journal of antimicrobial chemotherapy (1995). PMID: 8601544 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  518. [518]

    . “Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.” The Lancet. Infectious diseases (2024). PMID: 38640940 ↗

    L2OTHERCited in: History and Evolution of Treatment, Special Hosts and Populations
  519. [519]

    Gamell A, Velasco-Arnaiz E, López-Ramos MG et al.. “Off-label use of dalbavancin in children: a case series.” The Journal of antimicrobial chemotherapy (2024). PMID: 38958260 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment, Complications, Special Hosts and Populations
  520. [520]

    Belew H, Tegegne BA, Kindie Y et al.. “Bacterial neonatal sepsis, antimicrobial resistance, and risk factors among neonates in Ethiopia: a systematic review and meta-analysis.” Therapeutic advances in infectious disease (2026). PMID: 42222265 ↗

    L2SR_OBSCited in: History and Evolution of Treatment
  521. [521]

    Gomes AR, Westh H, de Lencastre H. “Origins and evolution of methicillin-resistant Staphylococcus aureus clonal lineages.” Antimicrobial agents and chemotherapy (2006). PMID: 17005800 ↗

    L5OTHERCited in: History and Evolution of Treatment
  522. [522]

    Liu X, Wang Y, Chang W et al.. “AgrA directly binds to the promoter of vraSR and downregulates its expression in Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2024). PMID: 38259090 ↗

    L5OTHERCited in: History and Evolution of Treatment
  523. [523]

    Campion JJ, McNamara PJ, Evans ME. “Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.” Antimicrobial agents and chemotherapy (2004). PMID: 15561851 ↗

    L5OTHERCited in: History and Evolution of Treatment
  524. [524]

    Chen F, Yin Y, Chen H et al.. “Global genetic diversity and Asian clades evolution: a phylogeographic study of Staphylococcus aureus sequence type 5.” Antimicrobial agents and chemotherapy (2024). PMID: 38259089 ↗

    L5OTHERCited in: History and Evolution of Treatment
  525. [525]

    Rolo J, Worning P, Nielsen JB et al.. “Evolutionary Origin of the Staphylococcal Cassette Chromosome mec (SCCmec).” Antimicrobial agents and chemotherapy (2017). PMID: 28373201 ↗

    L5OTHERCited in: History and Evolution of Treatment
  526. [526]

    Giulieri SG. “Case Commentary: The hidden side of oxacillin resistance in Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2023). PMID: 37655923 ↗

    L5OTHERCited in: History and Evolution of Treatment
  527. [527]

    Chen Y, Moran JC, Campbell-Lee S et al.. “Transcriptomic Responses and Survival Mechanisms of Staphylococci to the Antimicrobial Skin Lipid Sphingosine.” Antimicrobial agents and chemotherapy (2021). PMID: 34902269 ↗

    L5OTHERCited in: History and Evolution of Treatment
  528. [528]

    Petersen ME, Khamas AB, Østergaard LJ et al.. “Combination therapy delays antimicrobial resistance after adaptive laboratory evolution of Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2025). PMID: 40084881 ↗

    L5OTHERCited in: History and Evolution of Treatment
  529. [529]

    León-Sampedro R, Novais C, Peixe L et al.. “Diversity and Evolution of the Tn5801-tet(M)-Like Integrative and Conjugative Elements among Enterococcus, Streptococcus, and Staphylococcus.” Antimicrobial agents and chemotherapy (2016). PMID: 26729505 ↗

    L5OTHERCited in: History and Evolution of Treatment
  530. [530]

    Strommenger B, Bartels MD, Kurt K et al.. “Evolution of methicillin-resistant Staphylococcus aureus towards increasing resistance.” The Journal of antimicrobial chemotherapy (2013). PMID: 24150844 ↗

    L5OTHERCited in: History and Evolution of Treatment
  531. [531]

    Jiang N, Wyres KL, Li J et al.. “Evolution and genomic insight into methicillin-resistant Staphylococcus aureus ST9 in China.” The Journal of antimicrobial chemotherapy (2021). PMID: 33822977 ↗

    L5OTHERCited in: History and Evolution of Treatment
  532. [532]

    Duval J. “Evolution and epidemiology of MLS resistance.” The Journal of antimicrobial chemotherapy (1985). PMID: 3932300 ↗

    L5OTHERCited in: History and Evolution of Treatment
  533. [533]

    Liu P, Hao Z, Liu M et al.. “Genetic mutations in adaptive evolution of growth-independent vancomycin-tolerant Staphylococcus aureus.” The Journal of antimicrobial chemotherapy (2021). PMID: 34302174 ↗

    L5OTHERCited in: History and Evolution of Treatment
  534. [534]

    Olsen JE, Christensen H, Aarestrup FM. “Diversity and evolution of blaZ from Staphylococcus aureus and coagulase-negative staphylococci.” The Journal of antimicrobial chemotherapy (2006). PMID: 16449305 ↗

    L5OTHERCited in: History and Evolution of Treatment
  535. [535]

    Nuevo JJM, Fortaleza JAG, Cabuhat KSP et al.. “CRISPR-driven strategies to disrupt methicillin-resistant Staphylococcus aureus biofilms: a review.” Frontiers in cellular and infection microbiology (2026). PMID: 42211656 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  536. [536]

    Matsuo T, Hayashi K, Uehara Y et al.. “The STAPH Score: A Predictor of Staphylococcus aureus as the Causative Microorganism of Native Vertebral Osteomyelitis.” Open forum infectious diseases (2020). PMID: 33447627 ↗

    L3OTHERCited in: History and Evolution of Treatment
  537. [537]

    Peterson LR, Samia NI, Skinner AM et al.. “Antimicrobial Stewardship Lessons From Mupirocin Use and Resistance in Methicillin-Resitant Staphylococcus Aureus.” Open forum infectious diseases (2017). PMID: 28702468 ↗

    L2OTHERCited in: History and Evolution of Treatment, Antimicrobial Resistance and Stewardship
  538. [538]

    Lee YW, Bae S, Yang E et al.. “Clinical and Microbiological Characteristics of Hospital-Acquired Methicillin-Resistant Staphylococcus aureus Bacteremia Caused by a Community-Associated PVL-Negative Strain.” Open forum infectious diseases (2021). PMID: 34676275 ↗

    L2OTHERCited in: History and Evolution of Treatment
  539. [539]

    Theodore DA, Goodwin RD, Zhang YV et al.. “History of Depression and Increased Risk of Sternal Wound Infection After Cardiothoracic Surgery: A Novel and Potentially Modifiable Risk Factor.” Open forum infectious diseases (2019). PMID: 30949529 ↗

    L3OTHERCited in: History and Evolution of Treatment
  540. [540]

    Henig O, Pogue JM, Cha R et al.. “Epidemiology of Diabetic Foot Infection in the Metro-Detroit Area With a Focus on Independent Predictors for Pathogens Resistant to Recommended Empiric Antimicrobial Therapy.” Open forum infectious diseases (2018). PMID: 30402532 ↗

    L2OTHERCited in: History and Evolution of Treatment
  541. [541]

    Turabelidze G, Lin M, Wolkoff B et al.. “Personal hygiene and methicillin-resistant Staphylococcus aureus infection.” Emerging infectious diseases (2006). PMID: 16704779 ↗

    L3OTHERCited in: History and Evolution of Treatment
  542. [542]

    Odutola A, Bottomley C, Zaman SA et al.. “Staphylococcus aureus Bacteremia in Children of Rural Areas of The Gambia, 2008-2015.” Emerging infectious diseases (2019). PMID: 30882307 ↗

    L2OTHERCited in: History and Evolution of Treatment
  543. [543]

    Buck JM, Como-Sabetti K, Harriman KH et al.. “Community-associated methicillin-resistant Staphylococcus aureus, Minnesota, 2000-2003.” Emerging infectious diseases (2005). PMID: 16318692 ↗

    L3OTHERCited in: History and Evolution of Treatment
  544. [544]

    Brodíková K, Destanque T, Haenni M et al.. “Clonal Complex 398 Methicillin-Resistant Staphylococcus aureus Producing Panton-Valentine Leukocidin, Czech Republic, 2023.” Emerging infectious diseases (2025). PMID: 39714442 ↗

    L4OTHERCited in: History and Evolution of Treatment
  545. [545]

    Li M, Wang Y, Zhu Y et al.. “Increased Community-Associated Infections Caused by Panton-Valentine Leukocidin-Negative MRSA, Shanghai, 2005-2014.” Emerging infectious diseases (2016). PMID: 27767912 ↗

    L4OTHERCited in: History and Evolution of Treatment
  546. [546]

    Peters PJ, Brooks JT, McAllister SK et al.. “Methicillin-resistant Staphylococcus aureus colonization of the groin and risk for clinical infection among HIV-infected adults.” Emerging infectious diseases (2013). PMID: 23631854 ↗

    L2OTHERCited in: History and Evolution of Treatment
  547. [547]

    Moran GJ, Amii RN, Abrahamian FM et al.. “Methicillin-resistant Staphylococcus aureus in community-acquired skin infections.” Emerging infectious diseases (2005). PMID: 15963289 ↗

    L4OTHERCited in: History and Evolution of Treatment
  548. [548]

    Wuerth BA, Bonnewell JP, Wiemken TL et al.. “Trends in Pneumonia Mortality Rates and Hospitalizations by Organism, United States, 2002-2011(1).” Emerging infectious diseases (2016). PMID: 27532154 ↗

    L2OTHERCited in: History and Evolution of Treatment, Prognosis and Natural History
  549. [549]

    Lewis HC, Mølbak K, Reese C et al.. “Pigs as source of methicillin-resistant Staphylococcus aureus CC398 infections in humans, Denmark.” Emerging infectious diseases (2008). PMID: 18760004 ↗

    L3OTHERCited in: History and Evolution of Treatment
  550. [550]

    Lee JH, Cho MC. “Impact of bacteriospermia on sperm DNA fragmentation: a narrative review.” Translational andrology and urology (2026). PMID: 42293827 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  551. [551]

    Ansari I, Sindgi RP, Srivastava AK et al.. “Advances in Quorum-Sensing Inhibitors as Novel Therapeutic Targets.” Microbial pathogenesis (2026). PMID: 42285423 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  552. [552]

    Ilyas MH, Adio A, Gonzalez-Morgado D et al.. “Social Determinants of Health Are Associated With Increased Risk of Preoperative Methicillin-Resistant Staphylococcus aureus Colonization in Patients Undergoing Total Joint Arthroplasty.” Arthroplasty today (2026). PMID: 42434293 ↗

    L2OTHERCited in: History and Evolution of Treatment
  553. [553]

    Nathan H, Hiironen I, Harrington P et al.. “Distribution of putative SSI risk factors in adults undergoing open reduction and fixation of long bone fracture.” European journal of orthopaedic surgery & traumatology : orthopedie traumatologie (2026). PMID: 42406128 ↗

    L2OTHERCited in: History and Evolution of Treatment
  554. [554]

    Alexander AM, Loo HQ, Askew L et al.. “Intraspecific diversity of Staphylococcus aureus populations isolated from cystic fibrosis respiratory infections.” Microbiology spectrum (2026). PMID: 42405791 ↗

    L4OTHERCited in: History and Evolution of Treatment
  555. [555]

    Liu W, Guo W, Xiao D et al.. “Phthalazine-based quaternary ammonium salts: synthesis, biological evaluation and membrane-targeting mechanism against Staphylococcus aureus.” Frontiers in microbiology (2026). PMID: 42404800 ↗

    L5OTHERCited in: History and Evolution of Treatment
  556. [556]

    Krämer CL, Arndt F, Boschert AL et al.. “Bacterial resistance across habitats: from German schools to the International Space Station.” Frontiers in microbiology (2026). PMID: 42395912 ↗

    L5OTHERCited in: History and Evolution of Treatment
  557. [557]

    Hermsen ED, Amos J, Townsend A et al.. “Antimicrobial resistance among refugees and asylum seekers: a global systematic review and meta-analysis.” The Lancet. Infectious diseases (2024). PMID: 39527961 ↗

    L2SR_OBSCited in: Antimicrobial Resistance and Stewardship, Prevention and Infection Control
  558. [558]

    Stryjewski ME, Corey GR. “Methicillin-resistant Staphylococcus aureus: an evolving pathogen.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 24343827 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  559. [559]

    Saravolatz LD, Stein GE. “Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus Fluoroquinolone.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30060092 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  560. [560]

    Mody L, Bradley SF, Galecki A et al.. “Conceptual model for reducing infections and antimicrobial resistance in skilled nursing facilities: focusing on residents with indwelling devices.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21292670 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  561. [561]

    Miyakis S, Pefanis A, Tsakris A. “The challenges of antimicrobial drug resistance in Greece.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21690626 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  562. [562]

    Rossi F. “The challenges of antimicrobial resistance in Brazil.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21467020 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  563. [563]

    Moghnieh RA, Kanafani ZA, Tabaja HZ et al.. “Epidemiology of common resistant bacterial pathogens in the countries of the Arab League.” The Lancet. Infectious diseases (2018). PMID: 30292478 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  564. [564]

    Petit H, de Tymowski C, Dudoignon E et al.. “Epidemiology and Outcomes of Bloodstream Infections in Patients in a Burns Intensive Care Unit: An 8-Year Retrospective Study.” Open forum infectious diseases (2025). PMID: 40182133 ↗

    L2COHORTCited in: Antimicrobial Resistance and Stewardship
  565. [565]

    Périchon B, Courvalin P. “VanA-type vancomycin-resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2009). PMID: 19506057 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  566. [566]

    File TM, Ramirez JA, Wilde AM. “New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on M. abscessus).” Antimicrobial agents and chemotherapy (2025). PMID: 39817764 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  567. [567]

    Reynolds R. “Antimicrobial resistance in the UK and Ireland.” The Journal of antimicrobial chemotherapy (2009). PMID: 19675014 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  568. [568]

    Livermore DM. “Has the era of untreatable infections arrived?” The Journal of antimicrobial chemotherapy (2009). PMID: 19675016 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  569. [569]

    Bisgaard H, Hermansen MN, Buchvald F et al.. “Childhood asthma after bacterial colonization of the airway in neonates.” The New England journal of medicine (2007). PMID: 17928596 ↗

    L2OTHERCited in: Antimicrobial Resistance and Stewardship, Special Hosts and Populations
  570. [570]

    . “Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.” Lancet (London, England) (2022). PMID: 36423648 ↗

    L2OTHERCited in: Antimicrobial Resistance and Stewardship, Special Hosts and Populations
  571. [571]

    Mohamad M, Hurst MM, Elkrewi E et al.. “Nature of bacitracin resistance in Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2025). PMID: 41186227 ↗

    L5OTHERCited in: Antimicrobial Resistance and Stewardship
  572. [572]

    Woosley LN, Castanheira M, Jones RN. “CEM-101 activity against Gram-positive organisms.” Antimicrobial agents and chemotherapy (2010). PMID: 20176910 ↗

    L5OTHERCited in: Antimicrobial Resistance and Stewardship
  573. [573]

    Chatterjee SS, Chen L, Gilbert A et al.. “PBP4 Mediates β-Lactam Resistance by Altered Function.” Antimicrobial agents and chemotherapy (2017). PMID: 28807923 ↗

    L5OTHERCited in: Antimicrobial Resistance and Stewardship
  574. [574]

    Cazer CL, Westblade LF, Simon MS et al.. “Analysis of Multidrug Resistance in Staphylococcus aureus with a Machine Learning-Generated Antibiogram.” Antimicrobial agents and chemotherapy (2021). PMID: 33431415 ↗

    L4OTHERCited in: Antimicrobial Resistance and Stewardship
  575. [575]

    Petersiel N, Howden BP, Giulieri S et al.. “An Achilles' heel for methicillin-resistant Staphylococcus aureus? Re-evaluating β-lactam susceptibility of MRSA.” Antimicrobial agents and chemotherapy (2026). PMID: 42405967 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship, Prognosis and Natural History
  576. [576]

    Virgillio AM, Felton EA, Jackson JK et al.. “Genomic and Phenotypic Characterization of Mupirocin-resistant Staphylococcus aureus Clinical Isolates.” Open forum infectious diseases (2025). PMID: 40698033 ↗

    L4OTHERCited in: Antimicrobial Resistance and Stewardship
  577. [577]

    Tenover FC, Goff DA. “Surveillance and Stewardship: Where Infection Prevention and Antimicrobial Stewardship Intersect.” Open forum infectious diseases (2023). PMID: 37089778 ↗

    L5OTHERCited in: Antimicrobial Resistance and Stewardship, Prevention and Infection Control
  578. [578]

    Timbrook TT, Olin KE, Spaulding U et al.. “Epidemiology of Antimicrobial Resistance Among Blood and Respiratory Specimens in the United States Using Genotypic Analysis From a Cloud-Based Population Surveillance Network.” Open forum infectious diseases (2022). PMID: 35873295 ↗

    L2OTHERCited in: Antimicrobial Resistance and Stewardship
  579. [579]

    Diekema DJ, Pfaller MA, Shortridge D et al.. “Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program.” Open forum infectious diseases (2019). PMID: 30895214 ↗

    L2OTHERCited in: Antimicrobial Resistance and Stewardship
  580. [580]

    Wozniak TM, Dyda A, Lee X. “The Increased Length of Hospital Stay and Mortality Associated With Community-Associated Infections in Australia.” Open forum infectious diseases (2022). PMID: 35493114 ↗

    L3OTHERCited in: Antimicrobial Resistance and Stewardship
  581. [581]

    Becker K, van Alen S, Idelevich EA et al.. “Plasmid-Encoded Transferable mecB-Mediated Methicillin Resistance in Staphylococcus aureus.” Emerging infectious diseases (2018). PMID: 29350135 ↗

    L4OTHERCited in: Antimicrobial Resistance and Stewardship
  582. [582]

    Hsu LY, Tan TY, Jureen R et al.. “Antimicrobial drug resistance in Singapore hospitals.” Emerging infectious diseases (2007). PMID: 18258055 ↗

    L2OTHERCited in: Antimicrobial Resistance and Stewardship
  583. [583]

    Gooskens J, Konstantinovski MM, Kraakman MEM et al.. “Panton-Valentine Leukocidin-Positive CC398 MRSA in Urban Clinical Settings, the Netherlands.” Emerging infectious diseases (2023). PMID: 36913919 ↗

    L4OTHERCited in: Antimicrobial Resistance and Stewardship
  584. [584]

    Sharma T, Chandley P. “Host-pathogen interactions during ESKAPE-mediated urinary tract infections and ventilator-associated pneumonia: a review.” Folia microbiologica (2026). PMID: 42423835 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  585. [585]

    Kiani M, Mehboodi M, Khanbabaie H et al.. “Lactobacillus strains in the prevention and disruption of antimicrobial-resistance in pathogenic microbial biofilms: a review of mechanisms and clinical perspective.” Folia microbiologica (2026). PMID: 42412160 ↗

    L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship
  586. [586]

    Antoniolli A, Ruge T, Biron A et al.. “Emergence of antimicrobial resistance in New Caledonia: 20-year trends from laboratory-based surveillance (2005-2024).” The Lancet regional health. Western Pacific (2026). PMID: 42434433 ↗

    L2OTHERCited in: Antimicrobial Resistance and Stewardship
  587. [587]

    Piper KR, Buiatte ABG, Souza SSR et al.. “Plasmids of co-circulating Staphylococcus aureus serve as vehicles for antimicrobial resistance sharing across diseased host-species at short timescales.” BMC microbiology (2026). PMID: 42426609 ↗

    L3OTHERCited in: Antimicrobial Resistance and Stewardship
  588. [588]

    Abrahamian FM, Sakoulas G, Tzanis E et al.. “Omadacycline for Acute Bacterial Skin and Skin Structure Infections.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 31367742 ↗

    L1RCTCited in: Complications
  589. [589]

    Corey GR. “Staphylococcus aureus bloodstream infections: definitions and treatment.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19374581 ↗

    L5CASE_REPORTCited in: Complications
  590. [590]

    Boucher HW, Wilcox M, Talbot GH et al.. “Once-weekly dalbavancin versus daily conventional therapy for skin infection.” The New England journal of medicine (2014). PMID: 24897082 ↗

    L1RCTCited in: Complications
  591. [591]

    Eljaaly K, Alshehri S, Erstad BL. “Systematic Review and Meta-analysis of the Safety of Antistaphylococcal Penicillins Compared to Cefazolin.” Antimicrobial agents and chemotherapy (2018). PMID: 29437617 ↗

    L1SR_OBSCited in: Complications
  592. [592]

    Karanika S, Paudel S, Grigoras C et al.. “Systematic Review and Meta-analysis of Clinical and Economic Outcomes from the Implementation of Hospital-Based Antimicrobial Stewardship Programs.” Antimicrobial agents and chemotherapy (2016). PMID: 27246783 ↗

    L1SR_OBSCited in: Complications
  593. [593]

    Kidd JM, Sakon CM, Oleksiuk LM et al.. “Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation.” Antimicrobial agents and chemotherapy (2019). PMID: 31685468 ↗

    L4TRIAL_NONRANDOMCited in: Complications
  594. [594]

    Holland TL, Shorr AF, Overcash JS et al.. “Impact of obesity on clinical outcomes in patients treated with ceftobiprole: results from Phase 3 clinical trials.” The Journal of antimicrobial chemotherapy (2025). PMID: 40155066 ↗

    L2TRIAL_NONRANDOMCited in: Complications
  595. [595]

    Arbona-Lampaya A, Pérez-Ojeda RA, Santos-Marrero M et al.. “Below-knee amputation following osteomyelitis from multidrug-resistant Stenotrophomonas maltophilia in a diabetic foot ulcer.” The Lancet. Infectious diseases (2025). PMID: 41429139 ↗

    L4CASE_REPORTCited in: Complications
  596. [596]

    Beaumont AL, Mestre F, Decaux S et al.. “Long-term Oral Suppressive Antimicrobial Therapy in Infective Endocarditis (SATIE Study): An Observational Study.” Open forum infectious diseases (2024). PMID: 38737431 ↗

    L4TRIAL_NONRANDOMCited in: Complications, Prognosis and Natural History
  597. [597]

    Weber MA, Klein NJ, Hartley JC et al.. “Infection and sudden unexpected death in infancy: a systematic retrospective case review.” Lancet (London, England) (2008). PMID: 18514728 ↗

    L4REVIEW_NARRATIVECited in: Complications
  598. [598]

    Kristiansen JE, Hendricks O, Delvin T et al.. “Reversal of resistance in microorganisms by help of non-antibiotics.” The Journal of antimicrobial chemotherapy (2007). PMID: 17403708 ↗

    L5REVIEW_NARRATIVECited in: Complications
  599. [599]

    Principi N, Caironi M, Venturini F et al.. “Daptomycin in paediatrics: current knowledge and the need for future research.” The Journal of antimicrobial chemotherapy (2014). PMID: 25406298 ↗

    L5REVIEW_NARRATIVECited in: Complications, Special Hosts and Populations
  600. [600]

    Parkins MD, Elborn JS. “Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management.” The Journal of antimicrobial chemotherapy (2010). PMID: 20605846 ↗

    L5REVIEW_NARRATIVECited in: Complications
  601. [601]

    Akita S, Okamura T, Tanigawa K. “Clinical Efficacy and Broad-Spectrum Antimicrobial Activity of pH-Controlled Sodium Hypochlorite Solution (HACCP'ER) in Acute and Chronic Wound Management: A Retrospective Cohort Study.” Journal of clinical medicine (2026). PMID: 42278958 ↗

    L4COHORTCited in: Complications
  602. [602]

    Kiefer T, Park L, Tribouilloy C et al.. “Association between valvular surgery and mortality among patients with infective endocarditis complicated by heart failure.” JAMA (2011). PMID: 22110106 ↗

    L2OTHERCited in: Complications
  603. [603]

    Renzoni A, Von Dach E, Landelle C et al.. “Impact of Exposure of Methicillin-Resistant Staphylococcus aureus to Polyhexanide In Vitro and In Vivo.” Antimicrobial agents and chemotherapy (2017). PMID: 28784678 ↗

    L5OTHERCited in: Complications
  604. [604]

    Ortines RV, Liu H, Cheng LI et al.. “Neutralizing Alpha-Toxin Accelerates Healing of Staphylococcus aureus-Infected Wounds in Nondiabetic and Diabetic Mice.” Antimicrobial agents and chemotherapy (2018). PMID: 29311091 ↗

    L5OTHERCited in: Complications
  605. [605]

    Kwon DH, Lu CD. “Polyamine effects on antibiotic susceptibility in bacteria.” Antimicrobial agents and chemotherapy (2007). PMID: 17438056 ↗

    L5OTHERCited in: Complications
  606. [606]

    Wasielewski AS, Casapao AM, Jankowski CA et al.. “Impact of obesity on clinical outcomes of methicillin-susceptible Staphylococcus aureus bloodstream infections.” Antimicrobial agents and chemotherapy (2024). PMID: 39324801 ↗

    L2OTHERCited in: Complications
  607. [607]

    Couderc C, Thiébaut AC, Lawrence C et al.. “Fluoroquinolone Impact on Nasal Methicillin-Resistant and Methicillin-Sensitive Staphylococcus aureus Colonization Durations in Neurologic Long-Term-Care Facilities.” Antimicrobial agents and chemotherapy (2015). PMID: 26416866 ↗

    L2OTHERCited in: Complications
  608. [608]

    Barlow GD. “Swine flu and antibiotics.” The Journal of antimicrobial chemotherapy (2009). PMID: 19740909 ↗

    L5OTHERCited in: Complications
  609. [609]

    Shah S, Clarke LG, Balasubramani GK et al.. “Impact of hypoalbuminemia on patients receiving ertapenem combination therapy for methicillin-susceptible Staphylococcus aureus bacteraemia.” The Journal of antimicrobial chemotherapy (2025). PMID: 40448546 ↗

    L2OTHERCited in: Complications
  610. [610]

    Das S, Li J, Iaconis J et al.. “Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections.” The Journal of antimicrobial chemotherapy (2019). PMID: 30380060 ↗

    L2OTHERCited in: Complications, Special Hosts and Populations
  611. [611]

    Eustace MB, Braddick M, Alcorn K et al.. “Central Skull Base Osteomyelitis in Queensland, Australia, 2010-2020.” Open forum infectious diseases (2024). PMID: 39450399 ↗

    L4OTHERCited in: Complications, Prognosis and Natural History
  612. [612]

    Roberts K, Dewar S, Sutherland RK et al.. “Respiratory Virus Coinfection Is a Risk Factor for Adverse Outcomes During Staphylococcus aureus Bacteremia.” Open forum infectious diseases (2026). PMID: 41859699 ↗

    L2OTHERCited in: Complications
  613. [613]

    Hiskey L, Saifuddin H, Levy ER et al.. “First-Generation Cephalosporins for Treatment of Acute Hematogenous Osteomyelitis in Children: A Study of Efficacy and Adverse Effects.” Open forum infectious diseases (2023). PMID: 38156049 ↗

    L2OTHERCited in: Complications, Special Hosts and Populations
  614. [614]

    Richter SE, Miller L, Needleman J et al.. “Risk Factors for Development of Carbapenem Resistance Among Gram-Negative Rods.” Open forum infectious diseases (2019). PMID: 30863785 ↗

    L3OTHERCited in: Complications
  615. [615]

    Pettigrew MM, Gent JF, Revai K et al.. “Microbial interactions during upper respiratory tract infections.” Emerging infectious diseases (2008). PMID: 18826823 ↗

    L2OTHERCited in: Complications, Prevention and Infection Control, Special Hosts and Populations
  616. [616]

    McDanel JS, Perencevich EN, Storm J et al.. “Increased Mortality Rates Associated with Staphylococcus aureus and Influenza Co-infection, Maryland and Iowa, USA(1).” Emerging infectious diseases (2016). PMID: 27315549 ↗

    L2OTHERCited in: Complications, Prognosis and Natural History
  617. [617]

    Saxena S, Thompson P, Birger R et al.. “Increasing skin infections and Staphylococcus aureus complications in children, England, 1997-2006.” Emerging infectious diseases (2010). PMID: 20202439 ↗

    L2OTHERCited in: Complications
  618. [618]

    Magill SS, Dumyati G, Ray SM et al.. “Evaluating Epidemiology and Improving Surveillance of Infections Associated with Health Care, United States.” Emerging infectious diseases (2015). PMID: 26291035 ↗

    L5OTHERCited in: Complications, Prevention and Infection Control
  619. [619]

    Kreisel KM, Johnson JK, Stine OC et al.. “Illicit drug use and risk for USA300 methicillin-resistant Staphylococcus aureus infections with bacteremia.” Emerging infectious diseases (2010). PMID: 20735927 ↗

    L2OTHERCited in: Complications
  620. [620]

    Liang H, Mao ZF, Huang JY et al.. “Case Report: Moxibustion-induced burns leading to disseminated methicillin-resistant Staphylococcus aureus infection in a patient with type 2 diabetes mellitus.” Frontiers in endocrinology (2026). PMID: 42272806 ↗

    L4CASE_REPORTCited in: Complications
  621. [621]

    Carey GB, Holleck JL, Ein Alshaeba S et al.. “Estimated mortality with early empirical antibiotic coverage of methicillin-resistant Staphylococcus aureus in hospitalized patients with bacterial infections: a systematic review and meta-analysis.” The Journal of antimicrobial chemotherapy (2023). PMID: 36964648 ↗

    L1SR_OBSCited in: Prognosis and Natural History
  622. [622]

    Tacconelli E, De Angelis G, Cataldo MA et al.. “Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis.” The Journal of antimicrobial chemotherapy (2007). PMID: 17986491 ↗

    L1SR_OBSCited in: Prognosis and Natural History
  623. [623]

    Paulsen J, Solligård E, Damås JK et al.. “The Impact of Infectious Disease Specialist Consultation for Staphylococcus aureus Bloodstream Infections: A Systematic Review.” Open forum infectious diseases (2016). PMID: 27047985 ↗

    L2SR_OBSCited in: Prognosis and Natural History
  624. [624]

    Dancer SJ. “Controlling hospital-acquired infection: focus on the role of the environment and new technologies for decontamination.” Clinical microbiology reviews (2014). PMID: 25278571 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Natural History, Prevention and Infection Control
  625. [625]

    Kondo Y, Klompas M, McKenna CS et al.. “Association Between the Sequence of β-Lactam and Vancomycin Administration and Mortality in Patients With Suspected Sepsis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39657016 ↗

    L2OTHERCited in: Prognosis and Natural History
  626. [626]

    Saravolatz L, Gandhi TN, Vaughn VM et al.. “Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized With Pneumonia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 40601818 ↗

    L2OTHERCited in: Prognosis and Natural History
  627. [627]

    Gibert C, Marchetti C, Guery B et al.. “Outcome Predictors of Candida Prosthetic Joint Infections: A Systematic Review and Meta-analysis.” Open forum infectious diseases (2025). PMID: 40463834 ↗

    L2SR_OBSCited in: Prognosis and Natural History
  628. [628]

    Østergaard L, Voldstedlund M, Bruun NE et al.. “Prevalence and Mortality of Infective Endocarditis in Community-Acquired and Healthcare-Associated Staphylococcus aureus Bacteremia: A Danish Nationwide Registry-Based Cohort Study.” Open forum infectious diseases (2022). PMID: 36540385 ↗

    L2COHORTCited in: Prognosis and Natural History
  629. [629]

    Plumet L, Costechareyre D, Lavigne J-P et al.. “Zebrafish as an effective model for evaluating phage therapy in bacterial infections: a promising strategy against human pathogens.” Antimicrobial agents and chemotherapy (2024). PMID: 39248472 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Natural History
  630. [630]

    Marro FC, Abad L, Blocker AJ et al.. “In vitro antibiotic activity against intraosteoblastic Staphylococcus aureus: a narrative review of the literature.” The Journal of antimicrobial chemotherapy (2021). PMID: 34459881 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Natural History
  631. [631]

    Kuehl R, Morata L, Meylan S et al.. “When antibiotics fail: a clinical and microbiological perspective on antibiotic tolerance and persistence of Staphylococcus aureus.” The Journal of antimicrobial chemotherapy (2020). PMID: 32016348 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Natural History
  632. [632]

    Seaton RA. “Daptomycin: rationale and role in the management of skin and soft tissue infections.” The Journal of antimicrobial chemotherapy (2008). PMID: 18829721 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Natural History
  633. [633]

    Dancer SJ. “The effect of antibiotics on methicillin-resistant Staphylococcus aureus.” The Journal of antimicrobial chemotherapy (2007). PMID: 18057071 ↗

    L5REVIEW_NARRATIVECited in: Prognosis and Natural History
  634. [634]

    Ong SWX, Patrikar A, Pinto R et al.. “Application of a Novel Desirability of Outcome Ranking Endpoint Incorporating a Framework for Resistance Assessment and Microbiologic Evaluation in Antibiotic Trials: A Proof-of-Concept in a Post Hoc Analysis of the BALANCE Trial.” Open forum infectious diseases (2026). PMID: 42338985 ↗

    L2TRIAL_NONRANDOMCited in: Prognosis and Natural History
  635. [635]

    Lewandowski T, Huang J, Fan F et al.. “Staphylococcus aureus formyl-methionyl transferase mutants demonstrate reduced virulence factor production and pathogenicity.” Antimicrobial agents and chemotherapy (2013). PMID: 23571548 ↗

    L5OTHERCited in: Prognosis and Natural History
  636. [636]

    Clarke RS, Ha KP, Edwards AM. “RexAB Promotes the Survival of Staphylococcus aureus Exposed to Multiple Classes of Antibiotics.” Antimicrobial agents and chemotherapy (2021). PMID: 34310219 ↗

    L5OTHERCited in: Prognosis and Natural History
  637. [637]

    Truong-Bolduc QC, Yonker LM, Wang Y et al.. “NorA efflux pump mediates Staphylococcus aureus response to Pseudomonas aeruginosa pyocyanin toxicity.” Antimicrobial agents and chemotherapy (2024). PMID: 38231535 ↗

    L5OTHERCited in: Prognosis and Natural History, Special Hosts and Populations
  638. [638]

    Klein E, Smith DL, Laxminarayan R. “Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005.” Emerging infectious diseases (2007). PMID: 18258033 ↗

    L2OTHERCited in: Prognosis and Natural History
  639. [639]

    Gutierrez K, Halpern MS, Sarnquist C et al.. “Staphylococcal infections in children, California, USA, 1985-2009.” Emerging infectious diseases (2013). PMID: 23260060 ↗

    L2OTHERCited in: Prognosis and Natural History
  640. [640]

    Pastagia M, Kleinman LC, Lacerda de la Cruz EG et al.. “Predicting risk for death from MRSA bacteremia.” Emerging infectious diseases (2012). PMID: 22709685 ↗

    L2OTHERCited in: Prognosis and Natural History
  641. [641]

    Aguado JM, San-Juan R, Lalueza A et al.. “High vancomycin MIC and complicated methicillin-susceptible Staphylococcus aureus bacteremia.” Emerging infectious diseases (2011). PMID: 21749780 ↗

    L2OTHERCited in: Prognosis and Natural History
  642. [642]

    Robinson AL, Boyle MG, Hogan PG et al.. “Evaluating Personal and Environmental Decolonization Strategies for Children With Skin and Soft Tissue Infection and Their Households - A Randomized Clinical Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41276461 ↗

    L1RCTCited in: Prevention and Infection Control, Special Hosts and Populations
  643. [643]

    Anderson DJ, Moehring RW, Weber DJ et al.. “Effectiveness of targeted enhanced terminal room disinfection on hospital-wide acquisition and infection with multidrug-resistant organisms and Clostridium difficile: a secondary analysis of a multicentre cluster randomised controlled trial with crossover design (BETR Disinfection).” The Lancet. Infectious diseases (2018). PMID: 29880301 ↗

    L2RCTCited in: Prevention and Infection Control
  644. [644]

    Gemmell CG, Edwards DI, Fraise AP et al.. “Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK.” The Journal of antimicrobial chemotherapy (2006). PMID: 16507559 ↗

    L1GUIDELINECited in: Prevention and Infection Control
  645. [645]

    Gould FK, Brindle R, Chadwick PR et al.. “Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom.” The Journal of antimicrobial chemotherapy (2009). PMID: 19282331 ↗

    L1GUIDELINECited in: Prevention and Infection Control
  646. [646]

    Crawford T, Rodvold KA, Solomkin JS. “Vancomycin for surgical prophylaxis?” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2012). PMID: 22328468 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  647. [647]

    Daum RS, Spellberg B. “Progress toward a Staphylococcus aureus vaccine.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 22186773 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  648. [648]

    Hetem DJ, Bootsma MC, Bonten MJ. “Prevention of Surgical Site Infections: Decontamination With Mupirocin Based on Preoperative Screening for Staphylococcus aureus Carriers or Universal Decontamination?” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). PMID: 26658054 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  649. [649]

    Santos RP, Mayo TW, Siegel JD. “Healthcare epidemiology: active surveillance cultures and contact precautions for control of multidrug-resistant organisms: ethical considerations.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18491966 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  650. [650]

    Price JR, Cole K, Bexley A et al.. “Transmission of Staphylococcus aureus between health-care workers, the environment, and patients in an intensive care unit: a longitudinal cohort study based on whole-genome sequencing.” The Lancet. Infectious diseases (2016). PMID: 27863959 ↗

    L2COHORTCited in: Prevention and Infection Control
  651. [651]

    Bojang A, Baines SL, Donovan L et al.. “Genomic investigation of Staphylococcus aureus recovered from Gambian women and newborns following an oral dose of intra-partum azithromycin.” The Journal of antimicrobial chemotherapy (2019). PMID: 31424550 ↗

    L4RCTCited in: Prevention and Infection Control
  652. [652]

    Dancer SJ. “Importance of the environment in meticillin-resistant Staphylococcus aureus acquisition: the case for hospital cleaning.” The Lancet. Infectious diseases (2007). PMID: 17974481 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  653. [653]

    Okomo U, Fitzgerald F, Feasey N et al.. “Infection prevention and control in low- and middle-income countries: policy, practice, and implementation challenges in sub-Saharan Africa.” Clinical microbiology reviews (2026). PMID: 42132371 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  654. [654]

    Soge OO, Thibault CS, Cannon CA et al.. “Potential Impact of Doxycycline Post-Exposure Prophylaxis on Tetracycline Resistance in Neisseria gonorrhoeae and Colonization With Tetracycline-Resistant Staphylococcus aureus and Group A Streptococcus.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 40036749 ↗

    L2OTHERCited in: Prevention and Infection Control
  655. [655]

    Diekema DJ, Nori P, Stevens MP et al.. “Are Contact Precautions "Essential" for the Prevention of Healthcare-associated Methicillin-Resistant Staphylococcus aureus?” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37738565 ↗

    L5OTHERCited in: Prevention and Infection Control
  656. [656]

    Zong Z, Wu A, Hu B. “Infection Control in the Era of Antimicrobial Resistance in China: Progress, Challenges, and Opportunities.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 33367579 ↗

    L5OTHERCited in: Prevention and Infection Control
  657. [657]

    Evans ME, Simbartl LA, McCauley BP et al.. “Active Surveillance and Contact Precautions for Preventing Methicillin-Resistant Staphylococcus aureus Healthcare-Associated Infections During the COVID-19 Pandemic.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37390613 ↗

    L2OTHERCited in: Prevention and Infection Control
  658. [658]

    Cabral SM, Harris AD, Cosgrove SE et al.. “Adherence to Antimicrobial Prophylaxis Guidelines for Elective Surgeries Across 825 US Hospitals, 2019-2020.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36774539 ↗

    L2OTHERCited in: Prevention and Infection Control
  659. [659]

    Wyllie D, Paul J, Crook D. “Waves of trouble: MRSA strain dynamics and assessment of the impact of infection control.” The Journal of antimicrobial chemotherapy (2011). PMID: 21948966 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  660. [660]

    Cattoir V, Leclercq R. “Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce?” The Journal of antimicrobial chemotherapy (2012). PMID: 23208830 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  661. [661]

    Edgeworth JD. “Has decolonization played a central role in the decline in UK methicillin-resistant Staphylococcus aureus transmission? A focus on evidence from intensive care.” The Journal of antimicrobial chemotherapy (2010). PMID: 20852273 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  662. [662]

    Johnson AP, Davies J, Guy R et al.. “Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 years.” The Journal of antimicrobial chemotherapy (2012). PMID: 22223229 ↗

    L2REVIEW_NARRATIVECited in: Prevention and Infection Control
  663. [663]

    Harbarth S, Samore MH. “Interventions to control MRSA: high time for time-series analysis?” The Journal of antimicrobial chemotherapy (2008). PMID: 18556707 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  664. [664]

    . “Global burden of lower respiratory infections and aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.” The Lancet. Infectious diseases (2025). PMID: 41412141 ↗

    L2OTHERCited in: Prevention and Infection Control, Special Hosts and Populations
  665. [665]

    Grayson ML, Stewardson AJ, Russo PL et al.. “Effects of the Australian National Hand Hygiene Initiative after 8 years on infection control practices, health-care worker education, and clinical outcomes: a longitudinal study.” The Lancet. Infectious diseases (2018). PMID: 30274723 ↗

    L2OTHERCited in: Prevention and Infection Control
  666. [666]

    Handapangoda NP, Ruwansiri LP, Vidanapathirana GU et al.. “Prevalence of Streptococcus pneumoniae and Staphylococcus aureus co-colonization in healthy children under five years: a systematic review.” BMC pediatrics (2026). PMID: 41826897 ↗

    L3SR_OBSCited in: Prevention and Infection Control, Special Hosts and Populations
  667. [667]

    Ter Steeg L, Domínguez-Andrés J, Netea MG et al.. “Trained Immunity as a Preventive Measure for Surgical Site Infections.” Clinical microbiology reviews (2021). PMID: 34585978 ↗

    L5OTHERCited in: Prevention and Infection Control
  668. [668]

    Khairy TF, Lupien MA, Nava S et al.. “Infections Associated with Resterilized Pacemakers and Defibrillators.” The New England journal of medicine (2020). PMID: 32374963 ↗

    L2OTHERCited in: Prevention and Infection Control
  669. [669]

    Yang C, Peng C, Yan J et al.. “Cefazolin Alone versus Vancomycin Plus Cefazolin for Intravenous Prophylaxis in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis.” The Journal of arthroplasty (2026). PMID: 42069021 ↗

    L1SR_OBSCited in: Prevention and Infection Control
  670. [670]

    Hurley JC. “Arms-Based Meta-Analysis of Microbiological Endpoints of 88 VAP Prevention Studies Using Antimicrobial Versus Non-Antimicrobial Strategies-Towards 'VAP-Zero'?” Antibiotics (Basel, Switzerland) (2026). PMID: 41750518 ↗

    L1SR_OBSCited in: Prevention and Infection Control
  671. [671]

    Mostofi K, Caragliano G. “Surgical Site Infections in Spine Surgery: A Retrospective Study of 1,578 Procedures with Identification of Tattooed Skin as a Novel Risk Factor Associated with Surgical Site Infection.” The Journal of hospital infection (2026). PMID: 42314879 ↗

    L2COHORTCited in: Prevention and Infection Control
  672. [672]

    Takahashi H, Taku K, Mizuki K et al.. “Comparison of methicillin-resistant Staphylococcus aureus carriage in a neonatal intensive care unit between pre- and post-COVID-19 pandemic periods, following the introduction of strengthened infection control measures: a retrospective study.” The Journal of hospital infection (2026). PMID: 42162920 ↗

    L2COHORTCited in: Prevention and Infection Control
  673. [673]

    Nikolić D, Petrović K, Manojlović V et al.. “Increasing Methicillin-Resistant Staphylococcus aureus Burden in 90-Day Groin Surgical Site Infection After Femoral Arterial Exposure: A 15-Year Single-Centre Cohort Study.” International wound journal (2026). PMID: 42117325 ↗

    L2COHORTCited in: Prevention and Infection Control
  674. [674]

    Molendijk MM, Boekema BKHL, Lattwein KR et al.. “Bacteriophage therapy reduces Staphylococcus aureus in a porcine and human ex vivo burn wound infection model.” Antimicrobial agents and chemotherapy (2024). PMID: 39136463 ↗

    L5OTHERCited in: Prevention and Infection Control
  675. [675]

    Wei J, Tong K, Wang H et al.. “Dosage, Efficacy, and Safety of Intra-articular Vancomycin for Prophylaxis of Periprosthetic Joint Infection Caused by Methicillin-Resistant Staphylococcus aureus after Total Knee Arthroplasty in a Rat Model.” Antimicrobial agents and chemotherapy (2021). PMID: 34807762 ↗

    L5OTHERCited in: Prevention and Infection Control
  676. [676]

    Stiefel P, Mauerhofer S, Schneider J et al.. “Enzymes Enhance Biofilm Removal Efficiency of Cleaners.” Antimicrobial agents and chemotherapy (2016). PMID: 27044552 ↗

    L5OTHERCited in: Prevention and Infection Control
  677. [677]

    Tornero E, García-Ramiro S, Martínez-Pastor JC et al.. “Prophylaxis with teicoplanin and cefuroxime reduces the rate of prosthetic joint infection after primary arthroplasty.” Antimicrobial agents and chemotherapy (2014). PMID: 25403662 ↗

    L2OTHERCited in: Prevention and Infection Control
  678. [678]

    Mao Y, Valour F, Nguyen NTQ et al.. “Multimechanistic Monoclonal Antibody Combination Targeting Key Staphylococcus aureus Virulence Determinants in a Rabbit Model of Prosthetic Joint Infection.” Antimicrobial agents and chemotherapy (2021). PMID: 33903108 ↗

    L5OTHERCited in: Prevention and Infection Control
  679. [679]

    Diep BA, Hilliard JJ, Le VT et al.. “Targeting Alpha Toxin To Mitigate Its Lethal Toxicity in Ferret and Rabbit Models of Staphylococcus aureus Necrotizing Pneumonia.” Antimicrobial agents and chemotherapy (2017). PMID: 28115346 ↗

    L5OTHERCited in: Prevention and Infection Control
  680. [680]

    Freire MP, Pierrotti LC, Zerati AE et al.. “Role of Lock Therapy for Long-Term Catheter-Related Infections by Multidrug-Resistant Bacteria.” Antimicrobial agents and chemotherapy (2018). PMID: 29987150 ↗

    L4OTHERCited in: Prevention and Infection Control
  681. [681]

    McNeil JC, Kok EY, Vallejo JG et al.. “Clinical and Molecular Features of Decreased Chlorhexidine Susceptibility among Nosocomial Staphylococcus aureus Isolates at Texas Children's Hospital.” Antimicrobial agents and chemotherapy (2015). PMID: 26666947 ↗

    L4OTHERCited in: Prevention and Infection Control, Special Hosts and Populations
  682. [682]

    Saint-Genis Q, Marchand S, Chauzy A et al.. “Microdialysis assessment of gentamicin for second-line antimicrobial prophylaxis in abdominal surgery.” The Journal of antimicrobial chemotherapy (2026). PMID: 41744034 ↗

    L2OTHERCited in: Prevention and Infection Control
  683. [683]

    Pitt-Kendall R, Sun S, Hughes S et al.. “Investigating the cause of increased tetracycline-resistant Neisseria gonorrhoeae in England, 2016-20.” The Journal of antimicrobial chemotherapy (2024). PMID: 38517444 ↗

    L2OTHERCited in: Prevention and Infection Control
  684. [684]

    Bayston R, Vera L, Mills A et al.. “In vitro antimicrobial activity of silver-processed catheters for neurosurgery.” The Journal of antimicrobial chemotherapy (2009). PMID: 19942617 ↗

    L5OTHERCited in: Prevention and Infection Control
  685. [685]

    Houston A, Hooker E, Rankin A et al.. “Environmental surface sampling in health and care settings: a scoping review of published guidance.” The Journal of hospital infection (2026). PMID: 42025699 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  686. [686]

    Albaloul H, Nemer A, Saini N et al.. “Infectious Diseases: What You May Have Missed in 2025.” Annals of internal medicine (2026). PMID: 41974008 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control, Special Hosts and Populations
  687. [687]

    Pathinathan K, Sial A, Khalil O et al.. “Strategies to prevent post-operative surgical site infection in spinal surgery: a narrative review.” European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society (2026). PMID: 41936664 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  688. [688]

    Bosetti D, Lee A, Catho G et al.. “Beyond Methicillin-resistant Staphylococcus aureus: Prevention Strategies for Health Care-Associated Staphylococcus aureus Infection.” Infectious disease clinics of North America (2026). PMID: 41896065 ↗

    L5REVIEW_NARRATIVECited in: Prevention and Infection Control
  689. [689]

    Bryce A, Davison S, Currie BJ et al.. “Lower Rates of Staphylococcus aureus Bloodstream Infection in Patients on Hemodialysis Receiving Trimethoprim-Sulfamethoxazole Melioidosis Prophylaxis.” Open forum infectious diseases (2024). PMID: 39130084 ↗

    L4OTHERCited in: Prevention and Infection Control
  690. [690]

    Creech CB, Frenck RW, Fiquet A et al.. “Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag).” Open forum infectious diseases (2019). PMID: 31993453 ↗

    L4OTHERCited in: Prevention and Infection Control
  691. [691]

    DeSimone DC, Lahr BD, Anavekar NS et al.. “Temporal Trends of Infective Endocarditis in Olmsted County, Minnesota, Between 1970 and 2018: A Population-Based Analysis.” Open forum infectious diseases (2021). PMID: 33728357 ↗

    L2OTHERCited in: Prevention and Infection Control
  692. [692]

    Aslam S, Lampley E, Wooten D et al.. “Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States.” Open forum infectious diseases (2020). PMID: 33005701 ↗

    L4OTHERCited in: Prevention and Infection Control
  693. [693]

    Lesens O, Haus-Cheymol R, Dubrous P et al.. “Methicillin-susceptible, doxycycline-resistant Staphylococcus aureus, Côte d'Ivoire.” Emerging infectious diseases (2007). PMID: 17552109 ↗

    L4OTHERCited in: Prevention and Infection Control
  694. [694]

    Zilberberg MD, Shorr AF, Kollef MH. “Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005.” Emerging infectious diseases (2008). PMID: 18976563 ↗

    L2OTHERCited in: Prevention and Infection Control
  695. [695]

    Huson MA, Stolp SM, van der Poll T et al.. “Community-acquired bacterial bloodstream infections in HIV-infected patients: a systematic review.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2013). PMID: 24046307 ↗

    L2SR_OBSCited in: Special Hosts and Populations
  696. [696]

    Rice S, Carr K, Sobiesuo P et al.. “Economic evaluations of interventions to prevent and control health-care-associated infections: a systematic review.” The Lancet. Infectious diseases (2023). PMID: 37001543 ↗

    L2SR_OBSCited in: Special Hosts and Populations
  697. [697]

    Payne SC, Benninger MS. “Staphylococcus aureus is a major pathogen in acute bacterial rhinosinusitis: a meta-analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2007). PMID: 17968816 ↗

    L1SR_OBSCited in: Special Hosts and Populations
  698. [698]

    Doernberg SB, Arias CA, Altman DR et al.. “Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37843115 ↗

    L5REVIEW_NARRATIVECited in: Special Hosts and Populations
  699. [699]

    Fritz SA, Hogan PG, Camins BC et al.. “Mupirocin and chlorhexidine resistance in Staphylococcus aureus in patients with community-onset skin and soft tissue infections.” Antimicrobial agents and chemotherapy (2012). PMID: 23147738 ↗

    L2RCTCited in: Special Hosts and Populations
  700. [700]

    Campbell AJ, Al Yazidi LS, Phuong LK et al.. “Pediatric Staphylococcus aureus Bacteremia: Clinical Spectrum and Predictors of Poor Outcome.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34089594 ↗

    L2OTHERCited in: Special Hosts and Populations
  701. [701]

    Park DE, Baggett HC, Howie SRC et al.. “Colonization Density of the Upper Respiratory Tract as a Predictor of Pneumonia-Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, and Pneumocystis jirovecii.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2017). PMID: 28575367 ↗

    L3OTHERCited in: Special Hosts and Populations
  702. [702]

    Popovich KJ, Weinstein RA, Aroutcheva A et al.. “Community-associated methicillin-resistant Staphylococcus aureus and HIV: intersecting epidemics.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2010). PMID: 20192731 ↗

    L3OTHERCited in: Special Hosts and Populations
  703. [703]

    Dicko CH, N'Dri DN, Snoussi M et al.. “Etiology, prevalence, and mortality of sepsis among children under five years in Africa: a systematic review and meta-analysis.” BMC infectious diseases (2026). PMID: 42035015 ↗

    L1SR_OBSCited in: Special Hosts and Populations
  704. [704]

    Aleissa MM, Gonzalez-Bocco IH, Zekery-Saad S et al.. “The Relationship Between Antibiotic Agent and Mortality in Patients With Febrile Neutropenia due to Staphylococcal Bloodstream Infection: A Multicenter Cohort Study.” Open forum infectious diseases (2022). PMID: 35949404 ↗

    L2COHORTCited in: Special Hosts and Populations
  705. [705]

    Bodey GP. “The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Fever and neutropenia: the early years.” The Journal of antimicrobial chemotherapy (2009). PMID: 19372179 ↗

    L5REVIEW_NARRATIVECited in: Special Hosts and Populations
  706. [706]

    Musicha P, Cornick JE, Bar-Zeev N et al.. “Trends in antimicrobial resistance in bloodstream infection isolates at a large urban hospital in Malawi (1998-2016): a surveillance study.” The Lancet. Infectious diseases (2017). PMID: 28818544 ↗

    L2OTHERCited in: Special Hosts and Populations
  707. [707]

    Okike IO, Ribeiro S, Ramsay ME et al.. “Trends in bacterial, mycobacterial, and fungal meningitis in England and Wales 2004-11: an observational study.” The Lancet. Infectious diseases (2014). PMID: 24508198 ↗

    L2OTHERCited in: Special Hosts and Populations
  708. [708]

    Liou TG, Adler FR, Cox DR et al.. “Lung transplantation and survival in children with cystic fibrosis.” The New England journal of medicine (2007). PMID: 18032764 ↗

    L2OTHERCited in: Special Hosts and Populations
  709. [709]

    Mohamud SM, Nor LA, Doğan S et al.. “Antimicrobial resistance patterns of Staphylococcus aureus isolates in tertiary hospital in Somalia: a retrospective study.” BMC infectious diseases (2026). PMID: 42087083 ↗

    L4COHORTCited in: Special Hosts and Populations
  710. [710]

    Sng ECY, Teo DCH, Wong MJ et al.. “Microbiology and clinical characteristics of brain abscess in adults from 3 tertiary hospitals in Singapore - a 11-year multicenter retrospective study.” BMC infectious diseases (2026). PMID: 42062945 ↗

    L4COHORTCited in: Special Hosts and Populations
  711. [711]

    Wang C, Wang K, Zhu H et al.. “Analysis of risk factors for concurrent osteomyelitis in children with septic arthritis: A retrospective cohort study.” The American journal of emergency medicine (2026). PMID: 42061203 ↗

    L2COHORTCited in: Special Hosts and Populations
  712. [712]

    Krymko H, Abelson N, El Mahdi N et al.. “Predictors of definite and possible infective endocarditis in children with bacteremia: a reginal cohort study.” European journal of pediatrics (2026). PMID: 41866405 ↗

    L2COHORTCited in: Special Hosts and Populations
  713. [713]

    Attaianese F, Benhard J, Cohen JF et al.. “Oral switch therapy for paediatric Staphylococcus aureus bloodstream infections: A retrospective study in a tertiary hospital.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41846044 ↗

    L2COHORTCited in: Special Hosts and Populations
  714. [714]

    Autmizguine J, Melloni C, Hornik CP et al.. “Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children.” Antimicrobial agents and chemotherapy (2017). PMID: 29084742 ↗

    L4OTHERCited in: Special Hosts and Populations
  715. [715]

    McNeil JC, Hulten KG, Kaplan SL et al.. “Mupirocin resistance in Staphylococcus aureus causing recurrent skin and soft tissue infections in children.” Antimicrobial agents and chemotherapy (2011). PMID: 21282426 ↗

    L4OTHERCited in: Special Hosts and Populations
  716. [716]

    Szumowski JD, Cohen DE, Kanaya F et al.. “Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic.” Antimicrobial agents and chemotherapy (2006). PMID: 17116664 ↗

    L2OTHERCited in: Special Hosts and Populations
  717. [717]

    Tabor DE, Yu L, Mok H et al.. “Staphylococcus aureus Alpha-Toxin Is Conserved among Diverse Hospital Respiratory Isolates Collected from a Global Surveillance Study and Is Neutralized by Monoclonal Antibody MEDI4893.” Antimicrobial agents and chemotherapy (2016). PMID: 27324766 ↗

    L4OTHERCited in: Special Hosts and Populations
  718. [718]

    Verdejo MÁ, Malano-Barletta D, Pitart C et al.. “Empirical glycopeptide exposure and acute kidney injury during cloxacillin therapy in Staphylococcus aureus bacteremia.” Antimicrobial agents and chemotherapy (2026). PMID: 42080550 ↗

    L2OTHERCited in: Special Hosts and Populations
  719. [719]

    Kok EY, Vallejo JG, Sommer LM et al.. “Association of Vancomycin MIC and Molecular Characteristics with Clinical Outcomes in Methicillin-Susceptible Staphylococcus aureus Acute Hematogenous Osteoarticular Infections in Children.” Antimicrobial agents and chemotherapy (2018). PMID: 29530845 ↗

    L2OTHERCited in: Special Hosts and Populations
  720. [720]

    Brahami A, Karlowsky JA, McCracken M et al.. “Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007-23).” The Journal of antimicrobial chemotherapy (2025). PMID: 40873028 ↗

    L4OTHERCited in: Special Hosts and Populations
  721. [721]

    Nichol KA, Adam HJ, Golding GR et al.. “Characterization of MRSA in Canada from 2007 to 2016.” The Journal of antimicrobial chemotherapy (2019). PMID: 31505646 ↗

    L4OTHERCited in: Special Hosts and Populations
  722. [722]

    Helbo T, Boel JB, Bartels MD et al.. “Carriage of methicillin-resistant Staphylococcus aureus in children <6 years old: a retrospective follow-up study of the natural course and effectiveness of decolonization treatment.” The Journal of antimicrobial chemotherapy (2024). PMID: 38334373 ↗

    L2OTHERCited in: Special Hosts and Populations
  723. [723]

    Song JH, Hsueh PR, Chung DR et al.. “Spread of methicillin-resistant Staphylococcus aureus between the community and the hospitals in Asian countries: an ANSORP study.” The Journal of antimicrobial chemotherapy (2011). PMID: 21393157 ↗

    L2OTHERCited in: Special Hosts and Populations
  724. [724]

    Villar M, Marimón JM, García-Arenzana JM et al.. “Epidemiological and molecular aspects of rifampicin-resistant Staphylococcus aureus isolated from wounds, blood and respiratory samples.” The Journal of antimicrobial chemotherapy (2011). PMID: 21393177 ↗

    L4OTHERCited in: Special Hosts and Populations
  725. [725]

    Drewett GP, Jacob M, Culhane B et al.. “Malignant Otitis Externa in Central Australia: A 15-Year Retrospective Review Between 2009 and 2024.” The Medical journal of Australia (2026). PMID: 41837387 ↗

    L4REVIEW_NARRATIVECited in: Special Hosts and Populations
  726. [726]

    Morelli MK, Veve MP, Shorman MA. “Maternal Bacteremia Caused by Staphylococcus Aureus With a Focus on Infective Endocarditis.” Open forum infectious diseases (2020). PMID: 32766382 ↗

    L4OTHERCited in: Special Hosts and Populations
  727. [727]

    Sullivan SB, Kamath S, McConville TH et al.. “Staphylococcus epidermidis Protection Against Staphylococcus aureus Colonization in People Living With Human Immunodeficiency Virus in an Inner-City Outpatient Population: A Cross-Sectional Study.” Open forum infectious diseases (2016). PMID: 28018932 ↗

    L4OTHERCited in: Special Hosts and Populations
  728. [728]

    Crum-Cianflone NF, Wang X, Weintrob A et al.. “Specific Behaviors Predict Staphylococcus aureus Colonization and Skin and Soft Tissue Infections Among Human Immunodeficiency Virus-Infected Persons.” Open forum infectious diseases (2015). PMID: 26380335 ↗

    L2OTHERCited in: Special Hosts and Populations
  729. [729]

    Stavropoulou E, Ledergerber B, Fourré N et al.. “Infective Endocarditis and Antimicrobial Timing: A Case for Delay?” Open forum infectious diseases (2025). PMID: 41141452 ↗

    L2OTHERCited in: Special Hosts and Populations
  730. [730]

    Popovich KJ, Zawitz C, Weinstein RA et al.. “The Intersecting Epidemics of Human Immunodeficiency Virus, Community-Associated Methicillin-Resistant Staphylococcus aureus, and Incarceration.” Open forum infectious diseases (2015). PMID: 26543878 ↗

    L2OTHERCited in: Special Hosts and Populations
  731. [731]

    Koeck M, Como-Sabetti K, Boxrud D et al.. “Burdens of Invasive Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Disease, Minnesota, USA.” Emerging infectious diseases (2019). PMID: 30561319 ↗

    L4OTHERCited in: Special Hosts and Populations

Revision History

All updates applied to this page

Loading revisions…